
<html lang="en"     class="pb-page"  data-request-id="eb314856-20d7-4178-9f72-7e1390bede06"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-22;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b01039;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design" /></meta><meta name="dc.Creator" content="Shinmee  Mah" /></meta><meta name="dc.Creator" content="Jung Hee  Park" /></meta><meta name="dc.Creator" content="Hoi-Yun  Jung" /></meta><meta name="dc.Creator" content="Kukcheol  Ahn" /></meta><meta name="dc.Creator" content="Soyeon  Choi" /></meta><meta name="dc.Creator" content="Hyun Seop  Tae" /></meta><meta name="dc.Creator" content="Kyung Hee  Jung" /></meta><meta name="dc.Creator" content="Jin Kyung  Rho" /></meta><meta name="dc.Creator" content="Jae Cheol  Lee" /></meta><meta name="dc.Creator" content="Soon-Sun  Hong" /></meta><meta name="dc.Creator" content="Sungwoo  Hong" /></meta><meta name="dc.Description" content="Dysregulation of anaplastic lymphoma kinase (ALK) has been detected in nonsmall cell lung cancer (NSCLC) in the form of EML4-ALK fusion. Secondary mutations opposing activity of the first-generatio..." /></meta><meta name="Description" content="Dysregulation of anaplastic lymphoma kinase (ALK) has been detected in nonsmall cell lung cancer (NSCLC) in the form of EML4-ALK fusion. Secondary mutations opposing activity of the first-generatio..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 9, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01039" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01039" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01039" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01039" /></link>
        
    
    

<title>Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01039" /></meta><meta property="og:title" content="Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0016.jpeg" /></meta><meta property="og:description" content="Dysregulation of anaplastic lymphoma kinase (ALK) has been detected in nonsmall cell lung cancer (NSCLC) in the form of EML4-ALK fusion. Secondary mutations opposing activity of the first-generation ALK inhibitor crizotinib came into existence, requiring mutation-targeting drug discovery for the powerful second-line treatment. In this study, we report 4-phenoxyquinoline-based inhibitors that overcome crizotinib resistance to ALK L1196M, discovered by the fragment-growing strategy. The protonation of 4-aminoquinoline core could interrupt the ability the N atom of quinoline to act as a hydrogen bond acceptor; therefore, the pKa and calculated ionization pH values of relevant pyridine-based core moieties were carefully analyzed. The replacement of amine linkage with ether resulted in single-digit nanomolar range inhibitors. The inhibitors exhibited significant antiproliferative effects on H2228 CR crizotinib-resistant cells by decreasing PI3K/AKT and MAPK signaling. This work constitutes the first example for systematic investigation of the effect of ionization pH on activity in this system." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01039"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01039">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01039&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01039&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01039&amp;href=/doi/10.1021/acs.jmedchem.7b01039" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9205-9221</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00941" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00963" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.8b00212"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shinmee++Mah">Shinmee Mah</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>+</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jung+Hee++Park">Jung Hee Park</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>+</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hoi-Yun++Jung">Hoi-Yun Jung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kukcheol++Ahn">Kukcheol Ahn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soyeon++Choi">Soyeon Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyun+Seop++Tae">Hyun Seop Tae</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyung+Hee++Jung">Kyung Hee Jung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jin+Kyung++Rho">Jin Kyung Rho</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jae+Cheol++Lee">Jae Cheol Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soon-Sun++Hong">Soon-Sun Hong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sungwoo++Hong">Sungwoo Hong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-9371-1730" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Center for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212, Korea</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Asan Institute for Life Sciences and Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, Korea</span></div><div class="corresp-info"><strong>*</strong>For S.H.: phone, (+82) 42 3502811; E-mail: <a href="/cdn-cgi/l/email-protection#167e797871796471567d777f6562387775387d64"><span class="__cf_email__" data-cfemail="cfa7a0a1a8a0bda88fa4aea6bcbbe1aeace1a4bd">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For FS.S.H.: phone, (+82) 32-890-3683; E-mail: <a href="/cdn-cgi/l/email-protection#593136373e2a193037313877383a77322b"><span class="__cf_email__" data-cfemail="355d5a5b5246755c5b5d541b54561b5e47">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01039&amp;href=/doi/10.1021%2Facs.jmedchem.7b01039" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9205–9221</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 1, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 July 2017</li><li><span class="item_label"><b>Published</b> online</span>9 November 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 November 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01039" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01039</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9205%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShinmee%2BMah%252C%2BJung%2BHee%2BPark%252C%2BHoi-Yun%2BJung%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D22%26contentID%3Dacs.jmedchem.7b01039%26title%3DIdentification%2Bof%2B4-Phenoxyquinoline%2BBased%2BInhibitors%2Bfor%2BL1196M%2BMutant%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2Bby%2BStructure-Based%2BDesign%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9221%26publicationDate%3DNovember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01039"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2607</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01039" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shinmee&quot;,&quot;last_name&quot;:&quot;Mah&quot;},{&quot;first_name&quot;:&quot;Jung&quot;,&quot;last_name&quot;:&quot;Hee Park&quot;},{&quot;first_name&quot;:&quot;Hoi-Yun&quot;,&quot;last_name&quot;:&quot;Jung&quot;},{&quot;first_name&quot;:&quot;Kukcheol&quot;,&quot;last_name&quot;:&quot;Ahn&quot;},{&quot;first_name&quot;:&quot;Soyeon&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Hyun&quot;,&quot;last_name&quot;:&quot;Seop Tae&quot;},{&quot;first_name&quot;:&quot;Kyung&quot;,&quot;last_name&quot;:&quot;Hee Jung&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Kyung Rho&quot;},{&quot;first_name&quot;:&quot;Jae&quot;,&quot;last_name&quot;:&quot;Cheol Lee&quot;},{&quot;first_name&quot;:&quot;Soon-Sun&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Sungwoo&quot;,&quot;last_name&quot;:&quot;Hong&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9205-9221&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01039&quot;},&quot;abstract&quot;:&quot;Dysregulation of anaplastic lymphoma kinase (ALK) has been detected in nonsmall cell lung cancer (NSCLC) in the form of EML4-ALK fusion. Secondary mutations opposing activity of the first-generation ALK inhibitor crizotinib came into existence, requiring mutation-targeting drug discovery for the powerful second-line treatment. In this study, we report 4-phenoxyquinoline-based inhibitors that overcome crizotinib resistance to ALK L1196M, discovered by the fragment-growing strategy. The protonation of 4-aminoquinoline core could interrupt the ability the N atom of quinoline to act as a hydrogen bond acceptor; therefore, the pKa and calculated ionization pH values of relevant pyridine-based core moieties were carefully analyzed. The replacement of amine linkage with ether resulted in single-digit nanomolar range inhibitors. The inhibitors exhibited significant antiproliferative effects on H2228 CR crizotinib-resistant cells by decreasing PI3K/AKT and MAPK signaling. This work constitutes the first example for sy&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01039&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01039" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01039&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01039" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01039&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01039" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01039&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01039&amp;href=/doi/10.1021/acs.jmedchem.7b01039" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01039" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01039" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01039%26sid%3Dliteratum%253Aachs%26pmid%3D29091425%26genre%3Darticle%26aulast%3DMah%26date%3D2017%26atitle%3DIdentification%2Bof%2B4-Phenoxyquinoline%2BBased%2BInhibitors%2Bfor%2BL1196M%2BMutant%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2Bby%2BStructure-Based%2BDesign%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D22%26spage%3D9205%26epage%3D9221%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=290795" title="Quinolines">Quinolines</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/jmcmar.2017.60.issue-22/20171122/jmcmar.2017.60.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dysregulation of anaplastic lymphoma kinase (ALK) has been detected in nonsmall cell lung cancer (NSCLC) in the form of EML4-ALK fusion. Secondary mutations opposing activity of the first-generation ALK inhibitor crizotinib came into existence, requiring mutation-targeting drug discovery for the powerful second-line treatment. In this study, we report 4-phenoxyquinoline-based inhibitors that overcome crizotinib resistance to ALK L1196M, discovered by the fragment-growing strategy. The protonation of 4-aminoquinoline core could interrupt the ability the N atom of quinoline to act as a hydrogen bond acceptor; therefore, the p<i>K</i><sub>a</sub> and calculated ionization pH values of relevant pyridine-based core moieties were carefully analyzed. The replacement of amine linkage with ether resulted in single-digit nanomolar range inhibitors. The inhibitors exhibited significant antiproliferative effects on H2228 CR crizotinib-resistant cells by decreasing PI3K/AKT and MAPK signaling. This work constitutes the first example for systematic investigation of the effect of ionization pH on activity in this system.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is a member of the receptor tyrosine kinases (RTKs) and the insulin receptor superfamily, and it is activated through dimerization upon binding the growth factor midkine (MK) and pleiotrophin (PTN) in the extracellular region. Activated ALK phosphorylates intracellular substrates and thereby switches on downstream cell signaling pathways to facilitate cell proliferation and survival signaling through the PI3K/AKT, JAK/STAT3, and MEK/ERK pathways.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Dysregulation of ALK signaling has been implicated in various human cancers, including nonsmall cell lung cancer (NSCLC), inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, squamous cell carcinoma, and diffuse large B-cell lymphoma.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3-7)</a> Therefore, the hyperactivation of ALK kinase has become a well-validated target for the development of therapeutics to treat several cancers. In addition, it has been demonstrated that the impairment of ALK activity with small-molecule inhibitors is effective in suppressing the growth of cancer in xenograft models in vivo.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8-11)</a></div><div class="NLM_p">Accordingly, much effort has been devoted to the discovery of small-molecule ALK inhibitors, including crizotinib (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), the dual inhibitor of ALK and c-MET.<a onclick="showRef(event, 'ref9 ref10 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref12 ref13">(9, 10, 12, 13)</a> Despite the clear benefits of crizotinib, many ALK-dependent cancer cells tend to acquire various mutations that can render the ALK enzyme constitutively active by impeding the inhibitor binding in the ATP-binding site.<a onclick="showRef(event, 'ref8 ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref8 ref14 ref15 ref16 ref17 ref18 ref19 ref20">(8, 14-20)</a> The emergence of drug resistance has prevented the first-generation anti-NSCLC drug crizotinib from continued use in clinical treatment, which led to the development of the drug-resistant mutants of ALK. In particular, the mutation L1196M is most frequently identified in crizotinib-resistant patients. The emergence of the L1196M mutant has complicated clinical treatment, highlighting the importance of identifying new ALK inhibitors with high potency against the L1196M mutant. The substitution of Met for Leu could block the access of inhibitors to the deeper pocket near the gatekeeper residue in the ATP-binding site due to an increase in steric hindrance, representing a major obstacle for drug design.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a> In this regard, the identification of potent inhibitors that target the L1196M mutation would have important therapeutic implications.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structures of Crizotinib and Representative 4-Phenoxyquinoline-Based Inhibitor</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The accumulation of three-dimensional structure data on ALK–inhibitor interactions for various mutants has provided insight into overriding the drug resistance of ALK-dependent cancers.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24-27)</a> Recently, we have revealed new molecular scaffolds for the development of new inhibitors targeting the L1196M mutant by the virtual screening of a large chemical library.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Our research was stimulated by the possibility that new inhibitors of the L1196M mutant could be rationally designed utilizing 3D structural information. This study was undertaken to identify new 4-quinoline-based inhibitors of the L1196M mutant of ALK through structure-based design strategies and to demonstrate the biological evaluation of various quinoline derivatives in terms of their anticancer effects on H2228 CR cells, which are crizotinib-resistant cells. A design strategy for improving their potency using electrostatic features and the effect of ionization pH of 4-quinoline scaffold to analyze the binding mode in detail was also discussed.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Identification of 4-Aminoquinoline Moiety</h3><div class="NLM_p">With the goal of developing a new structural class of potent L1196M mutant inhibitors, we investigated the starting structure for de novo design and the affinity of various hinge-binding scaffolds to accommodate the increased bulk of the side chain of Met1196 in the ATP binding site, employing an L1196M crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>) as a template. <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a shows the lowest energy conformation as calculated with the Discovery Studio 4.5 software. On the basis of comparing structural features and the interactions formed between various fragments and the L1196M mutant, the 4-aminoquinoline core appeared to be stabilized through hydrogen bonding with the backbone amide groups of a residue in the hinge region (Met1199) of the ATP-binding site. Interestingly, a larger gatekeeper Met1196 residue was found at the interface formed by van der Waals contacts between 4-aminoquinoline and the L1196M mutant (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b), indicating that favorable hydrophobic interactions were formed in the L1196M mutant. The quinoline serves as a hydrogen-bond acceptor with the backbone amidic nitrogen of Met1199 in the middle of the hinge region, whereas the six-membered bicyclic aromatic ring of quinoline seems to be further stabilized through the van der Waals contacts of its aromatic rings with the side chains of Leu1122, Ala1148, and Leu1256. It is noteworthy that in the L1196M mutant, the increased steric hindrance of the gatekeeper mutation needs to be most carefully considered for drug design and the 4-aminoquinoline scaffold resides in proximity to the side chain of the Met1196 gatekeeper without causing a steric clash. Because the 4-aminoquinoline scaffold binds tightly at the hinge region (Met1199), it is predicted to serve as a good starting point from which potent inhibitors can be derived. In addition, the 4-aminoquinoline scaffold can be easily diversified via a convergent synthetic approach for the rapid elucidation of structure–activity relationship (SAR). The terminal 4-amino group points toward the DFG (Asp1270-Phe1271-Gly1272) motif in the activation loop (A-loop) and a vacant binding pocket comprising Arg1253-Asn1254-Cys1255-Leu1256-Gly1269-Asp1270 and Asp1203 to accommodate a suitable fragment.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> A significant improvement in potency is thus expected to result from introducing a suitable chemical moiety at the terminal amino group. Furthermore, the ATP pocket is connected to a narrow aisle composed of Glu1132, Leu1198, and Ala1200, implying that a fragment on C7 of quinoline would be stabilized through hydrophobic interactions with the region near the solvent front. Therefore, we planned to extend the structures by introducing various chemical moieties at these two positions (Frag 1 and Frag 2 in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b). For these reasons, 4-aminoquinoline was selected as a putative core from which more potent inhibitors could be derived in our studies.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Expected configuration of 4-aminoquinoline moiety in ATP binding site of ALK L1196M. (b) Design of new scaffolds and opportunities for modification in the schematic active site of ALK L1196M. Each dotted line represents a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemical Synthesis</h3><div class="NLM_p">The de novo design process identified a variety of promising (hetero)arene systems for introduction at the 4- and 7- positions of the quinoline core. The compound library was established by a convenient route allowing the rapid exploration of the SAR profile and the general synthetic route for representative quinoline derivatives, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The C4 position of quinoline was functionalized with NH- or O-linked aryl groups prior to performing a Suzuki coupling with the C7 (hetero)arene partners. The quinoline moiety can be easily equipped with a variety of substituted anilines via addition and elimination processes under acidic conditions to afford the key intermediate <b>B</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> An assortment of the C7 groups of 4-aminoquinolines were then explored through palladium-catalyzed Suzuki cross-coupling with corresponding arylboronic acids or esters, affording the desired product <b>C</b>. For a focused 4-phenoxy group array, S<sub>N</sub>Ar reactions between 7-bromo-4-chloroquinoline and substituted phenol were conducted under basic conditions.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> A variety of aryl groups were then installed at the 7-position by Pd-catalyzed cross-coupling with the appropriate aryl boronic acids or esters. An additional deprotection step removing the Boc-protection group of the solubilizing tail was conducted to produce the final compounds.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) aniline, 35% HCl, <i>i</i>PrOH, 80 °C, 1.5 h; (b) phenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C, 12 h; (c) R<sub>2</sub>-Bpin, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O = 1:1, 120 °C, 1 h, μW; (d) R<sub>2</sub>-Bpin, Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene/H<sub>2</sub>O = 2:1, 90 °C, 12 h, after c or d, additional deprotection under TFA, DCM, rt, 1 h for <b>11</b>, <b>14</b>–<b>30</b>.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Array at C7</h3><div class="NLM_p">To identify potent inhibitors, we initially focused our design attempts on the 4-aminoquinoline scaffold. First, we hypothesized that the overall activity of 4-aminoquinoline might be improved by introducing a suitable moiety into the molecule to establish additional π interactions with Gly1202 and hydrogen bonding or ionic interactions with polar amino acid residues at the solvent front. On the basis of our structural analysis, we planned to install a variety of (hetero)arene appendages at the C7 position to evaluate the substituent space of 4-aminoquinoline while the phenyl group at the C4 position remained fixed (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The resulting derivatives were subjected to a subsequent full IC<sub>50</sub> value determination. To the best of our knowledge, the 4-aminoquinoline scaffold is not present in any of the ALK inhibitors reported so far. The (hetero)arene groups at the 7 position seem to be stabilized in the internal region of the ATP-binding site because the chemical moiety group at the C7 position points to the center of the N-terminal domain in docking simulations (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Of particular significance is the observation that a profound effect on potency was displayed upon the installation of the 4-(1<i>H</i>-pyrazol-1-yl)piperidine group. Molecular docking study of compounds <b>11</b> consistently indicated that the pyrazolyl piperidine moiety of the appendage plays an important role in determining activity by establishing a hydrogen bonding interaction with Glu1210. This effect is apparently one of the reasons for the better inhibitory activity of compounds bearing the pyrazolyl piperidine moiety.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Exploration of Groups at the C7 Position of 4-Phenylaminoquinoline Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0013.gif" alt="" id="fx2" /></img><div></div></div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Binding mode of 4-anilinoquinoline obtained through preparing inhibitors at pH above 11.16 followed by normal docking study (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). (b) Calculated binding mode of 4-phenylaminoquinoline at pH 6.5–8.5. Protonated site is marked with red dashed circle (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). (c) Ionization pH of each marked unit and existing form in the blue- and orange-colored pH ranges.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Identification of O-Linked Quinoline Scaffold</h3><div class="NLM_p">Although compound <b>11</b> is a newly identified L1196M inhibitor with micromolar potency, we decided to make some modifications to the structural and electrostatic features of 4-aminoquinoline scaffold to find more potent inhibitors with at least submicromolar-level inhibitory activity. For the 4-aminoquinoline core, the acidic conditions can stabilize the quinoline tautomer where the quinoline is readily protonated to give the quinolinium ion. From this perspective, we speculated that errors in the binding modes and scoring function could occur from underestimation of the tautomerism and protonation of the 4-aminoquinoline scaffold, which might be invoked to explain, at least partly, the lower inhibitory activity. To determine the potential effect of the tautomerism, the binding modes of 4-phenylaminoquinoline at different pH values were thoroughly investigated with docking simulations. As depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, we note that the quinoline tends to be mostly protonated (marked with red dashed circle) in the physiologically relevant pH 6.5–8.5 range, preventing the quinoline scaffold from establishing a hydrogen bond at the hinge region. The introduction of the additional tautomerism and protonation factors seemed to guarantee better prediction accuracy of the ligand binding affinity. Therefore, it would be reasonable to consider their electrostatic features to design new inhibitors with increased potency. For this reason, we investigated the relevance of the effect of ionization pH and inhibitory activity.</div><div class="NLM_p"><a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>c shows the ionization pH and range of each protonated/deprotonated form of the pyridine and quinoline derivatives calculated in the Discovery Studio program. By the resonance effect of the 4-aminopyridine moiety, the lone pair electron at N of the 4-amino group is transferred to the C–N bond at the C4 of quinoline to form an N-positively charged imine and delocalized to raise the electron density of the quinoline nitrogen. The ionization pH reaches 9.1 in both pyridine and quinoline, even higher in 4-phenylamino-substituted scaffolds, to cause the compounds to mostly exist in protonated form at physiological pH. We speculated that decreasing the resonance stability by replacing the amino linker with an ether linkage would lower the ionization pH, and consequently, the deprotonated neutral form of 4-phenoxyquinoline scaffolds would be preferred. Indeed, the calculated ionization pH of 4-phenoxyquinoline is 6.44, revealing that the majority of this moiety exists in the neutral form so that the quinoline nitrogen is able to establish hydrogen bonding in the ATP-binding site. In addition, protonation and tautomerism can influence the structural length and bond rotatability of the compounds.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In this sense, the structure of the 4-phenoxyquinoline scaffold tends to be more flexible and could serve as a more effective surrogate for the corresponding 4-aminoquinoline core. To assess this hypothesis, the influence of protonation and tautomerism was investigated by changing the amino linkers along with studying the SAR profiles (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibition Effects of Quinoline Scaffold Attached with Different Linkages at C4</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0015.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p last">To our delight, changing the linking moiety from NH in the 4-aminoquinoline scaffolds to O results in remarkable increases in the inhibitory activity. For example, the biochemical potency appears to increase by a factor of 40 in going from <b>23</b> (L1196M, IC<sub>50</sub> = 129 nM) to <b>24</b> (L1196M, IC<sub>50</sub> = 3.3 nM) due to the replacement of the amine linker with ether, the latter of which is identified as the exclusively preferred linker (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). This result indicates the importance of the neutral form of quinoline moieties, participating in a hydrogen bond with the hinge to effectively impair the enzymatic activity in the sense that the 4-alkoxyquinoline scaffold is more capable of acting as a hydrogen bond acceptor than the corresponding 4-aminoquinoline moiety. Next, various substituents can be introduced on the 4-phenoxy ring to maximize the binding affinity in the DFG motif in the A-loop and the nearby vacant binding pocket. As can be inferred from the similar IC<sub>50</sub> values of <b>14</b>, <b>18</b>, and <b>22</b>, various patterns of substitution are acceptable at the 4-phenoxy ring to achieve submicromolar inhibitory activity. The phenol group in <b>30</b> is likely to function as a hydrogen bond acceptor to Lys1150, as reflected by the excellent IC<sub>50</sub> value (L1196M, IC<sub>50</sub> = 7 nM). Therefore, it becomes apparent that the biochemical potency of quinoline-based L1196M mutant inhibitors can be augmented to the low nanomolar level by introducing an ether linkage. The inhibitory activity of <b>14</b> compared to <b>13</b> with a CH<sub>2</sub>-linked moiety also indicates the superiority of the 4-phenoxy group as the optimal substructure for binding in mutant ALK (L1196M).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Binding Mode Analysis of Inhibitor</h3><div class="NLM_p">To address structural and mechanistic aspects relevant to the potent inhibition by the newly identified inhibitors, we analyzed the interactions that stabilize the binding mode of inhibitors in the mutant ALK (L1196M) protein structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). The binding modes of <b>30</b> in the ATP-binding sites of the L1196M mutant is presented in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. The lowest-energy conformation shows the hydrogen bond formation between the N of quinoline and the backbone of Met1199, and this quinoline core is stabilized via hydrophobic interaction with the alkyl chain of Leu1122 and Ala1148 on the upper side and Leu1256 at the bottom of the pocket. A small pocket formed by Val1130, Met1196, and Lys1150 is occupied by a 56.1° tilted phenyl headgroup, and this hydroxyl group serves as an anchor by forming additional two hydrogen bonds with the two opposite-charged side chains of Lys1150 and Asp1270. Interestingly, a larger gatekeeper Met1196 residue was found at the interface formed by van der Waals contacts between the terminal phenoxy moiety and the ALK mutant (L1196M) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The piperidine on the inhibitor appeared to point toward the solvent front by forming a salt bridge with Glu1210 located on the outside of the kinase domain. Further stabilization may be achieved through the van der Waals contacts of its the pyrazole moiety with the hydrophobic side chains of Leu1122, Gly1201, Gly1202, and Ala1200. A similar binding mode would be speculated to occur in the cases of compounds <b>20</b>, <b>28</b>, and <b>30</b>, which form interactions such as hydrogen bonding. The overall structural features derived from the docking simulations confirmed that the inhibitory activities of compound <b>30</b> were attributed to the multiple hydrogen bonds and hydrophobic interactions established simultaneously in the ATP-binding site of the L1196M mutant.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Calculated binding mode of <b>30</b> at the ATP binding site of ALK L1196M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). Each dashed blue line and orange line indicates a hydrogen bond and salt bridge, respectively. Gatekeeper was displayed in semitransparent solid surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Mechanism of Action (MOA) Studies</h3><div class="NLM_p">To understand the interaction and binding modes of these inhibitors with ALK L1196M, mechanism of action (MOA) studies including ATP competition evaluation and <i>K</i><sub><i>i</i></sub> determination were performed. As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, the progress curves are linear regardless of the amount of inhibitor, suggesting the inhibition by <b>24</b> is not time-dependent.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Progress curves for ALK (L1196M) with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The apparent <i>K</i><sub>m</sub> is increased when inhibitor concentration is increased in Michaelis–Menten plot (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A) and all lines are converged on the <i>Y</i>-axis in the double-reciprocal plot (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). As shown in the Lineweaver–Burk plots (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B), <b>24</b> appears to impair the kinase activity of the mutant in the ATP-competitive fashion.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Michaelis–Menten plot (A) and Lineweaver–Burk plot (B) for ALK (L1196M) with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When % enzymatic activities of slopes relative to that of DMSO control at each ATP concentration are plotted against inhibitor concentration and draw IC<sub>50</sub> curves, the IC<sub>50</sub> values of <b>24</b> were increased when ATP concentration was increased, as expected for common ATP-competitive inhibitors (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. IC<sub>50</sub> curves for ALK (L1196M) at different ATP concentrations with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, global fit was performed for <b>24</b> and results are listed in the table in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>. The high value of <i>K</i><sub>i</sub>′ (almost infinity) means the compound has very little affinity for enzyme/ATP complex, which turns ATP-competitive inhibition of ALK L1196M by <b>24</b>. The results from MOA studies show that <b>24</b> is not time-dependent and competitive with respect to ATP with the <i>K</i><sub>i</sub> value of 22 nM and <i>K</i><sub>m</sub> value of 32.6 μM.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. IC<sub>50</sub> curves for ALK (L1196M) at different ATP concentrations with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> ALK Mutant and Kinase Selectivity Profiling</h3><div class="NLM_p">As summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, compounds <b>24</b>, <b>28</b>, and <b>30</b> were tested against a panel of the most common secondary ALK mutants (L1196M, C1156Y, F1174L, G1269A, L1152R, G1202R).<a onclick="showRef(event, 'ref13 ref26 ref32'); return false;" href="javascript:void(0);" class="ref ref13 ref26 ref32">(13, 26, 32)</a> Notably, compound <b>30</b> exhibited good potency against the secondary ALK mutants (L1196M, C1156Y, F1174L, G1269A, L1152R) with IC<sub>50</sub> values ranging from 7 to 30 nM, although it showed an inhibitory activity against the G1202R mutant in the micromolar range.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values of <b>24</b>, <b>28</b>, and <b>30</b> against ALK Mutants</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">L1196M</th><th class="colsep0 rowsep0" align="center" char=".">C1156Y</th><th class="colsep0 rowsep0" align="center" char=".">F1174L</th><th class="colsep0 rowsep0" align="center" char=".">G1269A</th><th class="colsep0 rowsep0" align="center" char=".">L1152R</th><th class="colsep0 rowsep0" align="center" char=".">G1202R</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0033</td><td class="colsep0 rowsep0" align="char" char=".">0.0409</td><td class="colsep0 rowsep0" align="char" char=".">0.141</td><td class="colsep0 rowsep0" align="char" char=".">0.0351</td><td class="colsep0 rowsep0" align="char" char=".">0.159</td><td class="colsep0 rowsep0" align="char" char=".">9.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0284</td><td class="colsep0 rowsep0" align="char" char=".">0.0422</td><td class="colsep0 rowsep0" align="char" char=".">0.154</td><td class="colsep0 rowsep0" align="char" char=".">0.0384</td><td class="colsep0 rowsep0" align="char" char=".">0.155</td><td class="colsep0 rowsep0" align="char" char=".">8.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0071</td><td class="colsep0 rowsep0" align="char" char=".">0.0115</td><td class="colsep0 rowsep0" align="char" char=".">0.0093</td><td class="colsep0 rowsep0" align="char" char=".">0.0162</td><td class="colsep0 rowsep0" align="char" char=".">0.0296</td><td class="colsep0 rowsep0" align="char" char=".">4.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">staurosporine</td><td class="colsep0 rowsep0" align="char" char=".">0.00073</td><td class="colsep0 rowsep0" align="char" char=".">0.0017</td><td class="colsep0 rowsep0" align="char" char=".">0.0016</td><td class="colsep0 rowsep0" align="char" char=".">0.00074</td><td class="colsep0 rowsep0" align="char" char=".">0.0029</td><td class="colsep0 rowsep0" align="char" char=".">0.0038</td></tr></tbody></table></div></div><div class="NLM_p last">To obtain a detailed picture of the selectivity profile of this series, potent inhibitor <b>24</b> was further subjected to kinase selectivity profiling with a panel of 85 cancer related kinases on the kinome tree in a high-throughput binding assay at a concentration of 1 μM (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_001.pdf" class="ext-link">Table S1</a> in Supporting Information for more detail). Overall, <b>24</b> showed moderate to good specificity profiles, and kinases against which <b>24</b> demonstrated meaningful off-target activity percent of control (POC < 10) were ALK (POC = 2.3), AURKA (POC = 9.1), FLT3 (POC = 5.2), KIT (POC = 4.4), RET (POC = 3.3), TIE2 (POC = 4.9), and VEGFR2 (POC = 2.3). Other kinases inhibited by <b>24</b> are ACVR1B (POC = 14), LTK (POC = 13), FGFR1 (POC = 12), MEK2 (POC = 17), and MET (POC = 15).</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Effect on Cell Proliferation and Cell-Signaling Downstream</h3><div class="NLM_p">This series of potent inhibitors were further tested for cellular growth inhibition against cancer cells. We tested cell viability assay with FDA approved ALK inhibitors (crizotinib, ceritinib, and alectinib) along with the representative compound <b>30</b> against Ba/F3 EML4-ALK WT (EA WT) and Ba/F3 EML4-ALK L1196M (EA L1196M) cells. As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>a, crizotinib did not effectively inhibit cell proliferation of Ba/F3 EA L1196M cells while crizotinib significantly inhibited proliferation in Ba/F3 EA WT cells. On the other hand, compound <b>30</b> effectively inhibited the cell growth and was comparable to ceritinib and alectinib against both wild-type BaF3 EML4-ALK cells and BaF3 EML4-ALK cells with L1196M in a dose-dependent manner.<a onclick="showRef(event, 'ref8 ref16 ref33'); return false;" href="javascript:void(0);" class="ref ref8 ref16 ref33">(8, 16, 33)</a> Next, we carried out an evaluation of their antiproliferative activity on the H2228 and H2228 CR cell lines, the latter of which is crizotinib-resistant.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Next, H2228 and H2228 CR cells were treated with different doses of crizotinib for 72 h, and then MTT assays were performed. As expected, crizotinib significantly inhibited proliferation in H2228 crizotinib-sensitive cells (IC<sub>50</sub> = 2.5 μM) but did not effectively inhibit cell proliferation of H2228 CR crizotinib-resistant cells (IC<sub>50</sub> = 10 μM). To investigate whether <b>30</b> could overcome the resistance to crizotinib, H2228 CR cells were treated with different doses of crizotinib, ceritinib, alectinib, and <b>30</b> for 72 h. The results from the MTT assay indicated that H2228 CR cells exhibited high resistance to crizotinib, whereas <b>30</b>, ceritinib, and alectinib effectively inhibited the cell growth of H2228 CR cells in a dose-dependent manner (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>b).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cell viability of crizotinib, ceritinib, alectinib, and <b>30</b>. Cell viability of crizotinib, ceritinib, alectinib, and <b>30</b> were measured in (a) Ba/F3 EML4-ALK WT (EA WT), EML4-ALK L1196M (EA L1196M), and H2228 and (b) H2228 CR human lung cancer cells by MTT assay. EA = EML4-ALK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To identify the molecular mechanism of <b>30</b> in overcoming acquired crizotinib resistance, we examined the effect of <b>30</b> on PI3K/AKT and MAPK signaling activation, which were reported to be not only the main downstream signaling pathways of ALK but also the key mechanism for crizotinib resistance. In H2228 crizotinib-sensitive cells, crizotinib obviously inhibited the expression of p-AKT, downstream of PI3K/AKT signaling, but not p-ERK, downstream of MAPK signaling. However, <b>30</b> inhibited the expresssion of both p-AKT and p-ERK (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>). More importantly, <b>30</b> remarkably inhibited the expression of both p-AKT and p-ERK in H2228 CR crizotinib-resistant cells compared with crizotinib (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>). Overall, these results showed that <b>30</b> successfully overcame crizotinib resistance by decreasing PI3K/AKT and MAPK signaling.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>30</b> increased crizotinib sensitivity and overcame crizotinib resistance by decreasing PI3K/AKT and MAPK signaling in crizotinib-sensitive and -resistant human lung cancer cells. H2228 and H2228 CR human lung cancer cells were treated with the indicated concentrations of <b>30</b> and crizotinib for 3 h, and then the expression levels of p-AKT and p-ERK were measured by Western blotting. Data are presented as means ± SD (***<i>P</i> < 0.005).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two leading compounds <b>24</b> and <b>28</b> were subjected to pharmacokinetic studies. As shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>a, rat pharmacokinetic parameters were determined after oral administration and intravenous injection, which showed fair oral bioavailability (<b>24</b>, 44.8%; <b>28</b>, 45.5%; <b>30</b>, 24.8%). Next, we assessed the hERG inhibition of representative compounds of this series, and IC<sub>50</sub> values for <b>24</b>, <b>28</b>, and <b>30</b> were determined as shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>b. The assay is based on the competition of fluorescently labeled Tracer binding to the membrane preparation containing hERG. Compounds <b>24</b>, <b>28</b>, and <b>30</b> exhibited moderate inhibition of the hERG channel, with activities ranging from 2.46 to 3.12 μM.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. (a) Rat Pharmacokinetic Properties of Compounds <b>24</b> and <b>28</b> and (b) IC<sub>50</sub> Values of Compounds <b>24</b>, <b>28</b>, and <b>30</b> against hERG</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="8" align="center">(a)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">94.1</td><td class="colsep0 rowsep0" align="char" char=".">166.0</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">130.7</td><td class="colsep0 rowsep0" align="char" char=".">744.6</td><td class="colsep0 rowsep0" align="char" char=".">44.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">10.7</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">48.9</td><td class="colsep0 rowsep0" align="char" char=".">95.9</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">83.9</td><td class="colsep0 rowsep0" align="char" char=".">436.7</td><td class="colsep0 rowsep0" align="char" char=".">45.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">83.5</td><td class="colsep0 rowsep0" align="char" char=".">155.1</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">78.4</td><td class="colsep0 rowsep0" align="char" char=".">384.0</td><td class="colsep0 rowsep0" align="char" char=".">24.8</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="5" align="center">(b)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><b>24</b></th><th class="colsep0 rowsep0" align="center" char="."><b>28</b></th><th class="colsep0 rowsep0" align="center" char="."><b>30</b></th><th class="colsep0 rowsep0" align="center" char=".">E-4031</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="char" char=".">3.12</td><td class="colsep0 rowsep0" align="char" char=".">2.46</td><td class="colsep0 rowsep0" align="char" char=".">2.76</td><td class="colsep0 rowsep0" align="char" char=".">0.0012</td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By fragment-based drug design and modification followed by analysis of chemical properties, we identified 4-phenoxyquinoline derivatives as ALK and ALK L1196M inhibitors. Starting from the 4-aminoquinoline moiety, a fragment-growing strategy was adopted to promote hydrophobic interaction, solvation effect, and advanced interactions. The electrostatic properties of molecular structures in physiological conditions were carefully considered for the structural design of inhibitors. In the range of physiological pH conditions, electron delocalization from the 4-aminogroup to the quinoline nitrogen is likely to lead to protonation of the 4-aminoquinoline moiety that blocks the quinoline nitrogen from binding the hinge amino acid backbone. The scaffold was redesigned to eliminate this problematic character, altering the linker from NH to O. The enzymatic inhibition of ALK L1196M dramatically increased, especially in the case of 4-phenoxyquinoline bearing <i>p</i>-substitutuent, whose binding stability is demonstrated in the docking model. The new inhibitors exhibited significant antiproliferative effects on H2228 CR crizotinib-resistant cells by inhibiting the expression of both p-AKT and p-ERK. These results show the advantages of the 4-phenoxyquinoline moiety and have considerable implications for the drug design. Further studies to increase cellular potency by modifying cellular permeability and water solubility are currently in progress.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52511" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52511" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Methods and Materials</h3><div class="NLM_p last">Unless stated otherwise, reactions were performed in a flame-dried glassware under positive pressure of nitrogen using freshly distilled solvents. Analytical thin layer chromatography (TLC) was performed on precoated silica gel 60 F<sub>254</sub> plates, and visualization on TLC was achieved via UV light (254 and 354 nm). μW irritation was conducted by an Anton Paar Microwave 300 single-mode microwave synthesis reactor. Flash column chromatography was utilized on silica gel (400–630 mesh). <sup>1</sup>H NMR was recorded on 600, 400, or 300 MHz, and chemical shifts are quoted in parts per million (ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane. The following abbreviations are used to describe the peak splitting patterns when appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet. Coupling constants, <i>J</i>, are reported in hertz units (Hz). <sup>13</sup>C NMR was recorded on 100 or 150 MHz and was fully decoupled by broad band proton decoupling. Chemical shifts are reported in ppm referenced to the center line of a triplet at 77.0 ppm of chloroform-<i>d</i>. Mass spectral data were obtained from the KAIST Basic Science Institute by Bruker Daltonik HR-MS using the EI method or Agilent LR-MS. High-performance liquid chromatography analyses for checking mass spectral data (using EI method) of synthesized compounds were performed on a Agilent HPLC equipped with an Agilent Poroshell 120 EC-C18 reverse phase column (4.6 mm × 50 mm, 2.7 μm) and by quadrupole LC/MS. The mobile phase was a mixture of MeOH (0.1% TFA) and H<sub>2</sub>O (0.1% TFA). Compound purity was determined by integrating the peak areas of liquid chromatogram, monitored at 254 nm. Flow rate (0.5 mL/min). Gradient system: from MeOH (0.1% TFA) 10% and H<sub>2</sub>O (0.1% TFA) 90% (0 min) to MeOH (0.1% TFA) 90% and H<sub>2</sub>O (0.1% TFA) 10% (18 min), the solvent ratio was maintained for 23 min; the solvent ratio was changed to MeOH (0.1% TFA) 10% and H<sub>2</sub>O (0.1% TFA) 90% (25 min). All final compounds were found to have >95% purity. Commercial grade reagents and solvents were used without further purification except as indicated below. Unless stated otherwise, all commercial grade reagents and solvents were used without additional purification.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Preparation of Compounds</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Preparation of Boron Coupling Partners for Suzuki Coupling</h4><div class="NLM_p last">R<sub>2</sub>-Bpin (4,4,5,5-tetramethyl-1,3,2-dioxaborolane substituted compounds) reagents for Suzuki coupling (GP I-2 and II-2) were prepared by synthesis of iodo-substituted intermediates followed by miyaura borylation in the case of <b>11</b>–<b>30</b>. To synthesize <b>3</b>–<b>10</b>, commercially available boronic acid or Bpin-substituted reagents were used. Preparation of synthesized boron reagents were proceeded through reported synthetic procedures in ref <a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">12</a> (synthesis of <b>68</b>). In the case of R<sub>2</sub>-Bpin reagents for <b>12</b>, 1-(tetrahydro-2<i>H</i>-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole was prepared by following procedure: a solution of 4-iodo-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazole (95.5 mg, 0.3434 mmol) in anhydrous THF (1 mL) was cooled to 0 °C under an atmosphere of N<sub>2</sub>. Then 2 M <i>i</i>PrMgCl solution in THF (0.26 mL, 0.5151 mmol) was added dropwise for 10 min, and the mixture was stirred at rt for 1 h. To the reaction mixture at 0 °C was added 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (87.2 μL, 0.5323 mmol), and the resulting mixture was stirred at rt overnight. The reaction was quenched with saturated NaCl (aq) at 0 °C, and the mixture was extracted with EtOAc (100 mL × 3). The organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under redused pressure. The residue was directly used for Suzuki coupling without further purification.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure (GP) I-1 for the Synthesis of Compounds <b>1</b>, <b>2</b>, and <b>3</b> and 7-bromo-<i>N</i>-phenylquinolin-4-amine Intermediates</h4><div class="NLM_p last">In a round-bottom flask, 7-bromo-4-chloroquinoline (0.092 mmol) and aniline (0.10 mmol) were dissolved in 1 mL of <i>i</i>PrOH. A catalytic amount (1 drop) of 35% hydrochloric acid was added to this mixture at room temperature, and the final mixture was stirred for 2 h at 80 °C. The reaction mixture was cooled to room temperature, and the precipitate was filtered with <i>i</i>PrOH when the precipitate was observed in the crude mixture. When the whole materials were solved in the solvent after reaction, the solvent was evaporated and a small portion of diethyl ether was added to precipitate product from mixture. The precipitate was filtered with diethyl ether, and the solid was dried under reduced pressure, obtaining products or intermediates that was submitted to the next reaction without further purification.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure I-2 for Suzuki Coupling of 4-Anilinoquinoline Substrates</h4><div class="NLM_p last">The mixture of 7-bromo-<i>N</i>-phenylquinolin-4-amine substrate <b>2</b> (0.0334 mmol), proper boronic ester or boronic acid reagent (0.100 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.0033 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.100 mmol) in dioxane:H<sub>2</sub>O (= 1:1, 2 mL) was stirred for 1 h at 120 °C under μW irradiation. EtOAc and H<sub>2</sub>O were added to the mixture, and the organic materials were extracted with EtOAc (50 mL × 3), followed by drying with MgSO<sub>4</sub>. Filtered solution was concentrated under reduced pressure and purified on flash column chromatography (dichloromethane/methanol = 20:1) to give desired product. If inseparable impurity was observed, further purification was proceeded by flash column chromatography (EtOAc/diethyl ether = 20:1). If necessary, Boc deprotection was proceeded in the DCM (0.5 mL) solution of product. At 0 °C, trifluoroacetic acid (0.3 mL) was added dropwise and the resulted mixture was stirred at room temperature for 1 h. The solvent was evaporated under vacuo, and washed with diethyl ether (1 mL × 3) to give pure product as the TFA salt.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure II-1 for the Synthesis of 7-Bromo-4-phenoxyquinoline Intermediates</h4><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 7-Bromo-4-phenoxyquinoline</h5><div class="NLM_p last">7-Bromo-4-chloroquinoline (15.0 mg, 0.0623 mmol), phenol (5.9 mg, 0.062 mmol), and K<sub>2</sub>CO<sub>3</sub> (21.5 mg, 0.156 mmol) were placed in a round-bottom flask. The reagent mixture was dissolved in <i>N</i>,<i>N</i>-dimethylformamide under N<sub>2</sub> atmosphere, and the reaction mixture was stirred overnight at 140 °C. After cooling to room temperature, the mixture was diluted with EtOAc and H<sub>2</sub>O, and the organic materials were extracted with EtOAc (50 mL × 3). The combined organic phases were dried over anhydrous MgSO<sub>4</sub> and filtered. The organic layer was concentrated under reduced pressure and purified on flash column chromatography (dichloromethane/methanol = 40:1) to give desired product as a pale-yellow solid (15.0 mg, 80%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.60 (d, <i>J</i> = 5.3 Hz, 1H), 8.29 (d, <i>J</i> = 8.9 Hz, 1H), 8.17 (s, 1H), 7.74 (d, <i>J</i> = 8.9 Hz, 1H), 7.56–7.51 (m, 2H), 7.40–7.32 (m, 1H), 7.29–7.23 (m, 2H), 6.61 (d, <i>J</i> = 5.4 Hz, 1H).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure II-2 for Suzuki Coupling of 4-phenoxyquinoline Substrates</h4><div class="NLM_p last">The mixture of 7-bromo-4-phenoxyquinoline substrate (0.0500 mmol), <i>tert</i>-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate as a boronic ester reagent (0.060 mmol), Pd(dppf)Cl<sub>2</sub>.CH<sub>2</sub>Cl<sub>2</sub> (0.0025 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.165 mmol) in toluene:H<sub>2</sub>O (= 2:1, 1.5 mL) was stirred overnight at 90 °C. H<sub>2</sub>O were added, and the extraction was conducted with EtOAc (50 mL × 3). The combined organic phases were dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified on flash column chromatography (DCM/MeOH = 40:1) to give desired product. Inseparable impurity was purified with flash column chromatography (diethyl ether/EtOAc = 1:20). Additional deprotection of boc group was conducted with the solution of product in DCM (0.5 mL) in a 10 mL round-bottom flask. After cooling to 0 °C, trifluoroacetic acid (0.3 mL) was added dropwise and the resulted mixture was stirred at room temperature for 1 h. The solvent was evaporated under vacuo and washed with diethyl ether (1 mL × 3) to give desired product as the TFA salt.</div></div><div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-Phenylquinolin-4-amine (<b>1</b>)</h4><div class="NLM_p last">Compound <b>1</b> was prepared (11.7 mg, pale yellow solid, 58% yield) according to GP I-1 from 4-chloroquinoline (15.0 mg, 0.092 mmol) and aniline (9.2 μL, 0.10 mmol) as a starting material. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.35 (d, <i>J</i> = 5.8 Hz, 1H), 8.31 (d, <i>J</i> = 7.4 Hz, 1H), 7.88 (d, <i>J</i> = 8.5 Hz, 1H), 7.72 (dd, <i>J</i> = 8.4, 6.9 Hz, 1H), 7.58–7.49 (m, 1H), 7.47–7.33 (m, 4H), 7.21 (t, <i>J</i> = 7.2 Hz, 1H), 6.92 (d, <i>J</i> = 5.5 Hz, 1H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 151.3, 150.8, 149.2, 141.4, 131.0, 130.6, 128.7, 126.3, 126.0, 124.7, 122.7, 121.0, 102.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>15</sub>H<sub>13</sub>N<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 221.1073, found 221.1076.</div></div><div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 7-Bromo-<i>N</i>-phenylquinolin-4-amine (<b>2</b>)</h4><div class="NLM_p">Compound <b>2</b> was prepared (171.4 mg, yellow solid, 93%) according to GP I-1 from 7-bromo-4-chloroquinoline (150 mg, 0.619 mmol) and aniline (62.1 μL, 0.680 mmol) as a starting material. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.51 (d, <i>J</i> = 9.1 Hz, 1H), 8.37 (d, <i>J</i> = 7.1 Hz, 1H), 8.14 (s, 1H), 7.93 (d, <i>J</i> = 9.1 Hz, 1H), 7.60 (td, <i>J</i> = 7.3, 1.7 Hz, 2H), 7.53–7.41 (m, 3H), 6.89 (d, <i>J</i> = 7.1 Hz, 1H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 157.6, 144.1, 140.6, 138.1, 131.9, 131.3, 129.7, 129.4, 126.7, 126.1, 123.7, 117.6, 101.6. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>15</sub>H<sub>12</sub>BrN<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 299.0178, found 299.0193.</div><div class="NLM_p last">Compounds <b>3</b>–<b>10</b> and <b>12</b> were prepared by using a same procedure described for the synthesis of <b>2</b> as a GP I-1, followed by similar procedure to GP I-2.</div></div><div id="sec4_2_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>,7-Diphenylquinolin-4-amine (<b>3</b>)</h4><div class="NLM_p last">Compound <b>3</b> was prepared (4.6 mg, pale-yellow solid, 2 steps 29% yield) according to GP I. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1H), 8.52 (d, <i>J</i> = 8.9 Hz, 1H), 8.49 (d, <i>J</i> = 5.4 Hz, 1H), 8.14 (s, 1H), 7.91 (d, <i>J</i> = 8.7 Hz, 1H), 7.87 (d, <i>J</i> = 7.6 Hz, 2H), 7.55 (t, <i>J</i> = 7.6 Hz, 2H), 7.45 (t, <i>J</i> = 7.6 Hz, 3H), 7.40 (d, <i>J</i> = 7.8 Hz, 2H), 7.18 (t, <i>J</i> = 7.3 Hz, 1H), 6.93 (d, <i>J</i> = 5.4 Hz, 1H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.6, 148.5, 148.1, 141.1, 140.3, 139.2, 129.4, 129.1, 128.1, 127.0, 125.6, 124.0, 123.7, 123.1, 122.6, 118.7, 101.4. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>21</sub>H<sub>17</sub>N<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 297.1386, found 297.1409.</div></div><div id="sec4_2_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-Phenyl-7-(pyridin-4-yl)quinolin-4-amine (<b>4</b>)</h4><div class="NLM_p last">Compound <b>4</b> was prepared (3.9 mg, pale-yellow solid, 2 steps 24% yield) according to GP I. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.09 (s, 1H), 8.70 (d, <i>J</i> = 5.1 Hz, 2H), 8.54 (d, <i>J</i> = 8.8 Hz, 1H), 8.52 (d, <i>J</i> = 5.3 Hz, 1H), 8.30 (s, 1H), 7.98 (d, <i>J</i> = 8.6 Hz, 1H), 7.92 (d, <i>J</i> = 4.9 Hz, 2H), 7.44 (t, <i>J</i> = 7.7 Hz, 2H), 7.39 (d, <i>J</i> = 7.8 Hz, 2H), 7.17 (t, <i>J</i> = 7.3 Hz, 1H), 6.96 (d, <i>J</i> = 5.3 Hz, 1H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.5, 150.4, 149.2, 147.7, 146.2, 140.34, 137.7, 129.4, 127.1, 123.9, 123.4, 122.9, 122.5, 121.5, 120.0, 101.9. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>20</sub>H<sub>16</sub>N<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 298.1339, found 298.1362.</div></div><div id="sec4_2_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 7-(6-Aminopyridin-3-yl)-<i>N</i>-phenylquinolin-4-amine (<b>5</b>)</h4><div class="NLM_p last">Compound <b>5</b> was prepared (4.2 mg, ivory solid, 2 steps 25% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d,</i> methanol-<i>d</i><sub>4</sub> cosolvent) δ 8.37 (d, <i>J</i> = 5.5 Hz, 1H), 8.32 (s, 1H), 8.05 (d, <i>J</i> = 8.6 Hz, 1H), 8.00 (s, 1H), 7.81 (d, <i>J</i> = 8.7 Hz, 1H), 7.63 (d, <i>J</i> = 8.7 Hz, 1H), 7.36 (t, <i>J</i> = 7.7 Hz, 2H), 7.28 (s, 2H), 7.14 (t, <i>J</i> = 7.3 Hz, 1H), 6.88 (d, <i>J</i> = 5.5 Hz, 1H), 6.60 (d, <i>J</i> = 8.5 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.6, 151.0, 149.6, 147.5, 146.3, 140.6, 138.8, 135.6, 129.3, 124.1, 123.6, 122.9, 122.6, 122.3, 122.2, 118.2, 108.1, 101.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>20</sub>H<sub>17</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 313.1448, found 313.1458.</div></div><div id="sec4_2_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 7-(Furan-2-yl)-<i>N</i>-phenylquinolin-4-amine (<b>6</b>)</h4><div class="NLM_p last">Compound <b>6</b> was prepared (7.7 mg, yellowish-brown solid, 2 steps 50% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.32 (s, 1H), 8.49 (d, <i>J</i> = 8.9 Hz, 1H), 8.46 (d, <i>J</i> = 5.7 Hz, 1H), 8.14 (s, 1H), 7.94 (d, <i>J</i> = 8.8 Hz, 1H), 7.88 (dd, <i>J</i> = 1.8, 0.7 Hz, 1H), 7.53–7.42 (m, 2H), 7.42–7.35 (m, 2H), 7.25 (dd, <i>J</i> = 3.5, 0.8 Hz, 1H), 7.20 (tt, <i>J</i> = 7.2, 1.4 Hz, 1H), 6.87 (d, <i>J</i> = 5.6 Hz, 1H), 6.69 (dd, <i>J</i> = 3.4, 1.8 Hz, 1H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.1, 149.8, 148.9, 144.0, 139.8, 131.5, 129.5, 124.5, 123.3, 123.0, 121.0, 120.6, 118.2, 112.5, 108.2, 101.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>19</sub>H<sub>15</sub>N<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup> 287.1179, found 287.1199.</div></div><div id="sec4_2_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-Phenyl-7-(thiophen-2-yl)quinolin-4-amine (<b>7</b>)</h4><div class="NLM_p last">Compound <b>7</b> was prepared (6.3 mg, white solid, 2 steps 39% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>, methanol-<i>d</i><sub>4</sub> cosolvent) δ 8.35 (d, <i>J</i> = 5.5 Hz, 1H), 8.11 (s, 1H), 8.08 (d, <i>J</i> = 8.8 Hz, 1H), 7.73 (d, <i>J</i> = 8.8 Hz, 1H), 7.49 (dd, <i>J</i> = 3.6, 1.1 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5, 7.3 Hz, 2H), 7.34 (dd, <i>J</i> = 5.1, 1.1 Hz, 1H), 7.32–7.26 (m, 2H), 7.19–7.13 (m, 1H), 7.10 (dd, <i>J</i> = 5.1, 3.6 Hz, 1H), 6.89 (d, <i>J</i> = 5.5 Hz, 1H). <sup>13</sup>C NMR (100 MHz, chloroform-<i>d</i>, methanol-<i>d</i><sub>4</sub> cosolvent) δ 150.9, 148.9, 148.8, 143.3, 139.9, 135.8, 129.7, 128.4, 126.0, 124.8, 124.5, 124.5, 123.6, 123.1, 121.6, 119.0, 101.8. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>19</sub>H<sub>15</sub>N<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup> 303.0950, found 303.0975.</div></div><div id="sec4_2_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-Phenyl-7-(1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared (6.6 mg, white solid, 2 steps 43% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.06 (s, 1H), 8.93 (s, 1H), 8.42 (d, <i>J</i> = 5.3 Hz, 1H), 8.36 (d, <i>J</i> = 8.8 Hz, 2H), 8.14 (s, 1H), 8.09 (s, 1H), 7.83 (d, <i>J</i> = 8.7 Hz, 1H), 7.47–7.30 (m, 4H), 7.14 (tt, <i>J</i> = 7.1, 1.5 Hz, 1H), 6.86 (d, <i>J</i> = 5.3 Hz, 1H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.9, 149.6, 147.5, 140.6, 136.7, 133.8, 129.3, 126.3, 123.6, 123.6, 122.9, 122.6, 122.4, 120.6, 117.9, 101.0. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>18</sub>H<sub>15</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 287.1291, found 287.1302.</div></div><div id="sec4_2_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 7-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-phenylquinolin-4-amine (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was prepared (12.4 mg, pale-yellow solid, 2 steps 76% yield) according to GP I. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.12 (s, 1H), 8.42 (d, <i>J</i> = 5.4 Hz, 1H), 8.40 (d, <i>J</i> = 8.8 Hz, 1H), 8.37 (s, 1H), 8.07 (s, 1H), 8.03 (s, 1H), 7.80 (d, <i>J</i> = 8.7 Hz, 1H), 7.43 (t, <i>J</i> = 7.7 Hz, 2H), 7.38 (d, <i>J</i> = 7.8 Hz, 2H), 7.17 (t, <i>J</i> = 7.3 Hz, 1H), 6.85 (d, <i>J</i> = 5.5 Hz, 1H), 3.91 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.2, 148.6, 148.1, 140.3, 136.6, 133.9, 129.4, 128.7, 123.9, 122.9, 122.8, 122.6, 122.6, 121.2, 117.7, 100.9, 38.8. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>19</sub>H<sub>17</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 301.1448, found 301.1467.</div></div><div id="sec4_2_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 7-(1-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-phenylquinolin-4-amine (<b>10</b>)</h4><div class="NLM_p last">Compound <b>10</b> was prepared (8.1 mg, pale-yellow solid, 2 steps 48% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.09 (s, 1H), 8.57–8.45 (m, 2H), 7.93 (s, 1H), 7.64 (d, <i>J</i> = 8.7 Hz, 1H), 7.57 (d, <i>J</i> = 1.8 Hz, 1H), 7.44 (dd, <i>J</i> = 8.5, 7.1 Hz, 2H), 7.41–7.34 (m, 2H), 7.20–7.12 (m, 1H), 6.96 (d, <i>J</i> = 5.3 Hz, 1H), 6.54 (d, <i>J</i> = 1.8 Hz, 1H), 4.25 (q, <i>J</i> = 7.2 Hz, 2H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 151.5, 148.8, 147.7, 141.7, 140.4, 138.3, 131.1, 129.4, 128.4, 124.8, 123.9, 123.0, 122.5, 119.3, 106.5, 101.9, 44.3, 15.5. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>20</sub>H<sub>19</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 315.1604, found 315.1627.</div></div><div id="sec4_2_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-Phenyl-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> was prepared (11.1 mg, pale-yellow solid, 3 steps 69% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.55 (d, <i>J</i> = 8.8 Hz, 1H), 8.43 (s, 1H), 8.32 (d, <i>J</i> = 7.1 Hz, 1H), 8.16 (s, 1H), 8.09–7.93 (m, 2H), 7.59 (dd, <i>J</i> = 8.4, 7.1 Hz, 2H), 7.52–7.22 (m, 3H), 6.84 (d, <i>J</i> = 7.0 Hz, 1H), 4.67 (dt, <i>J</i> = 9.8, 4.8 Hz, 1H), 3.88–3.52 (m, 2H), 3.28–3.16 (m, 2H), 2.47–2.18 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 155.7, 142.1, 139.4, 138.7, 137.3, 137.0, 129.8, 127.7, 127.4, 125.3, 125.1, 123.4, 120.5, 115.5, 114.1, 99.4, 55.8, 42.7, 28.7. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>24</sub>N<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 370.2026, found 370.2070.</div></div><div id="sec4_2_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-Phenyl-7-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was prepared (7.8 mg, pale-yellow solid, 2 steps 30% yield) according to GP I. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.08 (s, 1H), 8.51 (s, 1H), 8.42 (d, <i>J</i> = 5.4 Hz, 1H), 8.39 (d, <i>J</i> = 8.8 Hz, 1H), 8.11 (s, 1H), 8.07 (s, 1H), 7.83 (d, <i>J</i> = 8.7 Hz, 1H), 7.43 (t, <i>J</i> = 7.9 Hz, 2H), 7.38 (d, <i>J</i> = 7.8 Hz, 2H), 7.20–7.11 (m, 1H), 6.85 (d, <i>J</i> = 5.3 Hz, 1H), 4.45 (tt, <i>J</i> = 10.4, 4.7 Hz, 1H), 4.05–3.91 (m, 2H), 3.50 (td, <i>J</i> = 11.6, 2.6 Hz, 2H), 2.11–1.91 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 150.3, 148.8, 148.0, 140.3, 136.3, 133.9, 129.4, 125.9, 123.9, 122.8, 122.8, 122.7, 122.6, 120.9, 117.8, 100.9, 65.9, 57.4, 32.9. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 371.1866, found 371.1872.</div></div><div id="sec4_2_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Procedure for the Synthesis of 4-Benzyl-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>13</b>)</h4><div class="NLM_p">Step 1: The mixture of 7-methoxyquinolin-4-ol (100 mg, 0.57 mmol) and phosphoryl tribromide (1.7 g, 5.9 mmol) was heated to 110 °C for 3 h. The reaction mixture was dropped in ice–water, and the mixture was basified with NH<sub>4</sub>OH to pH 8 and extraction proceeded with EtOAc several times. The combined organic phases were dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified with flash column chromatography (EtOAc/hexane = 1:3 to 1:1) to give 4-bromo-7-methoxyquinoline (white solid, 97.3 mg, 72%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.55 (d, <i>J</i> = 4.9 Hz, 1H), 8.03 (d, <i>J</i> = 9.2 Hz, 1H), 7.52 (d, <i>J</i> = 4.8 Hz, 1H), 7.39 (s, 1H), 7.25 (d, <i>J</i> = 9.3 Hz, 1H), 3.95 (s, 3H).</div><div class="NLM_p">Step 2: A solution of 4-bromo-7-methoxyquinoline (20.0 mg, 0.0840 mmol), 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (22.4 μL, 0.1008 mmol), K<sub>2</sub>CO<sub>3</sub> (34.8 mg, 0.252 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (4.9 mg, 0.0042 mmol) in 1,4-dioxane:H<sub>2</sub>O = 4:1 (1.25 mL) was heated to 100 °C for 6 h in a sealed tube. The resulting mixture was cooled to rt and extracted with EtOAc. The combined organic layer was dried with MgSO<sub>4</sub> and concentrated in vacuo. The residue was purified with flash column chromatography (hexane/EtOAc = 1:1) to give 4-benzyl-7-methoxyquinoline (colorless oil, 13.4 mg, 64%). <sup>1</sup>H NMR (600 MHz, chloroform-<i>d</i>) δ 8.74 (d, <i>J</i> = 4.5 Hz, 1H), 7.91 (d, <i>J</i> = 9.2 Hz, 1H), 7.46 (s, 1H), 7.30 (t, <i>J</i> = 7.5 Hz, 2H), 7.23 (t, <i>J</i> = 7.5 Hz, 1H), 7.20–7.14 (m, 3H), 7.02 (d, <i>J</i> = 4.5 Hz, 1H), 4.40 (s, 2H), 3.95 (s, 3H).</div><div class="NLM_p">Step 3: A solution of 4-benzyl-7-methoxyquinoline (97.4 mg, 0.391 mmol) in anhydrous DCM was cooled to 0 °C under N<sub>2</sub>. A 1 M solution of tribromoborane in DCM (3.9 mL, 3.9 mmol) was slowly added to the reaction mixture, and the reaction mixture was allowed to warm to rt over 2 h. The resulting solution was maintained at ambient temperature for an additional 20 h. The reaction was quenched by addition of ice, and the mixture was diluted with DCM and H<sub>2</sub>O. The organic materials were extracted with DCM (100 mL × 3) and washed with saturated NaHCO<sub>3</sub> (aq) followed by drying over Na<sub>2</sub>SO<sub>4</sub>. The filtered organic layer was concentrated under vacuo. The residue was washed with small portion of DCM (1 mL × 3), and the resulting solid was obtained as the desired product, 4-benzylquinolin-7-ol (beige solid, 74.9 mg, 81%). <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.82 (d, <i>J</i> = 5.9 Hz, 1H), 8.46 (d, <i>J</i> = 9.4 Hz, 1H), 7.55 (d, <i>J</i> = 5.9 Hz, 1H), 7.49 (d, <i>J</i> = 9.4 Hz, 1H), 7.39 (s, 1H), 7.39–7.23 (m, 5H), 4.72 (s, 2H).</div><div class="NLM_p">Step 4: The mixture of 4-benzylquinolin-7-ol (10.0 mg, 0.0425 mmol), 1,1,1-trifluoro-<i>N</i>-phenyl-<i>N</i>-((trifluoromethyl)sulfonyl)methanesulfonamide (15.2 mg, 0.0425 mmol), and K<sub>2</sub>CO<sub>3</sub> (17.6 mg, 0.128 mmol) in dry THF (0.5 mL) was stirred for 20 min at 120 °C under μW irradition. The mixture was filtered through a Celite pad and washed with dichloromethane:methanol = 15:1. The filtrate was concentrated under reduced pressure and purified by a flash column chromatography (EtOAc/hexane = 1:10 to 1:4) to give 4-benzylquinolin-7-yl trifluoromethanesulfonate (white solid, 7.8 mg, 50%). <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.86 (d, <i>J</i> = 4.7 Hz, 1H), 8.36 (d, <i>J</i> = 9.4 Hz, 1H), 8.00 (s, 1H), 7.59 (d, <i>J</i> = 9.4 Hz, 1H), 7.40 (d, <i>J</i> = 4.7 Hz, 1H), 7.35–7.27 (m, 2H), 7.27–7.19 (m, 3H), 4.54 (s, 2H).</div><div class="NLM_p last">Step 5: Compound <b>13</b> (yellow solid, 2.3 mg, 2 steps 46% yield) was prepared by using GP I-2. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.94 (d, <i>J</i> = 5.5 Hz, 1H), 8.48 (d, <i>J</i> = 8.9 Hz, 1H), 8.44 (s, 1H), 8.31 (s, 1H), 8.18 (d, <i>J</i> = 0.7 Hz, 1H), 8.14 (d, <i>J</i> = 8.9 Hz, 1H), 7.63 (d, <i>J</i> = 5.6 Hz, 1H), 7.39–7.22 (m, 5H), 4.72 (s, 2H), 4.66 (tt, <i>J</i> = 9.9, 5.2 Hz, 1H), 3.66–3.51 (m, 2H), 3.29–3.19 (m, 2H), 2.45–2.24 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 159.6, 146.2, 142.0, 139.8, 138.9, 138.7, 130.2, 130.1, 129.0, 128.7, 128.3, 127.6, 127.4, 122.6, 122.0, 117.4, 57.3, 44.1, 39.4, 30.1. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>25</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 369.2074, found 369.2095.</div></div><div id="sec4_2_5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Phenoxy-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>14</b>)</h4><div class="NLM_p last">Compound <b>14</b> was prepared (15.7 mg, pale-yellow solid, 3 steps 46% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.84 (d, <i>J</i> = 6.6 Hz, 1H), 8.63 (d, <i>J</i> = 8.8 Hz, 1H), 8.49 (s, 1H), 8.29 (s, 1H), 8.25–8.17 (m, 2H), 7.64 (dd, <i>J</i> = 8.5, 7.4 Hz, 2H), 7.54–7.45 (m, 1H), 7.42–7.37 (m, 2H), 6.91 (d, <i>J</i> = 6.6 Hz, 1H), 4.68 (tt, <i>J</i> = 9.9, 5.1 Hz, 1H), 3.71–3.54 (m, 2H), 3.30–3.19 (m, 2H), 2.47–2.28 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 169.6, 154.2, 147.9, 142.7, 141.2, 139.0, 132.1, 129.2, 128.7, 128.4, 125.1, 122.2, 121.9, 120.4, 115.8, 104.9, 57.3, 44.1, 30.1. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 371.1866, found 371.1918.</div></div><div id="sec4_2_5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(2-Fluorophenyl)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>15</b>)</h4><div class="NLM_p last">Compound <b>15</b> was prepared (15.3 mg, white solid, 3 steps 53% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.56 (d, <i>J</i> = 8.8 Hz, 1H), 8.43 (s, 1H), 8.39 (d, <i>J</i> = 6.9 Hz, 1H), 8.17 (s, 1H), 8.07 (d, <i>J</i> = 9.7 Hz, 2H), 7.62–7.49 (m, 2H), 7.46–7.36 (m, 2H), 6.59 (d, <i>J</i> = 7.0 Hz, 1H), 4.67 (tt, <i>J</i> = 10.0, 5.1 Hz, 1H), 3.69–3.56 (m, 2H), 3.28–3.16 (m, 2H), 2.46–2.28 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 159.0 (d, <i>J</i> = 249.8 Hz), 157.3, 143.9, 140.8, 140.2, 138.8, 131.5 (d, <i>J</i> = 7.9 Hz), 129.8, 128.9, 126.8 (d, <i>J</i> = 3.9 Hz), 126.7, 125.9 (d, <i>J</i> = 12.7 Hz), 124.8, 121.9, 118.2 (d, <i>J</i> = 19.8 Hz), 116.8, 115.6, 101.4, 57.3, 44.1, 30.2. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.9, −122.1. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 388.1932, found 388.1916.</div></div><div id="sec4_2_5_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-(2-Fluorophenoxy)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was prepared (11.2 mg, white solid, 3 steps 29% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.83 (d, <i>J</i> = 6.2 Hz, 1H), 8.58 (d, <i>J</i> = 8.8 Hz, 1H), 8.46 (s, 1H), 8.27 (s, 1H), 8.20 (s, 1H), 8.16 (d, <i>J</i> = 8.8 Hz, 1H), 7.56–7.36 (m, 4H), 6.87 (d, <i>J</i> = 6.2 Hz, 1H), 4.67 (dq, <i>J</i> = 9.9, 5.2 Hz, 1H), 3.71–3.54 (m, 2H), 3.30–3.17 (m, 2H), 2.57–2.23 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 167.7, 155.3 (d, <i>J</i> = 249.4 Hz), 148.8, 144.0, 141.2 (d, <i>J</i> = 12.4 Hz), 140.6, 139.0, 130.1 (d, <i>J</i> = 6.9 Hz), 129.1, 128.3, 127.3 (d, <i>J</i> = 3.8 Hz), 124.7 (d, <i>J</i> = 2.9 Hz), 122.1, 120.0, 118.9 (d, <i>J</i> = 17.8 Hz), 117.1, 111.4, 104.5, 57.3, 44.1, 30.2. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.9, −131.7. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>22</sub>FN<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 389.1772, found 389.1781.</div></div><div id="sec4_2_5_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(3-Fluorophenyl)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was prepared (9.3 mg, pale-yellow solid, 3 steps 48% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.54 (d, <i>J</i> = 9.2 Hz, 1H), 8.44 (s, 1H), 8.39 (d, <i>J</i> = 7.0 Hz, 1H), 8.17 (s, 1H), 8.10–8.01 (m, 2H), 7.60 (td, <i>J</i> = 8.2, 6.4 Hz, 1H), 7.38–7.28 (m, 2H), 7.21 (td, <i>J</i> = 8.2, 2.4 Hz, 1H), 6.95 (d, <i>J</i> = 7.0 Hz, 1H), 4.67 (tt, <i>J</i> = 9.9, 5.2 Hz, 1H), 3.71–3.53 (m, 2H), 3.29–3.20 (m, 2H), 2.54–2.22 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 164.9 (d, <i>J</i> = 246.8 Hz), 156.6, 144.1, 141.2, 140.4 (d, <i>J</i> = 9.8 Hz), 140.1, 138.8, 132.8 (d, <i>J</i> = 9.2 Hz), 128.8, 126.6, 124.8, 122.3 (d, <i>J</i> = 3.0 Hz), 121.9, 117.2, 115.8, 115.6 (d, <i>J</i> = 21.3 Hz), 113.7 (d, <i>J</i> = 24.0 Hz), 101.3, 57.3, 44.1, 30.2. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.9, −112.4. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 388.1932, found 388.1990.</div></div><div id="sec4_2_5_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-(3-Fluorophenoxy)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>18</b>)</h4><div class="NLM_p last">Compound <b>18</b> was prepared (4.8 mg, white solid, 3 steps 53% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.86 (d, <i>J</i> = 6.5 Hz, 1H), 8.60 (d, <i>J</i> = 8.8 Hz, 1H), 8.48 (s, 1H), 8.28 (s, 1H), 8.24–8.16 (m, 2H), 7.71–7.58 (m, 1H), 7.31–7.19 (m, 3H), 6.98 (d, <i>J</i> = 6.5 Hz, 1H), 4.68 (tt, <i>J</i> = 9.9, 4.9 Hz, 1H), 3.70–3.51 (m, 2H), 3.29–3.20 (m, 2H), 2.47–2.25 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 167.2, 165.1 (d, <i>J</i> = 248.4 Hz), 155.5 (d, <i>J</i> = 11.0 Hz), 149.4, 145.2, 139.8, 138.8, 133.2 (d, <i>J</i> = 9.5 Hz), 128.8, 127.8, 124.6, 122.3, 120.6, 118.2, 118.2, 115.1 (d, <i>J</i> = 21.2 Hz), 110.2 (d, <i>J</i> = 24.9 Hz), 105.2, 57.3, 44.1, 30.2. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.7, −110.7. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>22</sub>FN<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 389.1772, found 389.1782.</div></div><div id="sec4_2_5_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(4-Fluorophenyl)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>19</b>)</h4><div class="NLM_p last">Compound <b>19</b> was prepared (11.6 mg, pale-yellow solid, 3 steps 70% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.53 (d, <i>J</i> = 9.4 Hz, 1H), 8.43 (s, 1H), 8.34 (d, <i>J</i> = 7.1 Hz, 1H), 8.16 (s, 1H), 8.10–8.02 (m, 2H), 7.55–7.45 (m, 2H), 7.33 (t, <i>J</i> = 8.6 Hz, 2H), 6.76 (d, <i>J</i> = 7.0 Hz, 1H), 4.67 (dq, <i>J</i> = 9.8, 4.8 Hz, 1H), 3.67–3.53 (m, 2H), 3.29–3.22 (m, 2H), 2.50–2.23 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 163.3 (d, <i>J</i> = 246.6 Hz), 157.3, 143.6, 140.8, 140.2, 138.8, 134.6, 129.1 (d, <i>J</i> = 8.7 Hz), 128.9, 126.6, 124.8, 121.9, 118.0 (d, <i>J</i> = 23.2 Hz), 116.8, 115.5, 100.8, 57.3, 44.1, 30.2. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.9, −115.3. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 388.1932, found 388.1945.</div></div><div id="sec4_2_5_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(4-Fluorophenoxy)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>20</b>)</h4><div class="NLM_p last">Compound <b>20</b> was prepared (8.3 mg, white solid, 3 steps 27% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.86 (d, <i>J</i> = 6.4 Hz, 1H), 8.61 (d, <i>J</i> = 8.8 Hz, 1H), 8.49 (d, <i>J</i> = 2.3 Hz, 1H), 8.29 (s, 1H), 8.24–8.12 (m, 2H), 7.48–7.39 (m, 2H), 7.40–7.29 (m, 2H), 6.93 (d, <i>J</i> = 6.5 Hz, 1H), 4.68 (tt, <i>J</i> = 10.1, 5.1 Hz, 1H), 3.74–3.54 (m, 2H), 3.28–3.21 (m, 2H), 2.48–2.25 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 169.3, 162.6 (d, <i>J</i> = 245.3 Hz), 150.2, 148.2, 143.0, 141.0, 139.0, 129.1, 128.4, 125.0, 124.2 (d, <i>J</i> = 8.8 Hz), 121.9, 120.4, 118.7 (d, <i>J</i> = 24.2 Hz), 116.2, 104.8, 57.3, 44.2, 30.1. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.9, −116.6. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>22</sub>FN<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 389.1772, found 389.1786.</div></div><div id="sec4_2_5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(3,4-Difluorophenyl)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>21</b>)</h4><div class="NLM_p last">Compound <b>21</b> was prepared (14.7 mg, yellow solid, 3 steps 63% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.51 (d, <i>J</i> = 8.9 Hz, 1H), 8.43 (s, 1H), 8.39 (d, <i>J</i> = 7.0 Hz, 1H), 8.17 (s, 1H), 8.06 (d, <i>J</i> = 8.1 Hz, 2H), 7.55–7.42 (m, 2H), 7.37–7.27 (m, 1H), 6.88 (d, <i>J</i> = 6.9 Hz, 1H), 4.67 (tt, <i>J</i> = 10.0, 5.1 Hz, 1H), 3.72–3.56 (m, 2H), 3.29–3.18 (m, 2H), 2.48–2.23 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 157.0, 152.1 (dd, <i>J</i> = 249.5, 13.8 Hz), 150.9 (dd, <i>J</i> = 248.1, 12.6 Hz), 144.0, 140.9, 140.2, 138.8, 135.3 (d, <i>J</i> = 3.6 Hz), 128.9, 126.7, 124.8, 123.7 (dd, <i>J</i> = 6.6, 3.5 Hz), 121.8, 119.8 (d, <i>J</i> = 18.6 Hz), 117.0, 116.5 (d, <i>J</i> = 19.4 Hz), 115.6, 101.1, 57.3, 44.1, 30.2. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −76.9, −136.8 (d, <i>J</i> = 20.8 Hz), −140.5 (d, <i>J</i> = 20.8 Hz). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>22</sub>F<sub>2</sub>N<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 406.1838, found 406.1840.</div></div><div id="sec4_2_5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-(3,4-Difluorophenoxy)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>22</b>)</h4><div class="NLM_p last">Compound <b>22</b> was prepared (0.6 mg, pale-yellow solid, 3 steps 28% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.89 (d, <i>J</i> = 6.6 Hz, 1H), 8.59 (d, <i>J</i> = 8.8 Hz, 1H), 8.49 (s, 1H), 8.31 (s, 1H), 8.26–8.18 (m, 2H), 7.61–7.45 (m, 2H), 7.27 (dtd, <i>J</i> = 9.1, 3.2, 1.6 Hz, 1H), 7.03 (d, <i>J</i> = 6.6 Hz, 1H), 4.68 (tt, <i>J</i> = 9.9, 5.1 Hz, 1H), 3.68–3.55 (m, 2H), 3.30–3.20 (m, 2H), 2.52–2.24 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 169.1, 152.3 (dd, <i>J</i> = 251.1, 14.3 Hz), 150.6 (dd, <i>J</i> = 247.3, 12.4 Hz), 149.8 (dd, <i>J</i> = 8.6, 3.2 Hz), 148.0, 142.7, 141.3, 139.0, 129.2, 128.6, 124.0, 121.8, 120.3, 120.1 (d, <i>J</i> = 19.5 Hz), 119.2 (dd, <i>J</i> = 6.7, 3.9 Hz), 115.8, 112.72 (d, <i>J</i> = 20.5 Hz), 105.0, 57.3, 44.1, 30.1. <sup>19</sup>F NMR (376 MHz, methanol-<i>d</i><sub>4</sub>) δ −77.0, −135.8 (d, <i>J</i> = 20.6 Hz), −143.0 (d, <i>J</i> = 20.8 Hz). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 407.1678, found 407.1697.</div></div><div id="sec4_2_5_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 7-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-(<i>p</i>-tolyl)quinolin-4-amine (<b>23</b>)</h4><div class="NLM_p last">Compound <b>23</b> was prepared (14.7 mg, pale-brown solid, 3 steps 67% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.52 (d, <i>J</i> = 9.1 Hz, 1H), 8.42 (s, 1H), 8.30 (d, <i>J</i> = 7.1 Hz, 1H), 8.15 (s, 1H), 8.07–7.98 (m, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 2H), 7.34 (d, <i>J</i> = 8.1 Hz, 2H), 6.78 (d, <i>J</i> = 7.1 Hz, 1H), 4.66 (dq, <i>J</i> = 10.2, 5.5 Hz, 1H), 3.68–3.55 (m, 2H), 3.28–3.17 (m, 2H), 2.43 (s, 3H), 2.41–2.27 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 157.2, 143.4, 140.8, 140.0, 139.4, 138.7, 135.8, 131.8, 128.8, 126.6, 126.4, 124.8, 121.9, 116.9, 115.6, 100.8, 57.3, 44.1, 30.2, 21.1. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>26</sub>N<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 384.2183, found 384.2186.</div></div><div id="sec4_2_5_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 7-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)-4-(<i>p</i>-tolyloxy)quinoline (<b>24</b>)</h4><div class="NLM_p last">Compound <b>24</b> was prepared (15.7 mg, pale-yellow solid, 3 steps 53% yield) according to GP II. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.83 (d, <i>J</i> = 6.4 Hz, 1H), 8.60 (d, <i>J</i> = 8.8 Hz, 1H), 8.48 (s, 1H), 8.28 (s, 1H), 8.20 (d, <i>J</i> = 9.8 Hz, 2H), 7.43 (d, <i>J</i> = 8.0 Hz, 2H), 7.25 (d, <i>J</i> = 8.0 Hz, 2H), 6.90 (d, <i>J</i> = 6.4 Hz, 1H), 4.68 (tt, <i>J</i> = 9.8, 4.5 Hz, 1H), 3.68–3.58 (m, 2H), 3.30–3.22 (m, 2H), 2.45 (s, 3H), 2.44–2.28 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 169.7, 152.0, 147.9, 142.8, 141.1, 139.0, 138.8, 132.5, 129.1, 128.3, 125.1, 121.9, 121.8, 120.4, 115.9, 104.8, 57.3, 44.1, 30.1, 21.0. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 385.2023, found 385.2028.</div></div><div id="sec4_2_5_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-((7-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-yl)amino)benzonitrile (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was prepared (3.3 mg, pale-yellow solid, 3 steps 49% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.55 (d, <i>J</i> = 8.9 Hz, 1H), 8.45 (d, <i>J</i> = 7.0 Hz, 1H), 8.44 (s, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 8.07 (d, <i>J</i> = 8.9 Hz, 1H), 7.91 (d, <i>J</i> = 8.5 Hz, 2H), 7.68 (d, <i>J</i> = 8.5 Hz, 2H), 7.11 (d, <i>J</i> = 6.9 Hz, 1H), 4.67 (tt, <i>J</i> = 10.0, 5.3 Hz, 1H), 3.71–3.47 (m, 2H), 3.30–3.17 (m, 2H), 2.47–2.24 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 156.0, 144.1, 143.2, 140.9, 140.4, 138.8, 135.2, 128.9, 127.0, 126.3, 124.9, 121.7, 119.2, 117.6, 115.5, 111.5, 101.8, 57.3, 44.1, 30.1. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup> [M + H]<sup>+</sup> 395.1979, found 395.2017.</div></div><div id="sec4_2_5_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-((7-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-yl)oxy)benzonitrile (<b>26</b>)</h4><div class="NLM_p last">Compound <b>26</b> was prepared (8.6 mg, white solid, 3 steps 46% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.83 (d, <i>J</i> = 6.0 Hz, 1H), 8.49 (d, <i>J</i> = 8.8 Hz, 1H), 8.43 (s, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 8.11 (d, <i>J</i> = 8.8 Hz, 1H), 7.97 (d, <i>J</i> = 8.9 Hz, 2H), 7.54 (d, <i>J</i> = 8.7 Hz, 2H), 6.95 (d, <i>J</i> = 6.0 Hz, 1H), 4.67 (tt, <i>J</i> = 9.9, 4.8 Hz, 1H), 3.70–3.55 (m, 2H), 3.30–3.22 (m, 2H), 2.52–2.28 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 166.3, 158.2, 149.6, 145.5, 139.9, 138.9, 136.3, 128.9, 128.0, 124.5, 123.2, 122.2, 120.8, 118.9, 118.4, 111.8, 106.0, 57.3, 44.1, 30.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>22</sub>N<sub>5</sub>O<sup>+</sup> [M + H]<sup>+</sup> 396.1819, found 396.1828.</div></div><div id="sec4_2_5_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(4-Methoxyphenyl)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-amine (<b>27</b>)</h4><div class="NLM_p last">Compound <b>27</b> was prepared (13.2 mg, yellow solid, 3 steps 45% yield) according to GP I. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.51 (d, <i>J</i> = 9.3 Hz, 1H), 8.42 (s, 1H), 8.28 (d, <i>J</i> = 7.1 Hz, 1H), 8.15 (s, 1H), 8.06–7.98 (m, 2H), 7.38 (d, <i>J</i> = 8.8 Hz, 2H), 7.12 (d, <i>J</i> = 8.8 Hz, 2H), 6.71 (d, <i>J</i> = 7.1 Hz, 1H), 4.66 (tt, <i>J</i> = 10.0, 5.4 Hz, 1H), 3.87 (s, 3H), 3.67–3.55 (m, 2H), 3.29–3.19 (m, 2H), 2.47–2.25 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 160.9, 157.5, 143.3, 140.7, 140.0, 138.7, 130.8, 128.8, 128.3, 126.4, 124.8, 121.9, 116.7, 116.4, 115.5, 100.7, 57.3, 56.1, 44.1, 30.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sup>+</sup> [M + H]<sup>+</sup> 400.2132, found 400.2132.</div></div><div id="sec4_2_5_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-(4-Methoxyphenoxy)-7-(1-(piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinoline (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> was prepared (8.5 mg, white solid, 3 steps 37% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.77 (d, <i>J</i> = 6.3 Hz, 1H), 8.57 (d, <i>J</i> = 8.8 Hz, 1H), 8.44 (s, 1H), 8.22 (s, 1H), 8.19 (s, 1H), 8.13 (d, <i>J</i> = 8.8 Hz, 1H), 7.27 (d, <i>J</i> = 9.1 Hz, 2H), 7.13 (d, <i>J</i> = 9.1 Hz, 2H), 6.82 (d, <i>J</i> = 6.3 Hz, 1H), 4.67 (tt, <i>J</i> = 9.9, 4.8 Hz, 1H), 3.88 (s, 3H), 3.66–3.55 (m, 2H), 3.29–3.20 (m, 2H), 2.49–2.28 (m, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 167.6, 159.7, 150.1, 147.9, 139.0, 138.8, 128.6, 127.2, 127.2, 124.5, 123.2, 122.6, 120.7, 119.3, 116.7, 104.6, 57.2, 56.2, 44.1, 30.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 401.1972, found 401.1966.</div></div><div id="sec4_2_5_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-((7-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-yl)amino)phenol (<b>29</b>)</h4><div class="NLM_p last">Compound <b>29</b> was prepared (16.1 mg, yellow solid, 3 steps 66% yield) according to GP I. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.49 (d, <i>J</i> = 9.2 Hz, 1H), 8.41 (s, 1H), 8.26 (d, <i>J</i> = 7.1 Hz, 1H), 8.14 (s, 1H), 8.02–7.97 (m, 2H), 7.26 (d, <i>J</i> = 8.7 Hz, 2H), 6.96 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (d, <i>J</i> = 7.1 Hz, 1H), 4.66 (tt, <i>J</i> = 9.9, 4.8 Hz, 1H), 3.66–3.56 (m, 2H), 3.30–3.20 (m, 2H), 2.45–2.29 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 158.8, 157.6, 143.1, 140.6, 140.0, 138.7, 129.6, 128.8, 128.4, 126.3, 124.8, 121.9, 117.7, 116.6, 115.4, 100.7, 57.3, 44.1, 30.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sup>+</sup> [M + H]<sup>+</sup> 386.1975, found 386.1954.</div></div><div id="sec4_2_5_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-((7-(1-(Piperidin-4-yl)-1<i>H</i>-pyrazol-4-yl)quinolin-4-yl)oxy)phenol (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was prepared (4.8 mg, white solid, 3 steps 37% yield) according to GP II. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.80 (d, <i>J</i> = 6.5 Hz, 1H), 8.59 (d, <i>J</i> = 8.8 Hz, 1H), 8.46 (s, 1H), 8.25 (s, 1H), 8.20 (s, 1H), 8.17 (d, <i>J</i> = 8.9 Hz, 1H), 7.17 (d, <i>J</i> = 8.9 Hz, 2H), 6.97 (d, <i>J</i> = 8.9 Hz, 2H), 6.90 (d, <i>J</i> = 6.5 Hz, 1H), 4.67 (tt, <i>J</i> = 9.9, 5.0 Hz, 1H), 3.69–3.51 (m, 2H), 3.30–3.21 (m, 2H), 2.46–2.27 (m, 4H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 168.8, 157.6, 149.1, 146.8, 144.8, 139.8, 138.8, 128.8, 127.6, 124.7, 123.1, 122.3, 120.5, 118.0, 117.9, 104.6, 57.2, 44.1, 30.2. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> calcd C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 387.1816, found 387.1806.</div></div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Enzymatic Assay</h3><div class="NLM_p last">The inhibitory activities of all compounds with respect to ALK and ALK (L1196M) were measured by Reaction Biology Corp. (Malvern, PA, USA) by means of radiometric kinase assays ([γ-<sup>33</sup>P]ATP). The enzymatic activity of ALK and ALK (L1196M) was monitored using 20 μM of peptide substrate [YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE] dissolved in the freshly prepared reaction buffer (20 mM HEPES (pH 7.5), 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.02% BRIJ-35, 0.02 mg/mL BSA, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM DTT, 1% DMSO). Each putative ALK and ALK (L1196M) inhibitor was dissolved in 100% DMSO at the specific concentration and diluted in serial manner with epMotion 5070 in DMSO. Then 4 nM of ALK and ALK (L1196M) (Invitrogen) was added into the reaction buffer including 20 μM of peptide substrate. After delivering the candidate inhibitor dissolved in DMSO into the kinase reaction mixture by Acoustic Technology (Echo550; nanoliter range), the reaction mixture was incubated for 20 min at room temperature. To initiate the enzymatic reaction, <sup>33</sup>P-ATP with specific activity of 10 μCi/μL was delivered into the reaction mixture to reach the final ATP concentration of 10 μM. Radioactivity was then monitored by the filter binding method after the incubation of reaction mixture for 2 h at room temperature. At given concentrations of the inhibitor, biochemical potency was measured by the percent remaining kinase activity with respect to vehicle (dimethyl sulfoxide) reaction. Curve fits and IC<sub>50</sub> values were then obtained by using the PRISM program (GraphPad Software). The ATP-competitive inhibitor staurosporine (STSP) was employed as the positive control in this study because of its high biochemical potency against various kinases including ALK and ALK (L1196M). Kinase panel assays were carried out at Ambit Bioscience Corp. (San Diego, CA, USA) using the potent and broad-spectrum kinase inhibitor (staurosporine) as the reference.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Cells and Materials</h3><div class="NLM_p last">H2228 human lung cancer cells were purchased from the American Type Culture Collection (ATCC Manassas, VA). H2228 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. Crizotinib resistant subline and H2228 CR cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin/streptomycin, and 100 nM crizotinib. Cell culture media, FBS, penicillin/streptomycin, and other supplementary agents were purchased from GIBCO (Uxbridge, UK). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma-Aldrich (St. Louis, MO). All cell lines were maintained in a CO<sub>2</sub> incubator with a controlled humidified atmosphere composed of 95% air and 5% CO<sub>2</sub>. Crizotinib was purchased from LC laboratories (Woburn, MA) and dissolved in DMSO.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Generation of Crizotinib-Resistant Cells</h3><div class="NLM_p last">Crizotinib-resistant cells were generated as previously reported. In brief, H2228 CR cells were developed by chronic, repeated exposure to crizotinib. Over a period of 8 months, H2228 cells were continuously exposed to increasing concentrations of the drug in culture and the surviving cells were cloned. These cells could survive exposure >100 nM of crizotinib. In all studies, resistant cells were cultured in drug-free medium for >1 week to eliminate the effects of crizotinib.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Cell Growth Assay</h3><div class="NLM_p last">H2228 and H2228 CR were plated at a density of 4000 cells/well in 96-well plates and incubated for 24 h. The medium was then removed, and cells were treated with different concentrations of crizotinib and <b>30</b> for 72 h. Next, 20 μL of MTT solution (2 mg/mL) was added for 4 h at 37 °C in 5% CO<sub>2</sub> incubator. After the media was then removed, 200 μL of DMSO was added to each well, and the plate was incubated for an additional 4 h at 37 °C. The formazan crystals that formed in metabolically healthy cells were dissolved in DMSO (200 μL/well) with constant shaking for 30 min. Absorbance of the solution was then measured with a microplate reader at 540 nm.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Western Blotting</h3><div class="NLM_p last">H2228 and H2228CR were seeded in 10 cm plate dish and incubated overnight for attachment. Crizotinib and <b>30</b> were treated for 3 h in serum-free medium. Total cellular proteins were extracted with sterile RIPA lysis buffer (Biosesang, Korea) consisting of 150 mmol/L NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mmol/L Tris-HCl pH 7.5, and 2 mmol/L EDTA supplemented with Xpert Protease and Phosphatase Inhibitor cocktail (GenDEPOT, Barker, TX) solution (100×) prior to use. The proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. Membranes were incubated first with diluted primary antibodies overnight with gentle shaking at 4 °C, and then with horseradish peroxidase (HRP)-conjugated secondary antibodies. Thereafter, membranes were washed in PBS containing 0.1% Tween-20 (PBST) and were visualized using enhanced chemiluminescence reagents (Clarity Western ECL Substrate; Bio-Rad, Hercules, CA). Antibodies against p-AKT, AKT, p-ERK, ERK, and β-actin were purchased from Cell Signaling Technology (Danvers, MA) and Sigma-Aldrich.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01039">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07080" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07080" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01039" class="ext-link">10.1021/acs.jmedchem.7b01039</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Spectral data for all listed compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Atomic coordinates of computational models (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_003.zip" class="ext-link">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_001.pdf">jm7b01039_si_001.pdf (4.95 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_002.csv">jm7b01039_si_002.csv (1.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_003.zip">jm7b01039_si_003.zip (969.8 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01039" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soon-Sun Hong</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ea8285848d99aa8384828bc48b89c48198"><span class="__cf_email__" data-cfemail="1f777071786c5f7671777e317e7c31746d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sungwoo Hong</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 34141, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9371-1730" title="Orcid link">http://orcid.org/0000-0001-9371-1730</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6ded9d8d1d9c4d1f6ddd7dfc5c298d7d598ddc4"><span class="__cf_email__" data-cfemail="1c7473727b736e7b5c777d756f68327d7f32776e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shinmee Mah</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 34141, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jung Hee Park</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hoi-Yun Jung</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 34141, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kukcheol Ahn</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 34141, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soyeon Choi</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 34141, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyun Seop Tae</span> - <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute of Basic Science (IBS), Daejeon 34141, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyung Hee Jung</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Kyung Rho</span> - <span class="hlFld-Affiliation affiliation">Department
of Asan Institute for Life Sciences and Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jae Cheol Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Asan Institute for Life Sciences and Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul 05505, Korea</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.M. and J.H.P. contributed equally to this work</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d159e4443-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was supported by Institute for Basic Science (IBS-R010-G1) and a grant (HI15C0554) from the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i65" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i65"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i66" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i66"> Abbreviations Used</h2><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">MK</td><td class="NLM_def"><p class="first last">midkine</p></td></tr><tr><td class="NLM_term">PTN</td><td class="NLM_def"><p class="first last">pleiotrophin</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-4,5-bisphosphate 3-kinase</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription protein</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinases</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinases</p></td></tr><tr><td class="NLM_term">c-Met</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase Met</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">crizotinib-resistant</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">percent of control</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene K<sup>+</sup> channel</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40014" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40014" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Motegi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuraba, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span> </span><span class="NLM_article-title">ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3319</span><span class="NLM_x">–</span> <span class="NLM_lpage">3329</span><span class="refDoi"> DOI: 10.1242/jcs.01183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1242%2Fjcs.01183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=15226403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ensLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=3319-3329&author=A.+Motegiauthor=J.+Fujimotoauthor=M.+Kotaniauthor=H.+Sakurabaauthor=T.+Yamamoto&title=ALK+receptor+tyrosine+kinase+promotes+cell+growth+and+neurite+outgrowth&doi=10.1242%2Fjcs.01183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth</span></div><div class="casAuthors">Motegi, Akira; Fujimoto, Jiro; Kotani, Masaharu; Sakuraba, Hitoshi; Yamamoto, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3319-3329</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor-type protein tyrosine kinase that is expressed preferentially in neurons of the central and peripheral nervous systems at late embryonic stages.  To elucidate the role of ALK in neurons, we developed an agonist monoclonal antibody (mAb) against the extracellular domain of ALK.  Here we show that mAb16-39 elicits tyrosine phosphorylation of endogenously expressed ALK in human neuroblastoma (SK-N-SH) cells.  Stimulation of these cells with mAb16-39 markedly induces the tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1), Shc, and c-Cbl and also their interaction with ALK and activation of ERK1/2.  Furthermore, we show that continuous incubation with mAb16-39 induces the cell growth and neurite outgrowth of SK-N-SH cells.  These responses are completely blocked by MEK inhibitor PD98059 but not by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin, indicating an essential role of the mitogen-activated protein kinase (MAP kinase) signaling cascade in ALK-mediated growth and differentiation of neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1Bpvtz4TX7Vg90H21EOLACvtfcHk0ljW7RF_-Q9ZpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ensLk%253D&md5=1219574e37777433a6244819676c3294</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fjcs.01183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.01183%26sid%3Dliteratum%253Aachs%26aulast%3DMotegi%26aufirst%3DA.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKotani%26aufirst%3DM.%26aulast%3DSakuraba%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DALK%2520receptor%2520tyrosine%2520kinase%2520promotes%2520cell%2520growth%2520and%2520neurite%2520outgrowth%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2004%26volume%3D117%26spage%3D3319%26epage%3D3329%26doi%3D10.1242%2Fjcs.01183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">García-Regalado, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González-De la Rosa, C. H.</span><span> </span><span class="NLM_article-title">The role of anaplastic lymphoma kinase in human cancers</span> <span class="citation_source-journal">Oncol. Hematol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.17925/OHR.2013.09.2.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.17925%2FOHR.2013.09.2.149" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=149-153&author=A.+Garc%C3%ADa-Regaladoauthor=C.+H.+Gonz%C3%A1lez-De+la+Rosa&title=The+role+of+anaplastic+lymphoma+kinase+in+human+cancers&doi=10.17925%2FOHR.2013.09.2.149"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.17925%2FOHR.2013.09.2.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17925%252FOHR.2013.09.2.149%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Regalado%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez-De%2Bla%2BRosa%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520human%2520cancers%26jtitle%3DOncol.%2520Hematol.%2520Rev.%26date%3D2013%26volume%3D9%26spage%3D149%26epage%3D153%26doi%3D10.17925%2FOHR.2013.09.2.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hallberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, R. H.</span><span> </span><span class="NLM_article-title">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/nrc3580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1038%2Fnrc3580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24060861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=685-700&author=B.+Hallbergauthor=R.+H.+Palmer&title=Mechanistic+insight+into+ALK+receptor+tyrosine+kinase+in+human+cancer+biology&doi=10.1038%2Fnrc3580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span></div><div class="casAuthors">Hallberg, Bengt; Palmer, Ruth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">685-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC).  The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK.  In this review, we discuss our current understanding of ALK function in human cancer and the implications for tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADI-N0ZBEr7Vg90H21EOLACvtfcHk0ljW7RF_-Q9ZpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP&md5=fab66b12114ca01348df4ca08d3b3e4e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3580%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DMechanistic%2520insight%2520into%2520ALK%2520receptor%2520tyrosine%2520kinase%2520in%2520human%2520cancer%2520biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fnrc3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Roskoski, R.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0liDUz_M_aVa4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Koivunen, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarbaker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4275</span><span class="NLM_x">–</span> <span class="NLM_lpage">4283</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1078-0432.CCR-08-0168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=18594010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4275-4283&author=J.+P.+Koivunenauthor=C.+Mermelauthor=K.+Zejnullahuauthor=C.+Murphyauthor=E.+Lifshitsauthor=A.+J.+Holmesauthor=H.+G.+Choiauthor=J.+Kimauthor=D.+Chiangauthor=R.+Thomasauthor=J.+Leeauthor=W.+G.+Richardsauthor=D.+J.+Sugarbakerauthor=C.+Duckoauthor=N.+Lindemanauthor=J.+P.+Marcouxauthor=J.+A.+Engelmanauthor=N.+S.+Grayauthor=C.+Leeauthor=M.+Meyersonauthor=P.+A.+Janne&title=EML4-ALK+fusion+gene+and+efficacy+of+an+ALK+kinase+inhibitor+in+lung+cancer&doi=10.1158%2F1078-0432.CCR-08-0168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer</span></div><div class="casAuthors">Koivunen, Jussi P.; Mermel, Craig; Zejnullahu, Kreshnik; Murphy, Carly; Lifshits, Eugene; Holmes, Alison J.; Choi, Hwan Geun; Kim, Jhingook; Chiang, Derek; Thomas, Roman; Lee, Jinseon; Richards, William G.; Sugarbaker, David J.; Ducko, Christopher; Lindeman, Neal; Marcoux, J. Paul; Engelman, Jeffrey A.; Gray, Nathanael S.; Lee, Charles; Meyerson, Matthew; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4275-4283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell lung cancers (NSCLC).  We detd. the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines.  We also detd. whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-contg. cell lines in vitro and in vivo.  We screened 305 primary NSCLC [both U.S. (n = 138) and Korean (n = 167) patients] and 83 NSCLC cell lines using reverse transcription-PCR and by exon array analyses.  We evaluated the efficacy of TAE684 against NSCLC cell lines in vitro and in vivo.  We detected four different variants, including two novel variants, of EML4-ALK using reverse transcription-PCR in 8 of 305 tumors (3%) and 3 of 83 (3.6%) NSCLC cell lines.  All EML4-ALK-contg. tumors and cell lines were adenocarcinomas.  EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers (6% vs. 1%; P = 0.049).  TAE684 inhibited the growth of one of three (H3122) EML4-ALK-contg. cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis.  In another EML4-ALK cell line, DFCI032, TAE684 was ineffective due to coactivation of epidermal growth factor receptor and ERBB2.  The combination of TAE684 and CL-387,785 (epidermal growth factor receptor/ERBB2 kinase inhibitor) inhibited growth and Akt phosphorylation and led to apoptosis in the DFCI032 cell line.  EML4-ALK is found in the minority of NSCLC.  ALK kinase inhibitors alone or in combination may nevertheless be clin. effective treatments for NSCLC patients whose tumors contain EML4-ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOXKywqERg6rVg90H21EOLACvtfcHk0liDUz_M_aVa4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D&md5=6e29703c783e6a29cf77e3c4b93fc15f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0168%26sid%3Dliteratum%253Aachs%26aulast%3DKoivunen%26aufirst%3DJ.%2BP.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChiang%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DSugarbaker%26aufirst%3DD.%2BJ.%26aulast%3DDucko%26aufirst%3DC.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DEML4-ALK%2520fusion%2520gene%2520and%2520efficacy%2520of%2520an%2520ALK%2520kinase%2520inhibitor%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4275%26epage%3D4283%26doi%3D10.1158%2F1078-0432.CCR-08-0168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Palmer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernersson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, B.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: signalling in development and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">420</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1042/BJ20090387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1042%2FBJ20090387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+lymphoma+kinase%3A+signalling+in+development+and+disease&doi=10.1042%2FBJ20090387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBJ20090387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090387%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520signalling%2520in%2520development%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361%26doi%3D10.1042%2FBJ20090387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4%E2%80%93ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0liDUz_M_aVa4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4%25E2%2580%2593ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">673</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.-Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+inhibitor+ceritinib+overcomes+crizotinib+resistance+in+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0lhNieb2FbOEuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520inhibitor%2520ceritinib%2520overcomes%2520crizotinib%2520resistance%2520in%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhNieb2FbOEuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konagai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fushiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakagami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non–small cell lung cancer model mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+selective+anaplastic+lymphoma+receptor+tyrosine+kinase+inhibitor+ASP3026+induces+tumor+regression+and+prolongs+survival+in+non%E2%80%93small+cell+lung+cancer+model+mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0lh6MySKEVeBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520selective%2520anaplastic%2520lymphoma%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ASP3026%2520induces%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%2520model%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Learn, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruckheimer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7478</span><span class="NLM_x">–</span> <span class="NLM_lpage">7496</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7478-7496&author=G.+R.+Ottauthor=M.+Chengauthor=K.+S.+Learnauthor=J.+Wagnerauthor=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+Curryauthor=E.+F.+Mesarosauthor=A.+K.+Ghoseauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=P.+Dobrzanskiauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+Wells-Knechtauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=E.+Bruckheimerauthor=N.+Andersonauthor=J.+Friedmanauthor=S.+V.+Fernandezauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+clinical+candidate+CEP-37440%2C+a+selective+inhibitor+of+focal+adhesion+kinase+%28FAK%29+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Ott, Gregory R.; Cheng, Mangeng; Learn, Keith S.; Wagner, Jason; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew; Mesaros, Eugen F.; Ghose, Arup K.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Dobrzanski, Pawel; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin; Huang, Zeqi; Aimone, Lisa D.; Bruckheimer, Elizabeth; Anderson, Nathan; Friedman, Jay; Fernandez, Sandra V.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7478-7496</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Analogs structurally related to anaplastic lymphoma kinase (ALK) inhibitor (CEP-28122) were optimized for metabolic stability.  The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clin. derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK).  FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis.  The discovery of the clin. stage, dual FAK/ALK inhibitor 27b (CEP-37440), including details surrounding SAR, in vitro/in vivo pharmacol., and pharmacokinetics, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojryum63_LVg90H21EOLACvtfcHk0lh6MySKEVeBIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P&md5=3fcd1342d901b2379d0efbd118d3049f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DBruckheimer%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DN.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%2520CEP-37440%252C%2520a%2520selective%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7478%26epage%3D7496%26doi%3D10.1021%2Facs.jmedchem.6b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0liOO4Hmn6BiNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squillace, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadworny, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichinger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miret, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5527</span><span class="NLM_x">–</span> <span class="NLM_lpage">5538</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1078-0432.CCR-16-0569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=27780853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5527-5538&author=S.+Zhangauthor=R.+Anjumauthor=R.+Squillaceauthor=S.+Nadwornyauthor=T.+Zhouauthor=J.+Keatsauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=D.+Millerauthor=Y.+Songauthor=L.+Eichingerauthor=L.+Moranauthor=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=Y.+Wangauthor=Q.+Mohemmadauthor=H.+G.+Jangauthor=E.+Yeauthor=N.+Narasimhanauthor=F.+Wangauthor=J.+Miretauthor=X.+Zhuauthor=T.+Clacksonauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=V.+M.+Rivera&title=The+potent+ALK+inhibitor+brigatinib+%28AP26113%29+overcomes+mechanisms+of+resistance+to+first-and+second-generation+ALK+inhibitors+in+preclinical+models&doi=10.1158%2F1078-0432.CCR-16-0569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zhang, Sen; Anjum, Rana; Squillace, Rachel; Nadworny, Sara; Zhou, Tianjun; Keats, Jeff; Ning, Yaoyu; Wardwell, Scott D.; Miller, David; Song, Youngchul; Eichinger, Lindsey; Moran, Lauren; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Wang, Yihan; Mohemmad, Qurish; Jang, Hyun Gyung; Ye, Emily; Narasimhan, Narayana; Wang, Frank; Miret, Juan; Zhu, Xiaotian; Clackson, Tim; Dalgarno, David; Shakespeare, William C.; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5527-5538</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain.  Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified.  Here, we report the structure and first comprehensive preclin. evaluation of the next-generation ALK TKI brigatinib.  Exptl. Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib.  The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines.  The brigatinib-ALK co-structure was detd.  Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases.  Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib.  Superior efficacy of brigatinib was also obsd. in mice with ALK+ tumors implanted s.c. or intracranially.  Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clin. achievable concns.  Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R.  The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.  Conclusions: Brigatinib is a highly potent and selective ALK inhibitor.  These findings provide the mol. basis for the promising activity being obsd. in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clin. trials.  Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwQUn_qLy7bVg90H21EOLACvtfcHk0ljo1LMScVspAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O&md5=1ece23bf36e807562023d0b814c990c7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DSquillace%26aufirst%3DR.%26aulast%3DNadworny%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEichinger%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMohemmad%26aufirst%3DQ.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DYe%26aufirst%3DE.%26aulast%3DNarasimhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMiret%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DThe%2520potent%2520ALK%2520inhibitor%2520brigatinib%2520%2528AP26113%2529%2520overcomes%2520mechanisms%2520of%2520resistance%2520to%2520first-and%2520second-generation%2520ALK%2520inhibitors%2520in%2520preclinical%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5527%26epage%3D5538%26doi%3D10.1158%2F1078-0432.CCR-16-0569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Iwama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, Y.</span><span> </span><span class="NLM_article-title">Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span><span class="refDoi"> DOI: 10.2147/OTT.S38868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.2147%2FOTT.S38868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24623980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=375-385&author=E.+Iwamaauthor=I.+Okamotoauthor=T.+Haradaauthor=K.+Takayamaauthor=Y.+Nakanishi&title=Development+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+and+molecular+diagnosis+in+ALK+rearrangement-positive+lung+cancer&doi=10.2147%2FOTT.S38868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer</span></div><div class="casAuthors">Iwama, Eiji; Okamoto, Isamu; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">375-385, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The fusion of echinoderm microtubule-assocd. protein-like 4 with anaplastic lymphoma kinase (ALK) was identified as a transforming gene for lung cancer in 2007.  This genetic rearrangement accounts for 2%-5% of non-small-cell lung cancer (NSCLC) cases, occurring predominantly in younger individuals with adenocarcinoma who are never- or light smokers.  A small-mol. tyrosine-kinase inhibitor of ALK, crizotinib, was rapidly approved by the US Food and Drug Administration on the basis of its pronounced clin. activity in patients with ALK rearrangement-pos. NSCLC.  Next-generation ALK inhibitors, such as alectinib, LDK378, and AP26113, are also being developed in ongoing clin. trials.  In addn., the improvement and validation of methods for the detection of ALK rearrangement in NSCLC patients will be key to the optimal clin. use of ALK inhibitors.  We here summarize recent progress in the development of new ALK inhibitors and in the mol. diagnosis of ALK rearrangement-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql5NNTgVgC8bVg90H21EOLACvtfcHk0ljo1LMScVspAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynu7bI&md5=97dc145eadba8084eb324a33ee0eb271</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2147%2FOTT.S38868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S38868%26sid%3Dliteratum%253Aachs%26aulast%3DIwama%26aufirst%3DE.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DNakanishi%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520and%2520molecular%2520diagnosis%2520in%2520ALK%2520rearrangement-positive%2520lung%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2014%26volume%3D7%26spage%3D375%26epage%3D385%26doi%3D10.2147%2FOTT.S38868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">120ra17</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">953</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span><span class="refDoi"> DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0ljIYT2eOyTwlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Lin, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J.-Y.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK Inhibitor (s) failure in advanced ALK positive non–small-cell lung cancer: analysis and literature review</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">e77</span><span class="NLM_x">–</span> <span class="NLM_lpage">e94</span><span class="refDoi"> DOI: 10.1016/j.cllc.2016.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.cllc.2016.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=27130468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFCntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e77-e94&author=Y.-T.+Linauthor=C.-J.+Yuauthor=J.+C.-H.+Yangauthor=J.-Y.+Shih&title=Anaplastic+lymphoma+kinase+%28ALK%29+kinase+domain+mutation+following+ALK+Inhibitor+%28s%29+failure+in+advanced+ALK+positive+non%E2%80%93small-cell+lung+cancer%3A+analysis+and+literature+review&doi=10.1016%2Fj.cllc.2016.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review</span></div><div class="casAuthors">Lin, Yen-Ting; Yu, Chong-Jen; Yang, James Chih-Hsin; Shih, Jin-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e77-e94</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Secondary anaplastic lymphoma kinase (ALK) mutation may occur in patients with advanced ALK-pos. non-small cell lung cancer treated with ALK inhibitors, but its nature is not well-known.We analyzed tumor specimens after the failure of treatment with ALK inhibitor(s) (crizotinib, alectinib, and ceritinib) for secondary ALK kinase domain mutation, EGFR, K-ras, and PIK3CA mutations.  The literature regarding acquired ALK-inhibitor(s) resistance was also reviewed.Among 59 patients who received ALK inhibitor(s) during the period of Dec. 2010 to Apr. 2015, 7 had re-biopsied tumor specimens for analyses following ALK inhibitor(s) failure.  One had G1202R after crizotinib and alectinib failure, and 6 were wild type.  No EGFR, K-ras, or PIK3CA mutations were found.  In our review of the literature and taken together with our patients, 25 of the 88 (28%) patients with crizotinib failure had secondary ALK mutation; L1196M mutation was most common (n = 11).  Patients with secondary ALK mutation other than L1196M had a longer progression-free survival after crizotinib than patients with L1196M (median, 12.0 vs. 7.0 mo; P = .04).  Of the 9 patients with alectinib failure, 5 had I1171 mutation and 2 had G1202R.  Of the 11 patients with ceritinib failure, 2 had G1202R, 1 had F1174C, and 1 had both G1202R and F1174V.  I1171 mutation, G1202R, and F1174 mutations were also found in crizotinib-failed patients.Some acquired ALK mutations may cause co-resistance to other ALK inhibitors.  Re-biopsy for ALK mutation anal. might be suggested prior to choosing a second-line ALK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreRRKZfEHN2LVg90H21EOLACvtfcHk0ljIYT2eOyTwlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFCntLc%253D&md5=2ba6e81398afffdfbb9bd356e0a6d4bc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2016.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2016.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DY.-T.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DShih%26aufirst%3DJ.-Y.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520kinase%2520domain%2520mutation%2520following%2520ALK%2520Inhibitor%2520%2528s%2529%2520failure%2520in%2520advanced%2520ALK%2520positive%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%253A%2520analysis%2520and%2520literature%2520review%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2016%26volume%3D17%26spage%3De77%26epage%3De94%26doi%3D10.1016%2Fj.cllc.2016.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Toyokawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inamasu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamatsu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span> </span><span class="NLM_article-title">Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non–small-cell lung cancer exhibiting resistance to ceritinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e55</span><span class="NLM_x">–</span> <span class="NLM_lpage">e57</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1097%2FJTO.0000000000000509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=26134233" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e55-e57&author=G.+Toyokawaauthor=E.+Inamasuauthor=S.+Shimamatsuauthor=T.+Yoshidaauthor=K.+Nosakiauthor=F.+Hiraiauthor=M.+Yamaguchiauthor=T.+Setoauthor=M.+Takenoyamaauthor=Y.+Ichinose&title=Identification+of+a+novel+ALK+G1123S+mutation+in+a+patient+with+ALK-rearranged+non%E2%80%93small-cell+lung+cancer+exhibiting+resistance+to+ceritinib&doi=10.1097%2FJTO.0000000000000509"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000509%26sid%3Dliteratum%253Aachs%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DInamasu%26aufirst%3DE.%26aulast%3DShimamatsu%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DNosaki%26aufirst%3DK.%26aulast%3DHirai%26aufirst%3DF.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DTakenoyama%26aufirst%3DM.%26aulast%3DIchinose%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520a%2520novel%2520ALK%2520G1123S%2520mutation%2520in%2520a%2520patient%2520with%2520ALK-rearranged%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520exhibiting%2520resistance%2520to%2520ceritinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3De55%26epage%3De57%26doi%3D10.1097%2FJTO.0000000000000509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kain, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klempner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&author=S.-H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-generation+sequencing+reveals+a+Novel+NSCLC+ALK+F1174V+mutation+and+confirms+ALK+G1202R+mutation+confers+high-level+resistance+to+alectinib+%28CH5424802%2FRO5424802%29+in+ALK-rearranged+NSCLC+patients+who+progressed+on+crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-generation%2520sequencing%2520reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520mutation%2520and%2520confirms%2520ALK%2520G1202R%2520mutation%2520confers%2520high-level%2520resistance%2520to%2520alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-rearranged%2520NSCLC%2520patients%2520who%2520progressed%2520on%2520crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiappori, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisserie, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Laurenzio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span> </span><span class="NLM_article-title">Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1128</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70362-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2FS1470-2045%2814%2970362-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=25153538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1119-1128&author=S.+M.+Gadgeelauthor=L.+Gandhiauthor=G.+J.+Rielyauthor=A.+A.+Chiapporiauthor=H.+L.+Westauthor=M.+C.+Azadaauthor=P.+N.+Morcosauthor=R.-M.+Leeauthor=L.+Garciaauthor=L.+Yuauthor=F.+Boisserieauthor=L.+Di+Laurenzioauthor=S.+Goldingauthor=J.+Satoauthor=S.+Yokoyamaauthor=T.+Tanakaauthor=S.-H.+I.+Ou&title=Safety+and+activity+of+alectinib+against+systemic+disease+and+brain+metastases+in+patients+with+crizotinib-resistant+ALK-rearranged+non-small-cell+lung+cancer+%28AF-002JG%29%3A+results+from+the+dose-finding+portion+of+a+phase+1%2F2+study&doi=10.1016%2FS1470-2045%2814%2970362-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study</span></div><div class="casAuthors">Gadgeel, Shirish M.; Gandhi, Leena; Riely, Gregory J.; Chiappori, Alberto A.; West, Howard L.; Azada, Michele C.; Morcos, Peter N.; Lee, Ruey-Min; Garcia, Linta; Yu, Li; Boisserie, Frederic; Di Laurenzio, Laura; Golding, Sophie; Sato, Jotaro; Yokoyama, Shumpei; Tanaka, Tomohiro; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8-11 mo while on treatment with the ALK inhibitor crizotinib.  However, resistance inevitably develops, with the brain a common site of progression.  More potent ALK inhibitors with consistently demonstrable CNS activity and good tolerability are needed urgently.  Alectinib is a novel, highly selective, and potent ALK inhibitor that has shown clin. activity in patients with crizotinib-naive ALK-rearranged NSCLC.  We did a phase 1/2 study of alectinib to establish the recommended phase 2 dose of the drug and examine its activity in patients resistant or intolerant to crizotinib.  We enrolled patients with ALK-rearranged NSCLC who progressed on or were intolerant to crizotinib.  We administered various oral doses of alectinib (300-900 mg twice a day) during the dose-escalation portion of the study (phase 1), to ascertain the recommended dose for phase 2.  We used Response Evaluation Criteria in Solid Tumors criteria (version 1.1) to investigate the activity of alectinib in all patients with a baseline scan and at least one post-treatment scan (CT or MRI), with central radiol. review of individuals with brain metastases.  We assessed safety in all patients who received at least one dose of alectinib.  Here, we present data for the phase 1 portion of the study, the primary objective of which was to establish the recommended phase 2 dose; phase 2 is ongoing.  This trial is registered at ClinicalTrials.gov, no. NCT01588028.47 patients were enrolled.  Alectinib was well tolerated, with the most common adverse events being fatigue (14 [30%]; all grade 1-2), myalgia (eight [17%]; all grade 1-2), and peripheral edema (seven [15%] grade 1-2, one [2%] grade 3).  Dose-limiting toxic effects were recorded in two patients in the cohort receiving alectinib 900 mg twice a day; one individual had grade 3 headache and the other had grade 3 neutropenia.  The most common grade 3-4 adverse events were increased levels of γ-glutamyl transpeptidase (two [4%]), a redn. in the no. of neutrophils (two [4%]), and hypophosphatemia (two [4%]).  Three patients reported four grade 4 serious adverse events that were deemed unrelated to alectinib: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.  At data cut-off (median follow-up 126 days [IQR 84-217]), 44 patients could be assessed for activity.  Investigator-assessed objective responses were noted in 24 (55%) patients, with a confirmed complete response in one (2%), a confirmed partial response in 14 (32%), and an unconfirmed partial response in nine (20%). 16 (36%) patients had stable disease; the remaining four (9%) had progressive disease.  Of 21 patients with CNS metastases at baseline, 11 (52%) had an objective response; six (29%) had a complete response (three unconfirmed) and five (24%) had a partial response (one unconfirmed); eight (38%) patients had stable disease and the remaining two (10%) had progressive disease.  Pharmacokinetic data indicated that mean exposure (AUC0-10) after multiple doses of alectinib (300-600 mg twice a day) was dose-dependent.  Alectinib was well tolerated, with promising antitumor activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.  On the basis of activity, tolerability, and pharmacokinetic data, we chose alectinib 600 mg twice a day as the recommended dose for phase 2.  Chugai Pharmaceuticals, F Hoffmann La-Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriCeVttS5axrVg90H21EOLACvtfcHk0ljP4d8gsPdoIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K&md5=aa56d295472ea5dcb29070a4e39d420a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970362-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970362-6%26sid%3Dliteratum%253Aachs%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DChiappori%26aufirst%3DA.%2BA.%26aulast%3DWest%26aufirst%3DH.%2BL.%26aulast%3DAzada%26aufirst%3DM.%2BC.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DLee%26aufirst%3DR.-M.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBoisserie%26aufirst%3DF.%26aulast%3DDi%2BLaurenzio%26aufirst%3DL.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DSafety%2520and%2520activity%2520of%2520alectinib%2520against%2520systemic%2520disease%2520and%2520brain%2520metastases%2520in%2520patients%2520with%2520crizotinib-resistant%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520%2528AF-002JG%2529%253A%2520results%2520from%2520the%2520dose-finding%2520portion%2520of%2520a%2520phase%25201%252F2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1119%26epage%3D1128%26doi%3D10.1016%2FS1470-2045%2814%2970362-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2227</span><span class="NLM_x">–</span> <span class="NLM_lpage">2235</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1078-0432.CCR-14-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=25979929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2227-2235&author=R.+Katayamaauthor=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Therapeutic+targeting+of+anaplastic+lymphoma+kinase+in+lung+cancer%3A+a+paradigm+for+precision+cancer+medicine&doi=10.1158%2F1078-0432.CCR-14-2791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span></div><div class="casAuthors">Katayama, Ryohei; Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2227-2235</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).  Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others.  Importantly, ALK serves as a validated therapeutic target in these diseases.  Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clin. use.  These ALK inhibitors have all shown remarkable clin. outcomes in ALK-rearranged NSCLC.  Unfortunately, as is the case for other kinase inhibitors in clin. use, sensitive tumors inevitably relapse due to acquired resistance.  This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC.  Clin Cancer Res; 21(10); 2227-35. cpr2015 AACR.  See all articles in this section, "Progress in Lung Cancer".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr00cDhFZSKBrVg90H21EOLACvtfcHk0ljP4d8gsPdoIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D&md5=80994c4611159b7f7d007fd16e4f8472</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2791%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520targeting%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%253A%2520a%2520paradigm%2520for%2520precision%2520cancer%2520medicine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2227%26epage%3D2235%26doi%3D10.1158%2F1078-0432.CCR-14-2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lhXrVBfPVdEZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, J.</span><span> </span><span class="NLM_article-title">Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="refDoi"> DOI: 10.1007/s00894-016-3099-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1007%2Fs00894-016-3099-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=27585676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A280%3ADC%252BC2szntValug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=231&author=J.+Liauthor=W.+Liuauthor=H.+Luoauthor=J.+Bao&title=Insight+into+drug+resistance+mechanisms+and+discovery+of+potential+inhibitors+against+wild-type+and+L1196M+mutant+ALK+from+FDA-approved+drugs&doi=10.1007%2Fs00894-016-3099-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs</span></div><div class="casAuthors">Li Jianzong; Liu Wei; Luo Hao; Bao Jinku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of molecular modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) plays a crucial role in multiple malignant cancers.  It is known as a well-established target for the treatment of ALK-dependent cancers.  Even though substantial efforts have been made to develop ALK inhibitors, only crizotinib, ceritinib, and alectinib had been approved by the U.S.  Food and Drug Administration for patients with ALK-positive non-small cell lung cancer (NSCLC).  The secondary mutations with drug-resistance bring up difficulties to develop effective drugs for ALK-positive cancers.  To give a comprehensive understanding of molecular mechanism underlying inhibitor response to ALK tyrosine kinase mutations, we established an accurate assessment for the extensive profile of drug against ALK mutations by means of computational approaches.  The molecular mechanics-generalized Born surface area (MM-GBSA) method based on molecular dynamics (MD) simulation was carried out to calculate relative binding free energies for receptor-drug systems.  In addition, the structure-based virtual screening was utilized to screen effective inhibitors targeting wild-type ALK and the gatekeeper mutation L1196M from 3180 approved drugs.  Finally, the mechanism of drug resistance was discussed, several novel potential wild-type and L1196M mutant ALK inhibitors were successfully identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrEHWZb5KaqekdrW1FkXG-fW6udTcc2eapQoV4tgMU5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szntValug%253D%253D&md5=0012354bde8e60bda4cf5c559ac33184</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs00894-016-3099-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-016-3099-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DBao%26aufirst%3DJ.%26atitle%3DInsight%2520into%2520drug%2520resistance%2520mechanisms%2520and%2520discovery%2520of%2520potential%2520inhibitors%2520against%2520wild-type%2520and%2520L1196M%2520mutant%2520ALK%2520from%2520FDA-approved%2520drugs%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2016%26volume%3D22%26spage%3D231%26doi%3D10.1007%2Fs00894-016-3099-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span> </span><span class="NLM_article-title">An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer</span> <span class="citation_source-journal">Biochimie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span><span class="refDoi"> DOI: 10.1016/j.biochi.2015.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.biochi.2015.03.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=111-120&author=X.+Aiauthor=S.+Shenauthor=L.+Shenauthor=S.+Lu&title=An+interaction+map+of+small-molecule+kinase+inhibitors+with+anaplastic+lymphoma+kinase+%28ALK%29+mutants+in+ALK-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.biochi.2015.03.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2015.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2015.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DAn%2520interaction%2520map%2520of%2520small-molecule%2520kinase%2520inhibitors%2520with%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520mutants%2520in%2520ALK-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochimie%26date%3D2015%26volume%3D112%26spage%3D111%26epage%3D120%26doi%3D10.1016%2Fj.biochi.2015.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">–</span> <span class="NLM_lpage">6825</span><span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0lgf_eNT9qCJdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunker, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dack, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsaparikos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span><span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=J.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+potent+and+selective+inhibitors+to+overcome+clinical+anaplastic+lymphoma+kinase+mutations+resistant+to+crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0lgf_eNT9qCJdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520inhibitors%2520to%2520overcome%2520clinical%2520anaplastic%2520lymphoma%2520kinase%2520mutations%2520resistant%2520to%2520crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchiner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dardaei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1056/NEJMoa1508887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1056%2FNEJMoa1508887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=26698910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=54-61&author=A.+T.+Shawauthor=L.+Fribouletauthor=I.+Leshchinerauthor=J.+F.+Gainorauthor=S.+Bergqvistauthor=A.+Broounauthor=B.+J.+Burkeauthor=Y.-L.+Dengauthor=W.+Liuauthor=L.+Dardaeiauthor=R.+L.+Friasauthor=K.+R.+Schultzauthor=J.+Loganauthor=L.+P.+Jamesauthor=T.+Smealauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=A.+J.+Iafrateauthor=L.+Leauthor=M.+McTigueauthor=G.+Getzauthor=T.+W.+Johnsonauthor=J.+A.+Engelman&title=Resensitization+to+crizotinib+by+the+lorlatinib+ALK+resistance+mutation+L1198F&doi=10.1056%2FNEJMoa1508887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span></div><div class="casAuthors">Shaw, Alice T.; Friboulet, Luc; Leshchiner, Ignaty; Gainor, Justin F.; Bergqvist, Simon; Brooun, Alexei; Burke, Benjamin J.; Deng, Ya-Li; Liu, Wei; Dardaei, Leila; Frias, Rosa L.; Schultz, Kate R.; Logan, Jennifer; James, Leonard P.; Smeal, Tod; Timofeevski, Sergei; Katayama, Ryohei; John, Iafrate A.; Le, Long; McTigue, Michele; Getz, Gad; Johnson, Ted W.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.  This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y).  Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.  When her tumor relapsed, sequencing of the resistant tumor re- vealed an ALK L1198F mutation in addn. to the C1156Y mutation.  The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding.  However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib.  The patient received crizotinib again, and her cancer-related symptoms and liver failure re- solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphljr8b5kDw7Vg90H21EOLACvtfcHk0lgat_QoN1ARlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI&md5=993f41fc3918a73d4ba69276556572d8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1508887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1508887%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DSchultz%26aufirst%3DK.%2BR.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLe%26aufirst%3DL.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DResensitization%2520to%2520crizotinib%2520by%2520the%2520lorlatinib%2520ALK%2520resistance%2520mutation%2520L1198F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D54%26epage%3D61%26doi%3D10.1056%2FNEJMoa1508887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Shin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span> </span><span class="NLM_article-title">Discovery of low micromolar dual inhibitors for wild type and L1196M mutant of anaplastic lymphoma kinase through the structure-based virtual screening</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">810</span><span class="refDoi"> DOI: 10.1021/acs.jcim.6b00026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVOrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=802-810&author=S.+Shinauthor=S.+Mahauthor=S.+Hongauthor=H.+Park&title=Discovery+of+low+micromolar+dual+inhibitors+for+wild+type+and+L1196M+mutant+of+anaplastic+lymphoma+kinase+through+the+structure-based+virtual+screening&doi=10.1021%2Facs.jcim.6b00026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening</span></div><div class="casAuthors">Shin, Saemina; Mah, Shinmee; Hong, Sungwoo; Park, Hwangseo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">802-810</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although anaplastic lymphoma kinase (ALK) is involved in a variety of malignant human cancers, the emergence of constitutively active mutants with drug resistance has rendered it difficult to identify the new medicines for ALK-dependent cancers.  To find the common inhibitors of the wild type ALK and the most abundant drug-resistant mutant (L1196M), we performed mol. docking-based virtual screening of a large chem. library in parallel for the two target proteins.  As a consequence of augmenting the accuracy of the docking simulation by implementing a sophisticated hydration free energy term in the scoring function, 12 common inhibitors are discovered with the inhibitory activities ranging from submicromolar to low micromolar levels.  The results of the binding free energy decompn. indicate that the biochem. potency of ALK inhibitors can be optimized by reducing the dehydration cost for binding to the receptor protein as well as by strengthening the interactions with amino acid residues in the ATP-binding site.  The newly identified ALK inhibitors are found to have a little higher inhibitory activity for the L1196M mutant than for the wild type due to the strengthening of the hydrogen bond interactions in the ATP-binding site.  Of the 12 common inhibitors, 2-(5-methyl-benzooxazol-2-ylamino)-quinazolin-4-ol (3) is anticipated to serve as a new mol. scaffold to optimize the biochem. potency because it exhibits low micromolar inhibitory activity with respect to both the wild type and L1196M mutant in spite of the low mol. wt. (292.3 amu).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9yWue9aLBLrVg90H21EOLACvtfcHk0lgat_QoN1ARlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVOrtLo%253D&md5=7bd43d9e200fda3d54fa8e3b4c5f7a26</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00026%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DS.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520low%2520micromolar%2520dual%2520inhibitors%2520for%2520wild%2520type%2520and%2520L1196M%2520mutant%2520of%2520anaplastic%2520lymphoma%2520kinase%2520through%2520the%2520structure-based%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D802%26epage%3D810%26doi%3D10.1021%2Facs.jcim.6b00026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnekenburger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwergel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosconati, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gros, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimondo, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miele, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferretti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, A.</span><span> </span><span class="NLM_article-title">Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span><span class="refDoi"> DOI: 10.1021/jm4012627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFOisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=701-713&author=S.+Valenteauthor=Y.+Liuauthor=M.+Schnekenburgerauthor=C.+Zwergelauthor=S.+Cosconatiauthor=C.+Grosauthor=M.+Tardugnoauthor=D.+Labellaauthor=C.+Floreanauthor=S.+Mindenauthor=H.+Hashimotoauthor=Y.+Changauthor=X.+Zhangauthor=G.+Kirschauthor=E.+Novellinoauthor=P.+B.+Arimondoauthor=E.+Mieleauthor=E.+Ferrettiauthor=A.+Gulinoauthor=M.+Diederichauthor=X.+Chengauthor=A.+Mai&title=Selective+non-nucleoside+inhibitors+of+human+DNA+methyltransferases+active+in+cancer+including+in+cancer+stem+cells&doi=10.1021%2Fjm4012627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells</span></div><div class="casAuthors">Valente, Sergio; Yiwei, Liu; Schnekenburger, Michael; Zwergel, Clemens; Cosconati, Sandro; Gros, Christina; Tardugno, Maria; Labella, Donatella; Florean, Cristina; Minden, Steven; Hashimoto, Hideharu; Chang, Yanqi; Zhang, Xing; Kirsch, Gilbert; Novellino, Ettore; Arimondo, Paola B.; Miele, Evelina; Ferretti, Elisabetta; Gulino, Alberto; Diederich, Marc; Cheng, Xiaodong; Mai, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">701-713</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA methyltransferases (DNMTs) are important enzymes involved in epigenetic control of gene expression and represent valuable targets in cancer chemotherapy.  A no. of nucleoside DNMT inhibitors (DNMTi) have been studied in cancer, including in cancer stem cells, and two of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes.  However, only a few non-nucleoside DNMTi have been identified so far, and even fewer have been validated in cancer.  Through a process of hit-to-lead optimization, we report here the discovery of compd. 5 as a potent non-nucleoside DNMTi that is also selective toward other AdoMet-dependent protein methyltransferases.  Compd. 5 was potent at single-digit micromolar concns. against a panel of cancer cells and was less toxic in peripheral blood mononuclear cells than two other compds. tested.  In mouse medulloblastoma stem cells, 5 inhibited cell growth, whereas related compd. 2 showed high cell differentiation.  To the best of our knowledge, 2 and 5 are the first non-nucleoside DNMTi tested in a cancer stem cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxOcRR02xFkLVg90H21EOLACvtfcHk0ljISrJJykSLOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFOisw%253D%253D&md5=0749e33ad2324aa591342d7c7f23a955</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4012627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012627%26sid%3Dliteratum%253Aachs%26aulast%3DValente%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSchnekenburger%26aufirst%3DM.%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DCosconati%26aufirst%3DS.%26aulast%3DGros%26aufirst%3DC.%26aulast%3DTardugno%26aufirst%3DM.%26aulast%3DLabella%26aufirst%3DD.%26aulast%3DFlorean%26aufirst%3DC.%26aulast%3DMinden%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKirsch%26aufirst%3DG.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DArimondo%26aufirst%3DP.%2BB.%26aulast%3DMiele%26aufirst%3DE.%26aulast%3DFerretti%26aufirst%3DE.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DDiederich%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DMai%26aufirst%3DA.%26atitle%3DSelective%2520non-nucleoside%2520inhibitors%2520of%2520human%2520DNA%2520methyltransferases%2520active%2520in%2520cancer%2520including%2520in%2520cancer%2520stem%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D701%26epage%3D713%26doi%3D10.1021%2Fjm4012627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hazeldine, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biehl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwitz, J. P.</span><span> </span><span class="NLM_article-title">Part 3: synthesis and biological evaluation of some analogs of the antitumor agents, 2-{4-[(7-chloro-2-quinoxalinyl) oxy] phenoxy} propionic acid, and 2-{4-[(7-bromo-2-quinolinyl) oxy] phenoxy} propionic acid</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span><span class="refDoi"> DOI: 10.1016/j.bmc.2004.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.bmc.2004.11.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=1069-1081&author=S.+T.+Hazeldineauthor=L.+Polinauthor=J.+Kushnerauthor=K.+Whiteauthor=T.+H.+Corbettauthor=J.+Biehlauthor=J.+P.+Horwitz&title=Part+3%3A+synthesis+and+biological+evaluation+of+some+analogs+of+the+antitumor+agents%2C+2-%7B4-%5B%287-chloro-2-quinoxalinyl%29+oxy%5D+phenoxy%7D+propionic+acid%2C+and+2-%7B4-%5B%287-bromo-2-quinolinyl%29+oxy%5D+phenoxy%7D+propionic+acid&doi=10.1016%2Fj.bmc.2004.11.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DHazeldine%26aufirst%3DS.%2BT.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26aulast%3DBiehl%26aufirst%3DJ.%26aulast%3DHorwitz%26aufirst%3DJ.%2BP.%26atitle%3DPart%25203%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520some%2520analogs%2520of%2520the%2520antitumor%2520agents%252C%25202-%257B4-%255B%25287-chloro-2-quinoxalinyl%2529%2520oxy%255D%2520phenoxy%257D%2520propionic%2520acid%252C%2520and%25202-%257B4-%255B%25287-bromo-2-quinolinyl%2529%2520oxy%255D%2520phenoxy%257D%2520propionic%2520acid%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D1069%26epage%3D1081%26doi%3D10.1016%2Fj.bmc.2004.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Allen, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennard, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brammer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orpen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 2</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S19</span><span class="refDoi"> DOI: 10.1039/p298700000s1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1039%2Fp298700000s1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADyaL1cXmt1ylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=S1-S19&author=F.+H.+Allenauthor=O.+Kennardauthor=D.+G.+Watsonauthor=L.+Brammerauthor=A.+G.+Orpenauthor=R.+Taylor&title=Tables+of+bond+lengths+determined+by+X-ray+and+neutron+diffraction.+Part+1.+Bond+lengths+in+organic+compounds&doi=10.1039%2Fp298700000s1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tables of bond lengths determined by x-ray and neutron diffraction.  Part 1.  Bond lengths in organic compounds</span></div><div class="casAuthors">Allen, Frank H.; Kennard, Olga; Watson, David G.; Brammer, Lee; Orpen, A. Guy; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 2:  Physical Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">S1-S19</span>CODEN:
                <span class="NLM_cas:coden">JCPKBH</span>;
        ISSN:<span class="NLM_cas:issn">0300-9580</span>.
    </div><div class="casAbstract">The av. lengths of bonds involving the elements H, B, C, N, O, F, Si, P, S, Cl, As, Se, Br, Te, and I in org. compds. are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1t708GUnP6LVg90H21EOLACvtfcHk0lhWhqRAXY8CDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmt1ylsg%253D%253D&md5=d503dac6e5f2374e2d49a82f1ffd6a14</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fp298700000s1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp298700000s1%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DF.%2BH.%26aulast%3DKennard%26aufirst%3DO.%26aulast%3DWatson%26aufirst%3DD.%2BG.%26aulast%3DBrammer%26aufirst%3DL.%26aulast%3DOrpen%26aufirst%3DA.%2BG.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DTables%2520of%2520bond%2520lengths%2520determined%2520by%2520X-ray%2520and%2520neutron%2520diffraction.%2520Part%25201.%2520Bond%2520lengths%2520in%2520organic%2520compounds%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25202%26date%3D1987%26spage%3DS1%26epage%3DS19%26doi%3D10.1039%2Fp298700000s1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhWhqRAXY8CDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Hatcher, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahcall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9296</span><span class="NLM_x">–</span> <span class="NLM_lpage">9308</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9296-9308&author=J.+M.+Hatcherauthor=M.+Bahcallauthor=H.+G.+Choiauthor=Y.+Gaoauthor=T.+Simauthor=R.+Georgeauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+inhibitors+that+overcome+the+G1202R+anaplastic+lymphoma+kinase+resistance+mutation&doi=10.1021%2Facs.jmedchem.5b01136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span></div><div class="casAuthors">Hatcher, John M.; Bahcall, Magda; Choi, Hwan Geun; Gao, Yang; Sim, Taebo; George, Rani; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9296-9308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The treatment of patients with advanced nonsmall-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-mol. inhibitor of ALK, ROS1, and MET.  However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS).  This has motivated the development of "second-generation" ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance.  However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations.  Herein, the authors report the development of a structural analog of alectinib I that is potent against the G1202R mutant as well as a variety of other frequently obsd. mutants.  In addn., I is capable of penetrating the CNS of mice following oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_JJeOYNwybVg90H21EOLACvtfcHk0lg4dDN0Hl7awg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE&md5=711b0353b771b54990264565c901a76f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01136%26sid%3Dliteratum%253Aachs%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGeorge%26aufirst%3DR.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520inhibitors%2520that%2520overcome%2520the%2520G1202R%2520anaplastic%2520lymphoma%2520kinase%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9296%26epage%3D9308%26doi%3D10.1021%2Facs.jmedchem.5b01136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span><span class="refDoi"> DOI: 10.1016/j.molonc.2013.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.molonc.2013.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=23993685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=1093-1102&author=H.+R.+Kimauthor=W.+S.+Kimauthor=Y.+J.+Choiauthor=C.+H.+Choiauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Epithelial-mesenchymal+transition+leads+to+crizotinib+resistance+in+H2228+lung+cancer+cells+with+EML4-ALK+translocation&doi=10.1016%2Fj.molonc.2013.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span></div><div class="casAuthors">Kim, Hyeong Ryul; Kim, Woo Sung; Choi, Yun Jung; Choi, Chang Min; Rho, Jin Kyung; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1093-1102</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epithelial-mesenchymal transition (EMT) is assocd. with reduced sensitivity to many chemotherapeutic drugs, including EGFR tyrosine kinase inhibitors.  Here, we investigated if this reduced sensitivity also contributes to resistance to crizotinib, an ALK inhibitor of lung cancer that exhibits the EML4-ALK translocation.  We established a crizotinib-resistant subline (H2228/CR), which was derived from the parental H2228 cell line by long-term exposure to increasing concns. of crizotinib.  Characteristics assocd. with EMT, including morphol., EMT marker proteins, and cellular mobility, were analyzed.  Compared with H2228 cells, the growth of H2228/CR cells was independent of EML4-ALK, and H2228/CR cells showed cross-resistance to TAE-684 (a second-generation ALK inhibitor).  Phenotypic changes to the spindle-cell shape were noted in H2228/CR cells, which were accompanied by a decrease in E-cadherin and increase in vimentin and AXL.  In addn., H2228/CR cells showed increased secretion and expression of TGF-β1.  Invasion and migration capabilities were dramatically increased in H2228/CR cells.  Applying TGF-β1 treatment to parental H2228 cells for 72 h induced reversible EMT, leading to crizotinib resistance, but this was reversed by the removal of TGF-β1.  Suppression of vimentin in H2228/CR cells by siRNA treatment restored sensitivity to crizotinib.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitors, similar to the parental H2228 cells.  In conclusion, we suggest EMT is possibly involved in acquired resistance to crizotinib, and that HSP90 inhibitors could be a promising option for the treatment of EMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1f1A1JNCfobVg90H21EOLACvtfcHk0lg4dDN0Hl7awg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I&md5=c79e45e695141be621672bf47c663c7f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2013.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2013.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DEpithelial-mesenchymal%2520transition%2520leads%2520to%2520crizotinib%2520resistance%2520in%2520H2228%2520lung%2520cancer%2520cells%2520with%2520EML4-ALK%2520translocation%26jtitle%3DMol.%2520Oncol.%26date%3D2013%26volume%3D7%26spage%3D1093%26epage%3D1102%26doi%3D10.1016%2Fj.molonc.2013.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul N. Mortenson, Daniel A. Erlanson, Iwan J. P. de Esch, Wolfgang Jahnke, <span class="NLM_string-name hlFld-ContribAuthor">Christopher N. Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-to-Lead Medicinal Chemistry Publications in 2017. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3857-3872. <a href="https://doi.org/10.1021/acs.jmedchem.8b01472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01472%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-to-Lead%252BMedicinal%252BChemistry%252BPublications%252Bin%252B2017%26aulast%3DMortenson%26aufirst%3DPaul%2BN.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D21092018%26date%3D21112018%26volume%3D62%26issue%3D8%26spage%3D3857%26epage%3D3872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinzhe  Shi</span>, <span class="hlFld-ContribAuthor ">E. Daiann  Sosa Carrizo</span>, <span class="hlFld-ContribAuthor ">Marie  Cordier</span>, <span class="hlFld-ContribAuthor ">Julien  Roger</span>, <span class="hlFld-ContribAuthor ">Nadine  Pirio</span>, <span class="hlFld-ContribAuthor ">Jean‐Cyrille  Hierso</span>, <span class="hlFld-ContribAuthor ">Paul  Fleurat‐Lessard</span>, <span class="hlFld-ContribAuthor ">Jean‐François  Soulé</span>, <span class="hlFld-ContribAuthor ">Henri  Doucet</span>. </span><span class="cited-content_cbyCitation_article-title">C−H Bond Arylation of Pyrazoles at the β‐Position: General Conditions and Computational Elucidation for a High Regioselectivity. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (17)
                                     , 5546-5554. <a href="https://doi.org/10.1002/chem.202100031" title="DOI URL">https://doi.org/10.1002/chem.202100031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202100031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202100031%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DC%2525E2%252588%252592H%252BBond%252BArylation%252Bof%252BPyrazoles%252Bat%252Bthe%252B%2525CE%2525B2%2525E2%252580%252590Position%25253A%252BGeneral%252BConditions%252Band%252BComputational%252BElucidation%252Bfor%252Ba%252BHigh%252BRegioselectivity%26aulast%3DShi%26aufirst%3DXinzhe%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D17%26spage%3D5546%26epage%3D5554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hegira  Ramírez</span>, <span class="hlFld-ContribAuthor ">Esteban  Fernandez</span>, <span class="hlFld-ContribAuthor ">Juan  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Soriuska  Mayora</span>, <span class="hlFld-ContribAuthor ">Gricelis  Martínez</span>, <span class="hlFld-ContribAuthor ">Carmen  Celis</span>, <span class="hlFld-ContribAuthor ">Juan B.  De Sanctis</span>, <span class="hlFld-ContribAuthor ">Michael  Mijares</span>, <span class="hlFld-ContribAuthor ">Jaime  Charris</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antimalarial and anticancer evaluation of 7‐chlorquinoline‐4‐thiazoleacetic derivatives containing aryl hydrazide moieties. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em>33 </em><a href="https://doi.org/10.1002/ardp.202100002" title="DOI URL">https://doi.org/10.1002/ardp.202100002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202100002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202100002%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%252Band%252Bantimalarial%252Band%252Banticancer%252Bevaluation%252Bof%252B7%2525E2%252580%252590chlorquinoline%2525E2%252580%2525904%2525E2%252580%252590thiazoleacetic%252Bderivatives%252Bcontaining%252Baryl%252Bhydrazide%252Bmoieties%26aulast%3DRam%25C3%25ADrez%26aufirst%3DHegira%26date%3D2021%26date%3D2021%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Byeongseok  Kweon</span>, <span class="hlFld-ContribAuthor ">Yonghoon  Moon</span>, <span class="hlFld-ContribAuthor ">Yujin  Jeong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective C−H Functionalization of Heteroarene
              N
              ‐Oxides Enabled by a Traceless Nucleophile. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (50)
                                     , 22864-22872. <a href="https://doi.org/10.1002/ange.202010597" title="DOI URL">https://doi.org/10.1002/ange.202010597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202010597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202010597%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DRegioselective%252BC%2525E2%252588%252592H%252BFunctionalization%252Bof%252BHeteroarene%252BN%252B%2525E2%252580%252590Oxides%252BEnabled%252Bby%252Ba%252BTraceless%252BNucleophile%26aulast%3DMathi%26aufirst%3DGangadhar%2BRao%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D50%26spage%3D22864%26epage%3D22872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gangadhar Rao  Mathi</span>, <span class="hlFld-ContribAuthor ">Byeongseok  Kweon</span>, <span class="hlFld-ContribAuthor ">Yonghoon  Moon</span>, <span class="hlFld-ContribAuthor ">Yujin  Jeong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective C−H Functionalization of Heteroarene
              N
              ‐Oxides Enabled by a Traceless Nucleophile. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (50)
                                     , 22675-22683. <a href="https://doi.org/10.1002/anie.202010597" title="DOI URL">https://doi.org/10.1002/anie.202010597</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202010597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202010597%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DRegioselective%252BC%2525E2%252588%252592H%252BFunctionalization%252Bof%252BHeteroarene%252BN%252B%2525E2%252580%252590Oxides%252BEnabled%252Bby%252Ba%252BTraceless%252BNucleophile%26aulast%3DMathi%26aufirst%3DGangadhar%2BRao%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D50%26spage%3D22675%26epage%3D22683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hegira  Rámirez</span>, <span class="hlFld-ContribAuthor ">Juan R  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Michael R  Mijares</span>, <span class="hlFld-ContribAuthor ">Juan B  De Sanctis</span>, <span class="hlFld-ContribAuthor ">Jaime E  Charris</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity of 2-[2-(7-chloroquinolin-4-ylthio)-4-methylthiazol-5-yl]-
              N
              -phenylacetamide derivatives as antimalarial and cytotoxic agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2020,</strong> <em>44 </em>
                                    (5-6)
                                     , 305-314. <a href="https://doi.org/10.1177/1747519819899073" title="DOI URL">https://doi.org/10.1177/1747519819899073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1747519819899073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1747519819899073%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bof%252B2-%25255B2-%2525287-chloroquinolin-4-ylthio%252529-4-methylthiazol-5-yl%25255D-%252BN%252B-phenylacetamide%252Bderivatives%252Bas%252Bantimalarial%252Band%252Bcytotoxic%252Bagents%26aulast%3DR%25C3%25A1mirez%26aufirst%3DHegira%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D5-6%26spage%3D305%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Sicong  Liu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Yin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103456. <a href="https://doi.org/10.1016/j.bioorg.2019.103456" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-arylaminopyrimidine%252Bderivatives%252Bbearing%252B1%25252C3%25252C8-triazaspiro%25255B4%25252C5%25255Ddecan-4-one%252Bor%252Bpiperidine-3-carboxamide%252Bmoiety%252Bas%252Bnovel%252BType-I1%25252F2%252BALK%252Binhibitors%26aulast%3DMiao%26aufirst%3DXiuqi%26date%3D2020%26volume%3D94%26spage%3D103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinmee  Mah</span>, <span class="hlFld-ContribAuthor ">Jaebong  Jang</span>, <span class="hlFld-ContribAuthor ">Daesun  Song</span>, <span class="hlFld-ContribAuthor ">Yongje  Shin</span>, <span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Yongwon  Jung</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of fluorescent 3-heteroarylcoumarin derivatives as novel inhibitors of anaplastic lymphoma kinase. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (1)
                                     , 186-194. <a href="https://doi.org/10.1039/C8OB02874E" title="DOI URL">https://doi.org/10.1039/C8OB02874E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02874E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02874E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bfluorescent%252B3-heteroarylcoumarin%252Bderivatives%252Bas%252Bnovel%252Binhibitors%252Bof%252Banaplastic%252Blymphoma%252Bkinase%26aulast%3DMah%26aufirst%3DShinmee%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D1%26spage%3D186%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han‐Qing  Wu</span>, <span class="hlFld-ContribAuthor ">Shi‐He  Luo</span>, <span class="hlFld-ContribAuthor ">Liang  Cao</span>, <span class="hlFld-ContribAuthor ">Hao‐Nan  Shi</span>, <span class="hlFld-ContribAuthor ">Bo‐Wen  Wang</span>, <span class="hlFld-ContribAuthor ">Zhao‐Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">DABCO‐Mediated C−O Bond Formation from C
              sp2
              ‐Halogen Bond‐Containing Compounds and Alkyl Alcohols. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>7 </em>
                                    (12)
                                     , 2479-2483. <a href="https://doi.org/10.1002/ajoc.201800517" title="DOI URL">https://doi.org/10.1002/ajoc.201800517</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201800517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201800517%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDABCO%2525E2%252580%252590Mediated%252BC%2525E2%252588%252592O%252BBond%252BFormation%252Bfrom%252BC%252Bsp2%252B%2525E2%252580%252590Halogen%252BBond%2525E2%252580%252590Containing%252BCompounds%252Band%252BAlkyl%252BAlcohols%26aulast%3DWu%26aufirst%3DHan%25E2%2580%2590Qing%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D12%26spage%3D2479%26epage%3D2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Sidorov</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Davioud-Charvet</span>, <span class="hlFld-ContribAuthor ">Gilles  Marcou</span>, <span class="hlFld-ContribAuthor ">Dragos  Horvath</span>, <span class="hlFld-ContribAuthor ">Alexandre  Varnek</span>. </span><span class="cited-content_cbyCitation_article-title">AntiMalarial Mode of Action (AMMA) Database: Data Selection, Verification and Chemical Space Analysis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2018,</strong> <em>37 </em>
                                    (9-10)
                                     , 1800021. <a href="https://doi.org/10.1002/minf.201800021" title="DOI URL">https://doi.org/10.1002/minf.201800021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201800021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201800021%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DAntiMalarial%252BMode%252Bof%252BAction%252B%252528AMMA%252529%252BDatabase%25253A%252BData%252BSelection%25252C%252BVerification%252Band%252BChemical%252BSpace%252BAnalysis%26aulast%3DSidorov%26aufirst%3DPavel%26date%3D2018%26date%3D2018%26volume%3D37%26issue%3D9-10%26spage%3D1800021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structures of Crizotinib and Representative 4-Phenoxyquinoline-Based Inhibitor</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Expected configuration of 4-aminoquinoline moiety in ATP binding site of ALK L1196M. (b) Design of new scaffolds and opportunities for modification in the schematic active site of ALK L1196M. Each dotted line represents a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) aniline, 35% HCl, <i>i</i>PrOH, 80 °C, 1.5 h; (b) phenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C, 12 h; (c) R<sub>2</sub>-Bpin, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O = 1:1, 120 °C, 1 h, μW; (d) R<sub>2</sub>-Bpin, Pd(dppf)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene/H<sub>2</sub>O = 2:1, 90 °C, 12 h, after c or d, additional deprotection under TFA, DCM, rt, 1 h for <b>11</b>, <b>14</b>–<b>30</b>.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Binding mode of 4-anilinoquinoline obtained through preparing inhibitors at pH above 11.16 followed by normal docking study (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). (b) Calculated binding mode of 4-phenylaminoquinoline at pH 6.5–8.5. Protonated site is marked with red dashed circle (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). (c) Ionization pH of each marked unit and existing form in the blue- and orange-colored pH ranges.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Calculated binding mode of <b>30</b> at the ATP binding site of ALK L1196M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX">2YFX</a>). Each dashed blue line and orange line indicates a hydrogen bond and salt bridge, respectively. Gatekeeper was displayed in semitransparent solid surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Progress curves for ALK (L1196M) with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Michaelis–Menten plot (A) and Lineweaver–Burk plot (B) for ALK (L1196M) with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. IC<sub>50</sub> curves for ALK (L1196M) at different ATP concentrations with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. IC<sub>50</sub> curves for ALK (L1196M) at different ATP concentrations with <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cell viability of crizotinib, ceritinib, alectinib, and <b>30</b>. Cell viability of crizotinib, ceritinib, alectinib, and <b>30</b> were measured in (a) Ba/F3 EML4-ALK WT (EA WT), EML4-ALK L1196M (EA L1196M), and H2228 and (b) H2228 CR human lung cancer cells by MTT assay. EA = EML4-ALK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/medium/jm-2017-01039t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>30</b> increased crizotinib sensitivity and overcame crizotinib resistance by decreasing PI3K/AKT and MAPK signaling in crizotinib-sensitive and -resistant human lung cancer cells. H2228 and H2228 CR human lung cancer cells were treated with the indicated concentrations of <b>30</b> and crizotinib for 3 h, and then the expression levels of p-AKT and p-ERK were measured by Western blotting. Data are presented as means ± SD (***<i>P</i> < 0.005).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01039&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Motegi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuraba, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, T.</span><span> </span><span class="NLM_article-title">ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3319</span><span class="NLM_x">–</span> <span class="NLM_lpage">3329</span><span class="refDoi"> DOI: 10.1242/jcs.01183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1242%2Fjcs.01183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=15226403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ensLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=3319-3329&author=A.+Motegiauthor=J.+Fujimotoauthor=M.+Kotaniauthor=H.+Sakurabaauthor=T.+Yamamoto&title=ALK+receptor+tyrosine+kinase+promotes+cell+growth+and+neurite+outgrowth&doi=10.1242%2Fjcs.01183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth</span></div><div class="casAuthors">Motegi, Akira; Fujimoto, Jiro; Kotani, Masaharu; Sakuraba, Hitoshi; Yamamoto, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3319-3329</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor-type protein tyrosine kinase that is expressed preferentially in neurons of the central and peripheral nervous systems at late embryonic stages.  To elucidate the role of ALK in neurons, we developed an agonist monoclonal antibody (mAb) against the extracellular domain of ALK.  Here we show that mAb16-39 elicits tyrosine phosphorylation of endogenously expressed ALK in human neuroblastoma (SK-N-SH) cells.  Stimulation of these cells with mAb16-39 markedly induces the tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1), Shc, and c-Cbl and also their interaction with ALK and activation of ERK1/2.  Furthermore, we show that continuous incubation with mAb16-39 induces the cell growth and neurite outgrowth of SK-N-SH cells.  These responses are completely blocked by MEK inhibitor PD98059 but not by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin, indicating an essential role of the mitogen-activated protein kinase (MAP kinase) signaling cascade in ALK-mediated growth and differentiation of neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1Bpvtz4TX7Vg90H21EOLACvtfcHk0lieHSdoDXIrnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ensLk%253D&md5=1219574e37777433a6244819676c3294</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fjcs.01183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.01183%26sid%3Dliteratum%253Aachs%26aulast%3DMotegi%26aufirst%3DA.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKotani%26aufirst%3DM.%26aulast%3DSakuraba%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DT.%26atitle%3DALK%2520receptor%2520tyrosine%2520kinase%2520promotes%2520cell%2520growth%2520and%2520neurite%2520outgrowth%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2004%26volume%3D117%26spage%3D3319%26epage%3D3329%26doi%3D10.1242%2Fjcs.01183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">García-Regalado, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González-De la Rosa, C. H.</span><span> </span><span class="NLM_article-title">The role of anaplastic lymphoma kinase in human cancers</span> <span class="citation_source-journal">Oncol. Hematol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.17925/OHR.2013.09.2.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.17925%2FOHR.2013.09.2.149" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=149-153&author=A.+Garc%C3%ADa-Regaladoauthor=C.+H.+Gonz%C3%A1lez-De+la+Rosa&title=The+role+of+anaplastic+lymphoma+kinase+in+human+cancers&doi=10.17925%2FOHR.2013.09.2.149"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.17925%2FOHR.2013.09.2.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17925%252FOHR.2013.09.2.149%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Regalado%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez-De%2Bla%2BRosa%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520human%2520cancers%26jtitle%3DOncol.%2520Hematol.%2520Rev.%26date%3D2013%26volume%3D9%26spage%3D149%26epage%3D153%26doi%3D10.17925%2FOHR.2013.09.2.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hallberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, R. H.</span><span> </span><span class="NLM_article-title">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/nrc3580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1038%2Fnrc3580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24060861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=685-700&author=B.+Hallbergauthor=R.+H.+Palmer&title=Mechanistic+insight+into+ALK+receptor+tyrosine+kinase+in+human+cancer+biology&doi=10.1038%2Fnrc3580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span></div><div class="casAuthors">Hallberg, Bengt; Palmer, Ruth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">685-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC).  The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK.  In this review, we discuss our current understanding of ALK function in human cancer and the implications for tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADI-N0ZBEr7Vg90H21EOLACvtfcHk0lh4e9vgB_Da5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP&md5=fab66b12114ca01348df4ca08d3b3e4e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3580%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DMechanistic%2520insight%2520into%2520ALK%2520receptor%2520tyrosine%2520kinase%2520in%2520human%2520cancer%2520biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fnrc3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Roskoski, R.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lh4e9vgB_Da5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Koivunen, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarbaker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducko, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4275</span><span class="NLM_x">–</span> <span class="NLM_lpage">4283</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-0168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1078-0432.CCR-08-0168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=18594010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4275-4283&author=J.+P.+Koivunenauthor=C.+Mermelauthor=K.+Zejnullahuauthor=C.+Murphyauthor=E.+Lifshitsauthor=A.+J.+Holmesauthor=H.+G.+Choiauthor=J.+Kimauthor=D.+Chiangauthor=R.+Thomasauthor=J.+Leeauthor=W.+G.+Richardsauthor=D.+J.+Sugarbakerauthor=C.+Duckoauthor=N.+Lindemanauthor=J.+P.+Marcouxauthor=J.+A.+Engelmanauthor=N.+S.+Grayauthor=C.+Leeauthor=M.+Meyersonauthor=P.+A.+Janne&title=EML4-ALK+fusion+gene+and+efficacy+of+an+ALK+kinase+inhibitor+in+lung+cancer&doi=10.1158%2F1078-0432.CCR-08-0168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer</span></div><div class="casAuthors">Koivunen, Jussi P.; Mermel, Craig; Zejnullahu, Kreshnik; Murphy, Carly; Lifshits, Eugene; Holmes, Alison J.; Choi, Hwan Geun; Kim, Jhingook; Chiang, Derek; Thomas, Roman; Lee, Jinseon; Richards, William G.; Sugarbaker, David J.; Ducko, Christopher; Lindeman, Neal; Marcoux, J. Paul; Engelman, Jeffrey A.; Gray, Nathanael S.; Lee, Charles; Meyerson, Matthew; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4275-4283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell lung cancers (NSCLC).  We detd. the frequency of EML4-ALK in Caucasian NSCLC and in NSCLC cell lines.  We also detd. whether TAE684, a specific ALK kinase inhibitor, would inhibit the growth of EML4-ALK-contg. cell lines in vitro and in vivo.  We screened 305 primary NSCLC [both U.S. (n = 138) and Korean (n = 167) patients] and 83 NSCLC cell lines using reverse transcription-PCR and by exon array analyses.  We evaluated the efficacy of TAE684 against NSCLC cell lines in vitro and in vivo.  We detected four different variants, including two novel variants, of EML4-ALK using reverse transcription-PCR in 8 of 305 tumors (3%) and 3 of 83 (3.6%) NSCLC cell lines.  All EML4-ALK-contg. tumors and cell lines were adenocarcinomas.  EML4-ALK was detected more frequently in NSCLC patients who were never or light (<10 pack-years) cigarette smokers compared with current/former smokers (6% vs. 1%; P = 0.049).  TAE684 inhibited the growth of one of three (H3122) EML4-ALK-contg. cell lines in vitro and in vivo, inhibited Akt phosphorylation, and caused apoptosis.  In another EML4-ALK cell line, DFCI032, TAE684 was ineffective due to coactivation of epidermal growth factor receptor and ERBB2.  The combination of TAE684 and CL-387,785 (epidermal growth factor receptor/ERBB2 kinase inhibitor) inhibited growth and Akt phosphorylation and led to apoptosis in the DFCI032 cell line.  EML4-ALK is found in the minority of NSCLC.  ALK kinase inhibitors alone or in combination may nevertheless be clin. effective treatments for NSCLC patients whose tumors contain EML4-ALK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOXKywqERg6rVg90H21EOLACvtfcHk0lgN61jx7xZRAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFyks7s%253D&md5=6e29703c783e6a29cf77e3c4b93fc15f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0168%26sid%3Dliteratum%253Aachs%26aulast%3DKoivunen%26aufirst%3DJ.%2BP.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChiang%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DW.%2BG.%26aulast%3DSugarbaker%26aufirst%3DD.%2BJ.%26aulast%3DDucko%26aufirst%3DC.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DEML4-ALK%2520fusion%2520gene%2520and%2520efficacy%2520of%2520an%2520ALK%2520kinase%2520inhibitor%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4275%26epage%3D4283%26doi%3D10.1158%2F1078-0432.CCR-08-0168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Palmer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernersson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, B.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: signalling in development and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">420</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1042/BJ20090387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1042%2FBJ20090387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+lymphoma+kinase%3A+signalling+in+development+and+disease&doi=10.1042%2FBJ20090387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBJ20090387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090387%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520signalling%2520in%2520development%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361%26doi%3D10.1042%2FBJ20090387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4%E2%80%93ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0liMNlJMWr_AjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4%25E2%2580%2593ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">673</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.-Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+inhibitor+ceritinib+overcomes+crizotinib+resistance+in+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0liMNlJMWr_AjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520inhibitor%2520ceritinib%2520overcomes%2520crizotinib%2520resistance%2520in%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lgeOdD_85bpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konagai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fushiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakagami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non–small cell lung cancer model mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+selective+anaplastic+lymphoma+receptor+tyrosine+kinase+inhibitor+ASP3026+induces+tumor+regression+and+prolongs+survival+in+non%E2%80%93small+cell+lung+cancer+model+mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0lgeOdD_85bpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520selective%2520anaplastic%2520lymphoma%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ASP3026%2520induces%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%2520model%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Learn, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells-Knecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruckheimer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7478</span><span class="NLM_x">–</span> <span class="NLM_lpage">7496</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7478-7496&author=G.+R.+Ottauthor=M.+Chengauthor=K.+S.+Learnauthor=J.+Wagnerauthor=D.+E.+Gingrichauthor=J.+G.+Liskoauthor=M.+Curryauthor=E.+F.+Mesarosauthor=A.+K.+Ghoseauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=P.+Dobrzanskiauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=K.+Wells-Knechtauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=E.+Bruckheimerauthor=N.+Andersonauthor=J.+Friedmanauthor=S.+V.+Fernandezauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+clinical+candidate+CEP-37440%2C+a+selective+inhibitor+of+focal+adhesion+kinase+%28FAK%29+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Facs.jmedchem.6b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Ott, Gregory R.; Cheng, Mangeng; Learn, Keith S.; Wagner, Jason; Gingrich, Diane E.; Lisko, Joseph G.; Curry, Matthew; Mesaros, Eugen F.; Ghose, Arup K.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Dobrzanski, Pawel; Albom, Mark S.; Angeles, Thelma S.; Wells-Knecht, Kevin; Huang, Zeqi; Aimone, Lisa D.; Bruckheimer, Elizabeth; Anderson, Nathan; Friedman, Jay; Fernandez, Sandra V.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7478-7496</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Analogs structurally related to anaplastic lymphoma kinase (ALK) inhibitor (CEP-28122) were optimized for metabolic stability.  The results from this endeavor not only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity against clin. derived resistance mutations but also led to the incorporation of activity for focal adhesion kinase (FAK).  FAK activation, via amplification and/or overexpression, is characteristic of multiple invasive solid tumors and metastasis.  The discovery of the clin. stage, dual FAK/ALK inhibitor 27b (CEP-37440), including details surrounding SAR, in vitro/in vivo pharmacol., and pharmacokinetics, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojryum63_LVg90H21EOLACvtfcHk0lhmkySKG7Vnqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaru77P&md5=3fcd1342d901b2379d0efbd118d3049f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DLearn%26aufirst%3DK.%2BS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DCurry%26aufirst%3DM.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDobrzanski%26aufirst%3DP.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DWells-Knecht%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DBruckheimer%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DN.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DS.%2BV.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520clinical%2520candidate%2520CEP-37440%252C%2520a%2520selective%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%2520%2528FAK%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7478%26epage%3D7496%26doi%3D10.1021%2Facs.jmedchem.6b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lizZWsiYLY41Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squillace, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadworny, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichinger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miret, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5527</span><span class="NLM_x">–</span> <span class="NLM_lpage">5538</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-0569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1078-0432.CCR-16-0569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=27780853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5527-5538&author=S.+Zhangauthor=R.+Anjumauthor=R.+Squillaceauthor=S.+Nadwornyauthor=T.+Zhouauthor=J.+Keatsauthor=Y.+Ningauthor=S.+D.+Wardwellauthor=D.+Millerauthor=Y.+Songauthor=L.+Eichingerauthor=L.+Moranauthor=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=Y.+Wangauthor=Q.+Mohemmadauthor=H.+G.+Jangauthor=E.+Yeauthor=N.+Narasimhanauthor=F.+Wangauthor=J.+Miretauthor=X.+Zhuauthor=T.+Clacksonauthor=D.+Dalgarnoauthor=W.+C.+Shakespeareauthor=V.+M.+Rivera&title=The+potent+ALK+inhibitor+brigatinib+%28AP26113%29+overcomes+mechanisms+of+resistance+to+first-and+second-generation+ALK+inhibitors+in+preclinical+models&doi=10.1158%2F1078-0432.CCR-16-0569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zhang, Sen; Anjum, Rana; Squillace, Rachel; Nadworny, Sara; Zhou, Tianjun; Keats, Jeff; Ning, Yaoyu; Wardwell, Scott D.; Miller, David; Song, Youngchul; Eichinger, Lindsey; Moran, Lauren; Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Wang, Yihan; Mohemmad, Qurish; Jang, Hyun Gyung; Ye, Emily; Narasimhan, Narayana; Wang, Frank; Miret, Juan; Zhu, Xiaotian; Clackson, Tim; Dalgarno, David; Shakespeare, William C.; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5527-5538</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain.  Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified.  Here, we report the structure and first comprehensive preclin. evaluation of the next-generation ALK TKI brigatinib.  Exptl. Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib.  The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines.  The brigatinib-ALK co-structure was detd.  Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases.  Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib.  Superior efficacy of brigatinib was also obsd. in mice with ALK+ tumors implanted s.c. or intracranially.  Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clin. achievable concns.  Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R.  The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.  Conclusions: Brigatinib is a highly potent and selective ALK inhibitor.  These findings provide the mol. basis for the promising activity being obsd. in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clin. trials.  Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwQUn_qLy7bVg90H21EOLACvtfcHk0lizZWsiYLY41Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqur3O&md5=1ece23bf36e807562023d0b814c990c7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-0569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-0569%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DSquillace%26aufirst%3DR.%26aulast%3DNadworny%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEichinger%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMohemmad%26aufirst%3DQ.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DYe%26aufirst%3DE.%26aulast%3DNarasimhan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMiret%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DThe%2520potent%2520ALK%2520inhibitor%2520brigatinib%2520%2528AP26113%2529%2520overcomes%2520mechanisms%2520of%2520resistance%2520to%2520first-and%2520second-generation%2520ALK%2520inhibitors%2520in%2520preclinical%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5527%26epage%3D5538%26doi%3D10.1158%2F1078-0432.CCR-16-0569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Iwama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, Y.</span><span> </span><span class="NLM_article-title">Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span><span class="refDoi"> DOI: 10.2147/OTT.S38868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.2147%2FOTT.S38868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24623980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=375-385&author=E.+Iwamaauthor=I.+Okamotoauthor=T.+Haradaauthor=K.+Takayamaauthor=Y.+Nakanishi&title=Development+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+and+molecular+diagnosis+in+ALK+rearrangement-positive+lung+cancer&doi=10.2147%2FOTT.S38868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer</span></div><div class="casAuthors">Iwama, Eiji; Okamoto, Isamu; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">375-385, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The fusion of echinoderm microtubule-assocd. protein-like 4 with anaplastic lymphoma kinase (ALK) was identified as a transforming gene for lung cancer in 2007.  This genetic rearrangement accounts for 2%-5% of non-small-cell lung cancer (NSCLC) cases, occurring predominantly in younger individuals with adenocarcinoma who are never- or light smokers.  A small-mol. tyrosine-kinase inhibitor of ALK, crizotinib, was rapidly approved by the US Food and Drug Administration on the basis of its pronounced clin. activity in patients with ALK rearrangement-pos. NSCLC.  Next-generation ALK inhibitors, such as alectinib, LDK378, and AP26113, are also being developed in ongoing clin. trials.  In addn., the improvement and validation of methods for the detection of ALK rearrangement in NSCLC patients will be key to the optimal clin. use of ALK inhibitors.  We here summarize recent progress in the development of new ALK inhibitors and in the mol. diagnosis of ALK rearrangement-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql5NNTgVgC8bVg90H21EOLACvtfcHk0ljDta7aar-A0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynu7bI&md5=97dc145eadba8084eb324a33ee0eb271</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2147%2FOTT.S38868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S38868%26sid%3Dliteratum%253Aachs%26aulast%3DIwama%26aufirst%3DE.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DNakanishi%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520and%2520molecular%2520diagnosis%2520in%2520ALK%2520rearrangement-positive%2520lung%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2014%26volume%3D7%26spage%3D375%26epage%3D385%26doi%3D10.2147%2FOTT.S38868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">120ra17</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">953</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span><span class="refDoi"> DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0ljDta7aar-A0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Lin, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J.-Y.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) kinase domain mutation following ALK Inhibitor (s) failure in advanced ALK positive non–small-cell lung cancer: analysis and literature review</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">e77</span><span class="NLM_x">–</span> <span class="NLM_lpage">e94</span><span class="refDoi"> DOI: 10.1016/j.cllc.2016.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.cllc.2016.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=27130468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFCntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e77-e94&author=Y.-T.+Linauthor=C.-J.+Yuauthor=J.+C.-H.+Yangauthor=J.-Y.+Shih&title=Anaplastic+lymphoma+kinase+%28ALK%29+kinase+domain+mutation+following+ALK+Inhibitor+%28s%29+failure+in+advanced+ALK+positive+non%E2%80%93small-cell+lung+cancer%3A+analysis+and+literature+review&doi=10.1016%2Fj.cllc.2016.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review</span></div><div class="casAuthors">Lin, Yen-Ting; Yu, Chong-Jen; Yang, James Chih-Hsin; Shih, Jin-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e77-e94</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Secondary anaplastic lymphoma kinase (ALK) mutation may occur in patients with advanced ALK-pos. non-small cell lung cancer treated with ALK inhibitors, but its nature is not well-known.We analyzed tumor specimens after the failure of treatment with ALK inhibitor(s) (crizotinib, alectinib, and ceritinib) for secondary ALK kinase domain mutation, EGFR, K-ras, and PIK3CA mutations.  The literature regarding acquired ALK-inhibitor(s) resistance was also reviewed.Among 59 patients who received ALK inhibitor(s) during the period of Dec. 2010 to Apr. 2015, 7 had re-biopsied tumor specimens for analyses following ALK inhibitor(s) failure.  One had G1202R after crizotinib and alectinib failure, and 6 were wild type.  No EGFR, K-ras, or PIK3CA mutations were found.  In our review of the literature and taken together with our patients, 25 of the 88 (28%) patients with crizotinib failure had secondary ALK mutation; L1196M mutation was most common (n = 11).  Patients with secondary ALK mutation other than L1196M had a longer progression-free survival after crizotinib than patients with L1196M (median, 12.0 vs. 7.0 mo; P = .04).  Of the 9 patients with alectinib failure, 5 had I1171 mutation and 2 had G1202R.  Of the 11 patients with ceritinib failure, 2 had G1202R, 1 had F1174C, and 1 had both G1202R and F1174V.  I1171 mutation, G1202R, and F1174 mutations were also found in crizotinib-failed patients.Some acquired ALK mutations may cause co-resistance to other ALK inhibitors.  Re-biopsy for ALK mutation anal. might be suggested prior to choosing a second-line ALK inhibitor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreRRKZfEHN2LVg90H21EOLACvtfcHk0li-m79Lnt4LBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFCntLc%253D&md5=2ba6e81398afffdfbb9bd356e0a6d4bc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2016.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2016.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DY.-T.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DShih%26aufirst%3DJ.-Y.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520kinase%2520domain%2520mutation%2520following%2520ALK%2520Inhibitor%2520%2528s%2529%2520failure%2520in%2520advanced%2520ALK%2520positive%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%253A%2520analysis%2520and%2520literature%2520review%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2016%26volume%3D17%26spage%3De77%26epage%3De94%26doi%3D10.1016%2Fj.cllc.2016.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Toyokawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inamasu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamatsu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nosaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenoyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span> </span><span class="NLM_article-title">Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non–small-cell lung cancer exhibiting resistance to ceritinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e55</span><span class="NLM_x">–</span> <span class="NLM_lpage">e57</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1097%2FJTO.0000000000000509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=26134233" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e55-e57&author=G.+Toyokawaauthor=E.+Inamasuauthor=S.+Shimamatsuauthor=T.+Yoshidaauthor=K.+Nosakiauthor=F.+Hiraiauthor=M.+Yamaguchiauthor=T.+Setoauthor=M.+Takenoyamaauthor=Y.+Ichinose&title=Identification+of+a+novel+ALK+G1123S+mutation+in+a+patient+with+ALK-rearranged+non%E2%80%93small-cell+lung+cancer+exhibiting+resistance+to+ceritinib&doi=10.1097%2FJTO.0000000000000509"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000509%26sid%3Dliteratum%253Aachs%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DInamasu%26aufirst%3DE.%26aulast%3DShimamatsu%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DNosaki%26aufirst%3DK.%26aulast%3DHirai%26aufirst%3DF.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DTakenoyama%26aufirst%3DM.%26aulast%3DIchinose%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520a%2520novel%2520ALK%2520G1123S%2520mutation%2520in%2520a%2520patient%2520with%2520ALK-rearranged%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520exhibiting%2520resistance%2520to%2520ceritinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3De55%26epage%3De57%26doi%3D10.1097%2FJTO.0000000000000509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kain, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klempner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&author=S.-H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-generation+sequencing+reveals+a+Novel+NSCLC+ALK+F1174V+mutation+and+confirms+ALK+G1202R+mutation+confers+high-level+resistance+to+alectinib+%28CH5424802%2FRO5424802%29+in+ALK-rearranged+NSCLC+patients+who+progressed+on+crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-generation%2520sequencing%2520reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520mutation%2520and%2520confirms%2520ALK%2520G1202R%2520mutation%2520confers%2520high-level%2520resistance%2520to%2520alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-rearranged%2520NSCLC%2520patients%2520who%2520progressed%2520on%2520crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiappori, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisserie, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Laurenzio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span> </span><span class="NLM_article-title">Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1128</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70362-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2FS1470-2045%2814%2970362-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=25153538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1119-1128&author=S.+M.+Gadgeelauthor=L.+Gandhiauthor=G.+J.+Rielyauthor=A.+A.+Chiapporiauthor=H.+L.+Westauthor=M.+C.+Azadaauthor=P.+N.+Morcosauthor=R.-M.+Leeauthor=L.+Garciaauthor=L.+Yuauthor=F.+Boisserieauthor=L.+Di+Laurenzioauthor=S.+Goldingauthor=J.+Satoauthor=S.+Yokoyamaauthor=T.+Tanakaauthor=S.-H.+I.+Ou&title=Safety+and+activity+of+alectinib+against+systemic+disease+and+brain+metastases+in+patients+with+crizotinib-resistant+ALK-rearranged+non-small-cell+lung+cancer+%28AF-002JG%29%3A+results+from+the+dose-finding+portion+of+a+phase+1%2F2+study&doi=10.1016%2FS1470-2045%2814%2970362-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study</span></div><div class="casAuthors">Gadgeel, Shirish M.; Gandhi, Leena; Riely, Gregory J.; Chiappori, Alberto A.; West, Howard L.; Azada, Michele C.; Morcos, Peter N.; Lee, Ruey-Min; Garcia, Linta; Yu, Li; Boisserie, Frederic; Di Laurenzio, Laura; Golding, Sophie; Sato, Jotaro; Yokoyama, Shumpei; Tanaka, Tomohiro; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8-11 mo while on treatment with the ALK inhibitor crizotinib.  However, resistance inevitably develops, with the brain a common site of progression.  More potent ALK inhibitors with consistently demonstrable CNS activity and good tolerability are needed urgently.  Alectinib is a novel, highly selective, and potent ALK inhibitor that has shown clin. activity in patients with crizotinib-naive ALK-rearranged NSCLC.  We did a phase 1/2 study of alectinib to establish the recommended phase 2 dose of the drug and examine its activity in patients resistant or intolerant to crizotinib.  We enrolled patients with ALK-rearranged NSCLC who progressed on or were intolerant to crizotinib.  We administered various oral doses of alectinib (300-900 mg twice a day) during the dose-escalation portion of the study (phase 1), to ascertain the recommended dose for phase 2.  We used Response Evaluation Criteria in Solid Tumors criteria (version 1.1) to investigate the activity of alectinib in all patients with a baseline scan and at least one post-treatment scan (CT or MRI), with central radiol. review of individuals with brain metastases.  We assessed safety in all patients who received at least one dose of alectinib.  Here, we present data for the phase 1 portion of the study, the primary objective of which was to establish the recommended phase 2 dose; phase 2 is ongoing.  This trial is registered at ClinicalTrials.gov, no. NCT01588028.47 patients were enrolled.  Alectinib was well tolerated, with the most common adverse events being fatigue (14 [30%]; all grade 1-2), myalgia (eight [17%]; all grade 1-2), and peripheral edema (seven [15%] grade 1-2, one [2%] grade 3).  Dose-limiting toxic effects were recorded in two patients in the cohort receiving alectinib 900 mg twice a day; one individual had grade 3 headache and the other had grade 3 neutropenia.  The most common grade 3-4 adverse events were increased levels of γ-glutamyl transpeptidase (two [4%]), a redn. in the no. of neutrophils (two [4%]), and hypophosphatemia (two [4%]).  Three patients reported four grade 4 serious adverse events that were deemed unrelated to alectinib: acute renal failure; pleural effusion and pericardial effusion; and brain metastasis.  At data cut-off (median follow-up 126 days [IQR 84-217]), 44 patients could be assessed for activity.  Investigator-assessed objective responses were noted in 24 (55%) patients, with a confirmed complete response in one (2%), a confirmed partial response in 14 (32%), and an unconfirmed partial response in nine (20%). 16 (36%) patients had stable disease; the remaining four (9%) had progressive disease.  Of 21 patients with CNS metastases at baseline, 11 (52%) had an objective response; six (29%) had a complete response (three unconfirmed) and five (24%) had a partial response (one unconfirmed); eight (38%) patients had stable disease and the remaining two (10%) had progressive disease.  Pharmacokinetic data indicated that mean exposure (AUC0-10) after multiple doses of alectinib (300-600 mg twice a day) was dose-dependent.  Alectinib was well tolerated, with promising antitumor activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.  On the basis of activity, tolerability, and pharmacokinetic data, we chose alectinib 600 mg twice a day as the recommended dose for phase 2.  Chugai Pharmaceuticals, F Hoffmann La-Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriCeVttS5axrVg90H21EOLACvtfcHk0liIHH0SFjPuQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt77K&md5=aa56d295472ea5dcb29070a4e39d420a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970362-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970362-6%26sid%3Dliteratum%253Aachs%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DChiappori%26aufirst%3DA.%2BA.%26aulast%3DWest%26aufirst%3DH.%2BL.%26aulast%3DAzada%26aufirst%3DM.%2BC.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DLee%26aufirst%3DR.-M.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBoisserie%26aufirst%3DF.%26aulast%3DDi%2BLaurenzio%26aufirst%3DL.%26aulast%3DGolding%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26atitle%3DSafety%2520and%2520activity%2520of%2520alectinib%2520against%2520systemic%2520disease%2520and%2520brain%2520metastases%2520in%2520patients%2520with%2520crizotinib-resistant%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520%2528AF-002JG%2529%253A%2520results%2520from%2520the%2520dose-finding%2520portion%2520of%2520a%2520phase%25201%252F2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1119%26epage%3D1128%26doi%3D10.1016%2FS1470-2045%2814%2970362-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2227</span><span class="NLM_x">–</span> <span class="NLM_lpage">2235</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1158%2F1078-0432.CCR-14-2791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=25979929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2227-2235&author=R.+Katayamaauthor=C.+M.+Lovlyauthor=A.+T.+Shaw&title=Therapeutic+targeting+of+anaplastic+lymphoma+kinase+in+lung+cancer%3A+a+paradigm+for+precision+cancer+medicine&doi=10.1158%2F1078-0432.CCR-14-2791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine</span></div><div class="casAuthors">Katayama, Ryohei; Lovly, Christine M.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2227-2235</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).  Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others.  Importantly, ALK serves as a validated therapeutic target in these diseases.  Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clin. use.  These ALK inhibitors have all shown remarkable clin. outcomes in ALK-rearranged NSCLC.  Unfortunately, as is the case for other kinase inhibitors in clin. use, sensitive tumors inevitably relapse due to acquired resistance.  This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC.  Clin Cancer Res; 21(10); 2227-35. cpr2015 AACR.  See all articles in this section, "Progress in Lung Cancer".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr00cDhFZSKBrVg90H21EOLACvtfcHk0liIHH0SFjPuQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOktbw%253D&md5=80994c4611159b7f7d007fd16e4f8472</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2791%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520targeting%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%253A%2520a%2520paradigm%2520for%2520precision%2520cancer%2520medicine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2227%26epage%3D2235%26doi%3D10.1158%2F1078-0432.CCR-14-2791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lglMYeyDvkBag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, J.</span><span> </span><span class="NLM_article-title">Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="refDoi"> DOI: 10.1007/s00894-016-3099-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1007%2Fs00894-016-3099-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=27585676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A280%3ADC%252BC2szntValug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=231&author=J.+Liauthor=W.+Liuauthor=H.+Luoauthor=J.+Bao&title=Insight+into+drug+resistance+mechanisms+and+discovery+of+potential+inhibitors+against+wild-type+and+L1196M+mutant+ALK+from+FDA-approved+drugs&doi=10.1007%2Fs00894-016-3099-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs</span></div><div class="casAuthors">Li Jianzong; Liu Wei; Luo Hao; Bao Jinku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of molecular modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) plays a crucial role in multiple malignant cancers.  It is known as a well-established target for the treatment of ALK-dependent cancers.  Even though substantial efforts have been made to develop ALK inhibitors, only crizotinib, ceritinib, and alectinib had been approved by the U.S.  Food and Drug Administration for patients with ALK-positive non-small cell lung cancer (NSCLC).  The secondary mutations with drug-resistance bring up difficulties to develop effective drugs for ALK-positive cancers.  To give a comprehensive understanding of molecular mechanism underlying inhibitor response to ALK tyrosine kinase mutations, we established an accurate assessment for the extensive profile of drug against ALK mutations by means of computational approaches.  The molecular mechanics-generalized Born surface area (MM-GBSA) method based on molecular dynamics (MD) simulation was carried out to calculate relative binding free energies for receptor-drug systems.  In addition, the structure-based virtual screening was utilized to screen effective inhibitors targeting wild-type ALK and the gatekeeper mutation L1196M from 3180 approved drugs.  Finally, the mechanism of drug resistance was discussed, several novel potential wild-type and L1196M mutant ALK inhibitors were successfully identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrEHWZb5KaqekdrW1FkXG-fW6udTcc2eY0HtYhSUMl0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szntValug%253D%253D&md5=0012354bde8e60bda4cf5c559ac33184</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs00894-016-3099-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-016-3099-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DBao%26aufirst%3DJ.%26atitle%3DInsight%2520into%2520drug%2520resistance%2520mechanisms%2520and%2520discovery%2520of%2520potential%2520inhibitors%2520against%2520wild-type%2520and%2520L1196M%2520mutant%2520ALK%2520from%2520FDA-approved%2520drugs%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2016%26volume%3D22%26spage%3D231%26doi%3D10.1007%2Fs00894-016-3099-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span> </span><span class="NLM_article-title">An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer</span> <span class="citation_source-journal">Biochimie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span><span class="refDoi"> DOI: 10.1016/j.biochi.2015.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.biochi.2015.03.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=111-120&author=X.+Aiauthor=S.+Shenauthor=L.+Shenauthor=S.+Lu&title=An+interaction+map+of+small-molecule+kinase+inhibitors+with+anaplastic+lymphoma+kinase+%28ALK%29+mutants+in+ALK-positive+non-small+cell+lung+cancer&doi=10.1016%2Fj.biochi.2015.03.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.biochi.2015.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biochi.2015.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DAi%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%26atitle%3DAn%2520interaction%2520map%2520of%2520small-molecule%2520kinase%2520inhibitors%2520with%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520mutants%2520in%2520ALK-positive%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DBiochimie%26date%3D2015%26volume%3D112%26spage%3D111%26epage%3D120%26doi%3D10.1016%2Fj.biochi.2015.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">–</span> <span class="NLM_lpage">6825</span><span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors</span></div><div class="casAuthors">Bossi, Roberto T.; Saccardo, M. Beatrice; Ardini, Elena; Menichincheri, Maria; Rusconi, Luisa; Magnaghi, Paola; Orsini, Paolo; Avanzi, Nilla; Borgia, Andrea Lombardi; Nesi, Marcella; Bandiera, Tiziano; Fogliatto, Gianpaolo; Bertrand, Jay A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">6813-6825</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the development of several human cancers and, as a result, is a recognized target for the development of small-mol. inhibitors for the treatment of ALK-pos. malignancies.  Here, the crystal structures of the unphosphorylated human ALK kinase domain in complex with the ATP competitive ligands PHA-E429 and NVP-TAE684 are presented.  Anal. of these structures provides valuable information concerning the specific characteristics of the ALK active site as well as giving indications about how to obtain selective ALK inhibitors.  In addn., the ALK-KD-PHA-E429 structure led to the identification of a potential regulatory mechanism involving a link made between a short helical segment immediately following the DFG motif and an N-terminal two-stranded β-sheet.  Finally, mapping of the activating mutations assocd. with neuroblastoma onto the structures may explain the roles these residues have in the activation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2b8yuzTuAYbVg90H21EOLACvtfcHk0li9jeWblomQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Clsbs%253D&md5=e8e9e3fde63a196a15c874300c995342</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunker, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dack, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsaparikos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1170</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span><span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=J.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+potent+and+selective+inhibitors+to+overcome+clinical+anaplastic+lymphoma+kinase+mutations+resistant+to+crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0lilUNLfWnOyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520inhibitors%2520to%2520overcome%2520clinical%2520anaplastic%2520lymphoma%2520kinase%2520mutations%2520resistant%2520to%2520crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchiner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dardaei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1056/NEJMoa1508887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1056%2FNEJMoa1508887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=26698910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=54-61&author=A.+T.+Shawauthor=L.+Fribouletauthor=I.+Leshchinerauthor=J.+F.+Gainorauthor=S.+Bergqvistauthor=A.+Broounauthor=B.+J.+Burkeauthor=Y.-L.+Dengauthor=W.+Liuauthor=L.+Dardaeiauthor=R.+L.+Friasauthor=K.+R.+Schultzauthor=J.+Loganauthor=L.+P.+Jamesauthor=T.+Smealauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=A.+J.+Iafrateauthor=L.+Leauthor=M.+McTigueauthor=G.+Getzauthor=T.+W.+Johnsonauthor=J.+A.+Engelman&title=Resensitization+to+crizotinib+by+the+lorlatinib+ALK+resistance+mutation+L1198F&doi=10.1056%2FNEJMoa1508887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F</span></div><div class="casAuthors">Shaw, Alice T.; Friboulet, Luc; Leshchiner, Ignaty; Gainor, Justin F.; Bergqvist, Simon; Brooun, Alexei; Burke, Benjamin J.; Deng, Ya-Li; Liu, Wei; Dardaei, Leila; Frias, Rosa L.; Schultz, Kate R.; Logan, Jennifer; James, Leonard P.; Smeal, Tod; Timofeevski, Sergei; Katayama, Ryohei; John, Iafrate A.; Le, Long; McTigue, Michele; Getz, Gad; Johnson, Ted W.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.  This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y).  Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.  When her tumor relapsed, sequencing of the resistant tumor re- vealed an ALK L1198F mutation in addn. to the C1156Y mutation.  The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding.  However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib.  The patient received crizotinib again, and her cancer-related symptoms and liver failure re- solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphljr8b5kDw7Vg90H21EOLACvtfcHk0lhG-qAICcpTIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurzI&md5=993f41fc3918a73d4ba69276556572d8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1508887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1508887%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLeshchiner%26aufirst%3DI.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDardaei%26aufirst%3DL.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DSchultz%26aufirst%3DK.%2BR.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DLe%26aufirst%3DL.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DResensitization%2520to%2520crizotinib%2520by%2520the%2520lorlatinib%2520ALK%2520resistance%2520mutation%2520L1198F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D54%26epage%3D61%26doi%3D10.1056%2FNEJMoa1508887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Shin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span> </span><span class="NLM_article-title">Discovery of low micromolar dual inhibitors for wild type and L1196M mutant of anaplastic lymphoma kinase through the structure-based virtual screening</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">810</span><span class="refDoi"> DOI: 10.1021/acs.jcim.6b00026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVOrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=802-810&author=S.+Shinauthor=S.+Mahauthor=S.+Hongauthor=H.+Park&title=Discovery+of+low+micromolar+dual+inhibitors+for+wild+type+and+L1196M+mutant+of+anaplastic+lymphoma+kinase+through+the+structure-based+virtual+screening&doi=10.1021%2Facs.jcim.6b00026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening</span></div><div class="casAuthors">Shin, Saemina; Mah, Shinmee; Hong, Sungwoo; Park, Hwangseo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">802-810</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although anaplastic lymphoma kinase (ALK) is involved in a variety of malignant human cancers, the emergence of constitutively active mutants with drug resistance has rendered it difficult to identify the new medicines for ALK-dependent cancers.  To find the common inhibitors of the wild type ALK and the most abundant drug-resistant mutant (L1196M), we performed mol. docking-based virtual screening of a large chem. library in parallel for the two target proteins.  As a consequence of augmenting the accuracy of the docking simulation by implementing a sophisticated hydration free energy term in the scoring function, 12 common inhibitors are discovered with the inhibitory activities ranging from submicromolar to low micromolar levels.  The results of the binding free energy decompn. indicate that the biochem. potency of ALK inhibitors can be optimized by reducing the dehydration cost for binding to the receptor protein as well as by strengthening the interactions with amino acid residues in the ATP-binding site.  The newly identified ALK inhibitors are found to have a little higher inhibitory activity for the L1196M mutant than for the wild type due to the strengthening of the hydrogen bond interactions in the ATP-binding site.  Of the 12 common inhibitors, 2-(5-methyl-benzooxazol-2-ylamino)-quinazolin-4-ol (3) is anticipated to serve as a new mol. scaffold to optimize the biochem. potency because it exhibits low micromolar inhibitory activity with respect to both the wild type and L1196M mutant in spite of the low mol. wt. (292.3 amu).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9yWue9aLBLrVg90H21EOLACvtfcHk0lhG-qAICcpTIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVOrtLo%253D&md5=7bd43d9e200fda3d54fa8e3b4c5f7a26</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00026%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DS.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520low%2520micromolar%2520dual%2520inhibitors%2520for%2520wild%2520type%2520and%2520L1196M%2520mutant%2520of%2520anaplastic%2520lymphoma%2520kinase%2520through%2520the%2520structure-based%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D802%26epage%3D810%26doi%3D10.1021%2Facs.jcim.6b00026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnekenburger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwergel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosconati, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gros, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimondo, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miele, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferretti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, A.</span><span> </span><span class="NLM_article-title">Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span><span class="refDoi"> DOI: 10.1021/jm4012627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFOisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=701-713&author=S.+Valenteauthor=Y.+Liuauthor=M.+Schnekenburgerauthor=C.+Zwergelauthor=S.+Cosconatiauthor=C.+Grosauthor=M.+Tardugnoauthor=D.+Labellaauthor=C.+Floreanauthor=S.+Mindenauthor=H.+Hashimotoauthor=Y.+Changauthor=X.+Zhangauthor=G.+Kirschauthor=E.+Novellinoauthor=P.+B.+Arimondoauthor=E.+Mieleauthor=E.+Ferrettiauthor=A.+Gulinoauthor=M.+Diederichauthor=X.+Chengauthor=A.+Mai&title=Selective+non-nucleoside+inhibitors+of+human+DNA+methyltransferases+active+in+cancer+including+in+cancer+stem+cells&doi=10.1021%2Fjm4012627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells</span></div><div class="casAuthors">Valente, Sergio; Yiwei, Liu; Schnekenburger, Michael; Zwergel, Clemens; Cosconati, Sandro; Gros, Christina; Tardugno, Maria; Labella, Donatella; Florean, Cristina; Minden, Steven; Hashimoto, Hideharu; Chang, Yanqi; Zhang, Xing; Kirsch, Gilbert; Novellino, Ettore; Arimondo, Paola B.; Miele, Evelina; Ferretti, Elisabetta; Gulino, Alberto; Diederich, Marc; Cheng, Xiaodong; Mai, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">701-713</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DNA methyltransferases (DNMTs) are important enzymes involved in epigenetic control of gene expression and represent valuable targets in cancer chemotherapy.  A no. of nucleoside DNMT inhibitors (DNMTi) have been studied in cancer, including in cancer stem cells, and two of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes.  However, only a few non-nucleoside DNMTi have been identified so far, and even fewer have been validated in cancer.  Through a process of hit-to-lead optimization, we report here the discovery of compd. 5 as a potent non-nucleoside DNMTi that is also selective toward other AdoMet-dependent protein methyltransferases.  Compd. 5 was potent at single-digit micromolar concns. against a panel of cancer cells and was less toxic in peripheral blood mononuclear cells than two other compds. tested.  In mouse medulloblastoma stem cells, 5 inhibited cell growth, whereas related compd. 2 showed high cell differentiation.  To the best of our knowledge, 2 and 5 are the first non-nucleoside DNMTi tested in a cancer stem cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxOcRR02xFkLVg90H21EOLACvtfcHk0ljntOeaW3hbtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFOisw%253D%253D&md5=0749e33ad2324aa591342d7c7f23a955</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4012627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012627%26sid%3Dliteratum%253Aachs%26aulast%3DValente%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSchnekenburger%26aufirst%3DM.%26aulast%3DZwergel%26aufirst%3DC.%26aulast%3DCosconati%26aufirst%3DS.%26aulast%3DGros%26aufirst%3DC.%26aulast%3DTardugno%26aufirst%3DM.%26aulast%3DLabella%26aufirst%3DD.%26aulast%3DFlorean%26aufirst%3DC.%26aulast%3DMinden%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKirsch%26aufirst%3DG.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DArimondo%26aufirst%3DP.%2BB.%26aulast%3DMiele%26aufirst%3DE.%26aulast%3DFerretti%26aufirst%3DE.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DDiederich%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DMai%26aufirst%3DA.%26atitle%3DSelective%2520non-nucleoside%2520inhibitors%2520of%2520human%2520DNA%2520methyltransferases%2520active%2520in%2520cancer%2520including%2520in%2520cancer%2520stem%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D701%26epage%3D713%26doi%3D10.1021%2Fjm4012627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hazeldine, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biehl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwitz, J. P.</span><span> </span><span class="NLM_article-title">Part 3: synthesis and biological evaluation of some analogs of the antitumor agents, 2-{4-[(7-chloro-2-quinoxalinyl) oxy] phenoxy} propionic acid, and 2-{4-[(7-bromo-2-quinolinyl) oxy] phenoxy} propionic acid</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">–</span> <span class="NLM_lpage">1081</span><span class="refDoi"> DOI: 10.1016/j.bmc.2004.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.bmc.2004.11.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=1069-1081&author=S.+T.+Hazeldineauthor=L.+Polinauthor=J.+Kushnerauthor=K.+Whiteauthor=T.+H.+Corbettauthor=J.+Biehlauthor=J.+P.+Horwitz&title=Part+3%3A+synthesis+and+biological+evaluation+of+some+analogs+of+the+antitumor+agents%2C+2-%7B4-%5B%287-chloro-2-quinoxalinyl%29+oxy%5D+phenoxy%7D+propionic+acid%2C+and+2-%7B4-%5B%287-bromo-2-quinolinyl%29+oxy%5D+phenoxy%7D+propionic+acid&doi=10.1016%2Fj.bmc.2004.11.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DHazeldine%26aufirst%3DS.%2BT.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DCorbett%26aufirst%3DT.%2BH.%26aulast%3DBiehl%26aufirst%3DJ.%26aulast%3DHorwitz%26aufirst%3DJ.%2BP.%26atitle%3DPart%25203%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520some%2520analogs%2520of%2520the%2520antitumor%2520agents%252C%25202-%257B4-%255B%25287-chloro-2-quinoxalinyl%2529%2520oxy%255D%2520phenoxy%257D%2520propionic%2520acid%252C%2520and%25202-%257B4-%255B%25287-bromo-2-quinolinyl%2529%2520oxy%255D%2520phenoxy%257D%2520propionic%2520acid%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D1069%26epage%3D1081%26doi%3D10.1016%2Fj.bmc.2004.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Allen, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennard, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brammer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orpen, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 2</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1</span><span class="NLM_x">–</span> <span class="NLM_lpage">S19</span><span class="refDoi"> DOI: 10.1039/p298700000s1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1039%2Fp298700000s1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADyaL1cXmt1ylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1987&pages=S1-S19&author=F.+H.+Allenauthor=O.+Kennardauthor=D.+G.+Watsonauthor=L.+Brammerauthor=A.+G.+Orpenauthor=R.+Taylor&title=Tables+of+bond+lengths+determined+by+X-ray+and+neutron+diffraction.+Part+1.+Bond+lengths+in+organic+compounds&doi=10.1039%2Fp298700000s1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tables of bond lengths determined by x-ray and neutron diffraction.  Part 1.  Bond lengths in organic compounds</span></div><div class="casAuthors">Allen, Frank H.; Kennard, Olga; Watson, David G.; Brammer, Lee; Orpen, A. Guy; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 2:  Physical Organic Chemistry (1972-1999)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">S1-S19</span>CODEN:
                <span class="NLM_cas:coden">JCPKBH</span>;
        ISSN:<span class="NLM_cas:issn">0300-9580</span>.
    </div><div class="casAbstract">The av. lengths of bonds involving the elements H, B, C, N, O, F, Si, P, S, Cl, As, Se, Br, Te, and I in org. compds. are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1t708GUnP6LVg90H21EOLACvtfcHk0lj1CcDCJodfDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmt1ylsg%253D%253D&md5=d503dac6e5f2374e2d49a82f1ffd6a14</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fp298700000s1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp298700000s1%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DF.%2BH.%26aulast%3DKennard%26aufirst%3DO.%26aulast%3DWatson%26aufirst%3DD.%2BG.%26aulast%3DBrammer%26aufirst%3DL.%26aulast%3DOrpen%26aufirst%3DA.%2BG.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DTables%2520of%2520bond%2520lengths%2520determined%2520by%2520X-ray%2520and%2520neutron%2520diffraction.%2520Part%25201.%2520Bond%2520lengths%2520in%2520organic%2520compounds%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25202%26date%3D1987%26spage%3DS1%26epage%3DS19%26doi%3D10.1039%2Fp298700000s1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lj1CcDCJodfDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Hatcher, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahcall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9296</span><span class="NLM_x">–</span> <span class="NLM_lpage">9308</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9296-9308&author=J.+M.+Hatcherauthor=M.+Bahcallauthor=H.+G.+Choiauthor=Y.+Gaoauthor=T.+Simauthor=R.+Georgeauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+inhibitors+that+overcome+the+G1202R+anaplastic+lymphoma+kinase+resistance+mutation&doi=10.1021%2Facs.jmedchem.5b01136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</span></div><div class="casAuthors">Hatcher, John M.; Bahcall, Magda; Choi, Hwan Geun; Gao, Yang; Sim, Taebo; George, Rani; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9296-9308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The treatment of patients with advanced nonsmall-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-mol. inhibitor of ALK, ROS1, and MET.  However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS).  This has motivated the development of "second-generation" ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance.  However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations.  Herein, the authors report the development of a structural analog of alectinib I that is potent against the G1202R mutant as well as a variety of other frequently obsd. mutants.  In addn., I is capable of penetrating the CNS of mice following oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI_JJeOYNwybVg90H21EOLACvtfcHk0lizpcVB_gAwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7vE&md5=711b0353b771b54990264565c901a76f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01136%26sid%3Dliteratum%253Aachs%26aulast%3DHatcher%26aufirst%3DJ.%2BM.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGeorge%26aufirst%3DR.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520inhibitors%2520that%2520overcome%2520the%2520G1202R%2520anaplastic%2520lymphoma%2520kinase%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9296%26epage%3D9308%26doi%3D10.1021%2Facs.jmedchem.5b01136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Kim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span><span class="refDoi"> DOI: 10.1016/j.molonc.2013.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=10.1016%2Fj.molonc.2013.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=23993685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=1093-1102&author=H.+R.+Kimauthor=W.+S.+Kimauthor=Y.+J.+Choiauthor=C.+H.+Choiauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Epithelial-mesenchymal+transition+leads+to+crizotinib+resistance+in+H2228+lung+cancer+cells+with+EML4-ALK+translocation&doi=10.1016%2Fj.molonc.2013.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</span></div><div class="casAuthors">Kim, Hyeong Ryul; Kim, Woo Sung; Choi, Yun Jung; Choi, Chang Min; Rho, Jin Kyung; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1093-1102</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epithelial-mesenchymal transition (EMT) is assocd. with reduced sensitivity to many chemotherapeutic drugs, including EGFR tyrosine kinase inhibitors.  Here, we investigated if this reduced sensitivity also contributes to resistance to crizotinib, an ALK inhibitor of lung cancer that exhibits the EML4-ALK translocation.  We established a crizotinib-resistant subline (H2228/CR), which was derived from the parental H2228 cell line by long-term exposure to increasing concns. of crizotinib.  Characteristics assocd. with EMT, including morphol., EMT marker proteins, and cellular mobility, were analyzed.  Compared with H2228 cells, the growth of H2228/CR cells was independent of EML4-ALK, and H2228/CR cells showed cross-resistance to TAE-684 (a second-generation ALK inhibitor).  Phenotypic changes to the spindle-cell shape were noted in H2228/CR cells, which were accompanied by a decrease in E-cadherin and increase in vimentin and AXL.  In addn., H2228/CR cells showed increased secretion and expression of TGF-β1.  Invasion and migration capabilities were dramatically increased in H2228/CR cells.  Applying TGF-β1 treatment to parental H2228 cells for 72 h induced reversible EMT, leading to crizotinib resistance, but this was reversed by the removal of TGF-β1.  Suppression of vimentin in H2228/CR cells by siRNA treatment restored sensitivity to crizotinib.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitors, similar to the parental H2228 cells.  In conclusion, we suggest EMT is possibly involved in acquired resistance to crizotinib, and that HSP90 inhibitors could be a promising option for the treatment of EMT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1f1A1JNCfobVg90H21EOLACvtfcHk0lizpcVB_gAwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrtr7I&md5=c79e45e695141be621672bf47c663c7f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2013.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2013.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DEpithelial-mesenchymal%2520transition%2520leads%2520to%2520crizotinib%2520resistance%2520in%2520H2228%2520lung%2520cancer%2520cells%2520with%2520EML4-ALK%2520translocation%26jtitle%3DMol.%2520Oncol.%26date%3D2013%26volume%3D7%26spage%3D1093%26epage%3D1102%26doi%3D10.1016%2Fj.molonc.2013.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YFX','PDB','2YFX'); return false;">PDB: 2YFX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01039">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46288"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01039">10.1021/acs.jmedchem.7b01039</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Spectral data for all listed compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_002.csv">CSV</a>)</p></li><li><p class="inline">Atomic coordinates of computational models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_003.zip">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_001.pdf">jm7b01039_si_001.pdf (4.95 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_002.csv">jm7b01039_si_002.csv (1.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01039/suppl_file/jm7b01039_si_003.zip">jm7b01039_si_003.zip (969.8 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01039&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-22%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01039%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01039" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0fef1392dd94a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
